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Breast cancer is the most common malignancy and the second highest cause of
cancer death in women. Many of these tumours are oestrogen dependent and can be
treated using compounds which are themselves antioestrogenic or reduce the
production of oestrogen. Until recently, the selective oestrogen receptor modulator
(SERM) tamoxifen was prescribed as standard adjuvant therapy for postmenopausal
women with hormone sensitive tumours. Several studies have shown that in
postmenopausal women, the newer aromatase inhibitors (AIs) are effective at
suppressing plasma oestrogen levels and are more efficacious than tamoxifen.
Although their use is increasing there remain concerns about their side-effects. There
are two classes of AIs: type 1 which are irreversible, steroidal inhibitors and include
the drug exemestane; type II that are reversible, non-steroidal inhibitors and include
the drugs letrozole and anastrozole. Each has similar but different levels of oestrogen
suppression and it remains to be determined whether these differences in suppression
of aromatase translate into differences in clinical benefits and side-effects.
The purpose of the following studies was to assess the pharmacodynamic differences
between the AIs anastrozole, letrozole and exemestane in postmenopausal women
with early hormone sensitive breast cancer. The oestrogen-depriving effects of AIs
have been reported to be associated with an increased risk of osteoporosis and
cardiovascular disease alongside a potential reduction in the risk of thromboembolic
events. These studies therefore investigated the differential effects of the more
commonly used AIs, anastrozole, letrozole and exemestane on bone turnover
markers, lipid profiles, coagulation parameters and quality of life (QOL).
ALIQUOT (Anastrozole vs Letrozole, an Investigation of Quality of Life and
Tolerability) was an open randomised pharmacodynamic study in which 185 patients
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were randomised to receive either 3 months s of letrozole followed by 3 months of
anastrozole or 3 months of anastrozole followed by 3 months of letrozole. 39 patients
had received prior tamoxifen therapy. Blood and urine samples were collected at
baseline and after 3 months of each drug. Hormone naive (i.e. those who did not
receive prior tamoxifen) patients were switched to tamoxifen after 6 months and
further samples obtained after an additional 3 months. Validated QOL questionnaires
were collected during treatment.
ALEX (a randomised study of the effects of Anastrozole, Letrozole and Exemestane
on bone turnover, lipid metabolism and coagulation) was an open randomised
pharmacodynamic study in which 120 patients were randomised to receive 4 months
of either drug and then switched to tamoxifen. Similar blood and urine samples were
collected at baseline, after 3, 4 and 12 months.
Results demonstrated that each AI increased bone turnover markers. The non¬
steroidal AI exemestane showed a greater increase in markers of bone turnover
compared with the non-steroidal AIs. Significant changes in bone turnover were
observed when tamoxifen was withdrawn and a non-steroidal AI commenced. The
data from these studies suggest that any benefit from tamoxifen in increasing bone
density is likely to be lost in the months and years after treatment is stopped. Patients
who take anastrozole or letrozole following tamoxifen need the same bone
monitoring as any patient taking anastrozole or letrozole alone.
The non-steroidal AIs had different effects on lipid profiles compared to the steroidal
group. Exemestane caused an increase in atherogenic ratios and a decrease in the
cardioprotective high density lipoprotein (HDL) compared to the non-steroidal AIs.
This supports studies suggesting that exemestane may have a negative impact on
lipid levels and may increase the risk cardiovascular disease (CVD).
12
There were no significant differences between coagulation parameters in the patients
treated with non-steroidal AIs. However exemestane caused a significant reduction in
several anticoagulants predisposing to a potential increased risk of thromboembolic
disease.
Data presented in this thesis indicate that steroidal and non-steroidal AIs have
different metabolic effects on bone, lipids and coagulation and suggest each will
have different side effect and morbidity profiles. These observations have important
implications when considering which AI to use in the clinical setting and how
patients on different drugs should be monitored.
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ALEX A randomised study of the effects of Anastrozole, Letrozole and
Exemestane on bone turnover, lipid metabolism and coagulation
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1.1 Aims and objectives
AIs reduce circulating oestrogen and therefore affect not only hormone dependent
breast tumours but also have consequences on other non-tumour related systems
affected by oestrogen. Although extensive research on AIs has been undertaken,
there is very little research directly comparing the effects of the different drug types
on morbidity, tolerability and quality of life (QOL).
The aim of the ALIQUOT study was to evaluate the effects of the non-steroidal AIs
anastrozole and letrozole on bone, lipid and quality of life profiles in postmenopausal
women with oestrogen receptor positive (ER+ve) breast cancer.
The aim of the ALEX study was to further evaluate the effects of non-steroidal AIs
and also the effects of the steroidal AI, exemestane on bone, lipid, coagulation and
quality of life profiles in postmenopausal women with ER+ve breast cancer.
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1.2 Breast cancer epidemiology
1.2.1 Incidence and prevalence
Since 1950 the incidence of breast cancer has been rising. Breast cancer remains a
significant public health problem which impacts on the wellbeing of women
worldwide with considerable social and economic cost. By 2010 the annual global
burden of new breast cancer cases was expected to reach 1.5 million with an ever-
increasing number from developing countries1. The increasing incidence may be
explained by a number of factors including greater longevity, delays in starting a
family, the use of hormone replacement treatment (HRT) and an increased breast
cancer detection rate. There was a marked increase in the UK incidence of breast
cancer following the implementation of the National Breast Cancer Screening
Programme which was introduced in 1988. Breast cancer affects 1 in 10 women by
the age of 80 and is the most frequent cancer affecting elderly women2.
Despite the increase in incidence, there has been an improvement in overall survival
which is thought to be due to a combination of earlier diagnosis resulting from
improved public health initiatives including screening programmes; better treatments
including the use of tamoxifen; an increase in care specialisation; and a recent fall in
the use ofHRT. Notwithstanding this, breast cancer remains the leading cause ofUK
cancer death in women and resulted in 12,116 deaths in 2008 . The UK incidence
and mortality rates are shown in figure 1.1.
The prevalence of breast cancer is also increasing due to the increased incidence and
improvement in survival. Approximately 172,000 women are currently living with
breast cancer in the UK and over 75% of women diagnosed with breast cancer are
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Figure 1.1 Incidence and mortality rates from breast cancer in UK
(Adapted from the Office for National Statistics www.statistics.gov.uk 20083)
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1.2.2 Geography
In the UK breast cancer is the leading cause of death in women under 54 years of age
and is surpassed only by lung cancer mortality in those over this age. In 2007 45,972
women were diagnosed with breast cancer and 12,116 died from their disease in
20083. Age standardised incidence and mortality in the UK is among the highest in
the world. Of interest, some particular areas are associated with significantly lower
rates of breast cancer e.g. Wales and Yorkshire compared with the South West of
England. To a degree, these variations reflect the positive relationship between breast
cancer and socio-economic class with higher socio-economic status being associated
with increased risk. This disparity is largely explained by reproductive risk factors
e.g. women in lower socio-economic strata have more children at a younger age. It
may also be related to more affluent women attending screening more readily and
they therefore have an increased detection rate3.
There exists a marked variation in the rates of breast cancer among populations
worldwide with the highest incidence among women in the USA and Western and
Northern Europe. The lowest incidence is found in Asia, India and Africa however
this gap is closing with the transition towards Western lifestyles including a change
in diet and reproductive trends. Migrants from low to high risk countries acquire the
risk of their host country within two generations as observed in women from Japan
who migrated to USA4.
Despite the fact that breast cancer is predominantly viewed as a disease of developed
countries, the majority of breast cancer deaths each year occur in the developing




























Figure 1.2 International variation in breast cancer incidence among
women from 2000-2005, per 100,000 women-years
(Data adapted from GLOBOCAN5 and Cancer Research UK 20023)
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1.2.3 Age
The incidence of breast cancer increases sharply with increasing age as shown in
figure 1.3. It is extremely rare in those under the age of 20 years and uncommon in
those under the age of 30 years. The incidence of breast cancer continues to rise
through life but slows down between the ages 45-50 years. Non-hormone dependent
cancers do not exhibit this change of incidence and this is clear evidence suggesting
that breast cancer is caused by reproductive hormones6. Eighty per cent of cases
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Figure 1.3 Incidence of UK female breast cancers and rates by age
(Adapted from cancer statistics, Cancer Research UK 20013)
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1.3 History of breast cancer and hormonal treatments
Breast cancer is an ancient disease which transcends race, class and time. It was first
documented by the Egyptians as far back as 3000 years before the birth of Christ7.
During ancient times, breast cancer was cancer. People died of other malignancies
but few of these cancers were visible to the naked eye. Breast cancer however could
be easily and logically correlated with the external manifestation of the disease and
ultimately with the death that followed, it was therefore greatly feared8.
Breast cancer was later described by the godfather ofWestern Medicine, Hippocrates
born around 460BC. He taught medicine in the temple dedicated to the Asclepios, the
Greek god of medicine and healing. Hippocrates supplied the earliest and by far the
most enduring, description of cancer. Its appearance provoked Hippocrates to name it
'karkinos', a Greek work for crab. He found on close examination that tumours were
seen to have tentacles, like the legs of a crab, reaching out and grasping normal
tissue. From karkinos evolved the modern term 'carcinoma'. During these times it
was viewed as a systemic illness. Clarissimus Galen, the second century Greek
physician succeeded Hippocrates8 and he attributed breast cancer to a coagulum of
black bile within the breast and therapy was aimed at getting rid of this excess bile
by diets, purgation, venesection, cupping and leeching9. His humoral theories
disappeared into the dust of history until approximately 1000 years later when
monastic scribes translated Arab texts back into Latin in the late Middle Ages.
The professor of medicine at Padua University, Bernardino Ramazzia ruminated on
the puzzling epidemiology of breast cancer. In 1713 he documented that these
tumours were found more often in nuns than in any other women and blamed the
nuns' celibacy. He failed to make the true association with nulliparity8.
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The infamous American surgeon William Stewart Halsted graduated in 1877 and
became the professor of surgery at John Hopkins Hospital in Baltimore, USA. He
performed the first 'radical mastectomy' in 1882 which involved an 'en bloc
resection' removing the entire breast, skin and subcutaneous tissue alongside the
pectoralis major and minor muscles and axillary lymph nodes. The procedure
represented the most successful technique for treating cancer of its time and was
carried out worldwide throughout the first half of the twentieth century. Although his
surgery boosted survival, women were left feeling handicapped7'8. Prior to this era,
tumours were treated by local excision however the results were disappointing and
Sir James Paget concluded in 1863 that this operation was futile in terms of curative
potential. It soon became evident that radical mastectomy reduced local recurrence
rates but achieved little in terms of overall survival.
The first oophorectomy was carried out by a German surgeon, Alfred Hegar in 1872
for benign disease. Within one month, the American Robert Battey performed the
first bilateral oophorectomy on a young woman with multisystem malady and the
absence of regular menses. It was not until 1882 when Thomas William Nunn
reported the relationship of ovarian function to breast cancer. He described a
perimenopausal woman with breast cancer who went into remission after
menstruation ceased. In 1889 the German Albert Schinzinger proposed surgical
oophorectomy as a treatment for breast cancer. He suggested the possibility of
removing a patient's ovaries before mastectomy as a way of getting at more tumour
tissue. He believed oophorectomy would render the mammary glands atrophic,
giving rise to the possibility that cancer nodes might become demarcated in the
shrinking tissue. Despite this he never carried out the surgery himself8.
It is now over 100 years since the Glaswegian surgeon George Thomas Beatson
reported the effects of ovarian ablation on breast cancer in his paper titled 'On The
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Treatment Of Inoperable Cases of Carcinoma Of The Mamma: Suggestions for a
New Method Of Treatment, With Illustrative Cases' published in 189610. Beatson's
interest in the connection between the breast and ovary started when he embarked
upon his MD thesis. He observed lactation in sheep, cattle and rabbits and described
'the close intimacy between the ovary and the mamma, as seen in the absence, as a
rule, of the menstrual function during lactation'. He questioned the possible effects
of oophorectomy on the progress of cancerous growths of the breast. On June 15 th
1882 he performed his first bilateral salpingo-oophorectomy on a young woman with
recurrent breast tumour. The patient was also given ovine thyroid extract, pre and
post-operatively, as it was thought that this was a powerful lymphatic stimulant
which might help cure her disease. Her tumour regression was remarkable and she
survived for a further four years. The case was published along with several others.
Hence, Beatson demonstrated that many breast cancers were dependent on the
ovaries for growth and oophorectomy could result in tumour regression.
In 1886 Stanley Boyd carried out his first bilateral oophorectomy on a woman with
metastatic breast cancer and eleven years later performed the first oophorectomy as
adjuvant therapy for the treatment of metastatic breast cancer".
Radical mastectomy remained the surgical treatment of choice until a revolutionary
change of view occurred during in the 1970s regarding the mechanism by which
breast cancers grow and spread. The earlier belief that these tumours remained
confined to the breast and lymphatics before metastasising at a later date was
challenged. Studies showed that only 12% of Halsted's patients undergoing radical
mastectomies survived beyond one decade. The concept that tumours spread early in
the disease and that metastases were not clinically apparent led to the development
and subsequent introduction of adjuvant treatment. Both Hippocrates and his
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successor Galen believed that breast cancer was undoubtedly a systemic disease, and
that extirpation of the primary tumour made matters worse11.
Ethamoxytriphetol (MER25) was described by Lerner and co-workers in 1954 as the
first non-steroidal anti-oestrogen and was used as a treatment for a wide range of
gynaecological conditions including breast cancer. Its main side-effect was
neurotoxicity including hallucinations and it was therefore withdrawn from further
development12. Research in the triphenylethylene-based compounds continued and
this culminated in the introduction of clomiphene which was used to induce
ovulation and then in the late 1960s, tamoxifen which was first investigated as a
contraceptive and then used for the treatment of breast cancer11. Tamoxifen is a
SERM which has anti-oestrogenic effects on breast tissue and oestrogenic effects on
endometrium and bone. It was first used to treat advanced breast cancer in the UK in
1973 (ICI Pharmaceuticals, now known as Astra Zeneca). This pioneering advance
was not without concerns. In the mid-1980s it was predicted that tamoxifen would
increase the risk of endometrial cancer in post-menopausal women and later studies
confirmed that the incidence increased four-fold. However its overall toxicity was
low and it remains an extremely successful endocrine treatment and has been the
mainstay hormonal agent for breast cancer for the last 30 years. It has also been used
for breast cancer prevention however studies have demonstrated that the risk of
serious adverse events (AEs) is significant and a lack of survival benefit has led to its
selective use as a preventative medicament. To date, tamoxifen continues to be
associated with gynaecological problems including an increased risk of endometrial
bleeding, endometrial thickening and endometrial carcinoma together with an
increased risk of thromboembolism. These risks have reduced its use in prevention
and have resulted in the development of newer endocrine treatments including AIs.
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AIs have not only been shown to be more efficacious compared to tamoxifen but
they appear to have a more favourable side-effects profile, increasing the likelihood
of drug uptake and compliance.
Aromatase inhibition was first shown to be an effective clinical treatment for
postmenopausal breast cancer using the first generation AI, aminoglutethimide. The
development of aminoglutethimide as an endocrine therapy for breast cancer resulted
from the observation that the drug inhibited adrenal steroidogenesis during its earlier
investigation as an antiepileptic13. Its use was based on the principal that adrenal
androgens form the basic substrate for the synthesis of plasma oestrogens by
aromatase in the peripheral tissues of postmenopausal women. Removal of
androgens were therefore expected to lessen the oestrogenic stimulus to breast cancer
cells by a process of medical adrenalectomy. When administered in sufficient doses,
the drug inhibits the production of adrenal steroids by inhibiting cholesterol side
chain cleavage in the early steps of steroidogenesis and causing partial blockade of
lip-, 18- and 21-hydroxylases in the adrenal. Corticoid replacement is therefore
routinely required to avoid adrenal insufficiency14. Studies demonstrated that the
aminoglutethimide-corticoid regimen blocked the peripheral conversion of androgens
to oestrogen and suppressed circulating oestrogens in postmenopausal women with
breast cancer15. Amininoglutethimide's lack of specificity results in the need for
routine glucocorticoid replacement and largely results from its actions on other
cytochrome P450 systems16. Although early studies established aminoglutethimide as
a feasible treatment for advanced breast cancer in postmenopausal women, it was
poorly tolerated, required high doses to achieve oestrogen deficiency and had several
marked side effects including marked nausea, lethargy, and headache which affected
60%, 52% and 43% of patients respectively17. Other side effects include skin rashes
and serious bone marrow suppression14. Direct comparisons between
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aminoglutethimide and tamoxifen in relation to their effects on breast cancer
demonstrated equal clinical efficacy but fewer side effects and toxicity with
tamoxifen in the 1970s18. Second generation AIs were then developed in an attempt
to reduce associated toxicity and to improve specificity and efficacy19'20.
These second generation AIs fadrozole and formestane were better tolerated but
continued to lack selectivity. Formestane was introduced in 1993 and was
administered by intramuscular injection twice monthly rendering it less acceptable to
patients. The third-generation AIs letrozole, exemestane and anastrozole were
respectively introduced in 199321, 199522 and 199623. They have greater specificity
with fewer side-effects24.
Despite the extensive progress that has been achieved over the last century, there are
still many questions that remain unanswered about the treatment of this complex
disease.
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1.4 Breast development, anatomy and physiology
The development of breast tissue begins during the fifth week of gestation and
commences independent of hormonal influences. It evolves in utero from a primitive
milk streak which develops from the axilla to the groin. This then regresses to form a
mammary ridge in the thorax which gradually develops under the influence of
placental sex hormones to form mammary ducts, lobulo-alveolar structures and the
nipple-areolar complex.
During puberty there is a gradual enlargement in female breast tissue which occurs
under the control of the ovarian hormones, follicle stimulating hormone (FSH) and
luteinising hormone (LH). FSH initiates the development of ovarian follicles into
Graafian follicles which secrete oestrogen, primarily oestradiol. Prior to menarche,
ovarian oestrogen synthesis predominates over luteal progesterone synthesis and
these hormones together produce complete ductular-lobular-alveolar development.
The relative role of each remains unclear however studies have demonstrated that
oestrogen appears to have a much greater role in breast development6.
The mammary gland lies on the anterior chest wall between the second and sixth ribs
and extends into the axilla. It consists of glandular tissue, supporting dense fibrous
stroma and interlobar adipose tissue. The glandular tissue consists of approximately
8 to 20 lobules which produce milk and are arranged in a 'spoke-like' pattern.
Multiple ducts carry milk from the milk-secreting lobular units to the lactiferous
sinus at the base of the nipple. These lobules and ducts constitute the functional unit
of the breast which is otherwise known as the terminal duct lobular unit (TDLU).
Most breast cancers form in the TDLU and spread along the ductal system in the
radial axis of the lobe. At least half of all tumours are found in the upper outer breast
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quadrant where there is a greater abundance of glandular tissue. It has been shown
that women with invasive breast cancer and those with a familial pattern of cancer
have a different architectural pattern from those with normal tissue. Women carrying
the BRCA1 gene or related genes may have a different branching pattern during
lobular development25.
There are three phases of breast activity: puberty, ovulatory cycles and pregnancy.
Breast development requires the influence of various hormones, the most important
being oestrogen. After puberty, mammary tissue undergoes profound cyclical
changes during each ovulatory cycle under the control of oestrogen and
progesterone. During the follicular phase, FSH and LH increase the levels of
oestrogen secreted by the ovarian follicles which in turn stimulates breast epithelium
proliferation as shown in figure 1.4. During this proliferation the epithelium
undergoes increased cellular mitoses. Ovulation occurs at the time of maximum
oestrogen synthesis (mid-cycle). A second peak of oestrogen occurs in the mid-luteal
phase when luteal progesterone is at its maximum. Premenstrual breast fullness can
be explained by the increased ducto-lobular proliferation and interlobular oedema
which occurs under the influence of these hormones. At the end of the menstrual
cycle there is a marked fall in hormone levels and a resulting loss of breast cells due
to apoptosis. These normal monthly changes in breast proliferation and apoptosis
which occur in relation to the ovulatory cycle have been shown to differ from the
effects found in endometrium where the maximum mitotic activity occurs during the
follicular phase (days 6-14). The estimated peak for breast mitosis was shown to be
at day 25 while that for apoptosis was at day 2826. Breast apoptosis occurs in
response to decreasing levels of oestrogen and progesterone which occur toward the
end of the menstrual cycle. In summary, breast lobules of 'resting' human breast
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show a response, in terms of mitosis and apoptosis, which is a biorhythm in phase
0f\
with the ovulatory cycle .
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Figure 1.4 Cyclical changes affecting breast tissue
Pregnancy is associated with very high serum levels of oestrogens and progesterone
which stimulate growth of breast epithelium and promote differentiation of epithelial
tissue, reducing the number of epithelial structures most vulnerable to malignant
transformation. The long term effect of pregnancy therefore reduces the risk of breast
cancer27. Steroid hormone levels fall immediately after parturition and lactation is
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initiated by prolactin. After weaning there is rapid involution of the differentiated
lobular unit.
Further involutional changes occur within the breast with increasing age as a result of
decreasing oestrogen and progesterone levels which occurs with defaulting ovarian
function. The menopause results from follicular atresia of more than 400,000
follicles initially present in the human female foetus6. Breast involution leads to the
replacement of stroma by adipose tissue and shrinkage of lobules. This results in
softer and more ptotic breasts which are less dense and in turn result in
mammograms which reveal tumours more readily.
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1.4.1 Oestrogen
The endogenous oestrogens of greatest significance are oestradiol (E2, 17B-
oestradiol) and the structurally similar, but less potent, oestrone (El). Estriol (E3)
does not play a significant oestrogenic role outside of pregnancy and is the main
oestrogen secreted by the placenta. It is a thousand-fold less potent than oestradiol28.
Oestrogens are synthesised from cholesterol via the pathway shown in figure 1.5. All
oestrogens are synthesised through the action of the aromatase enzyme, which is a
product of the CYP19 gene. This enzyme converts the androgens testosterone and
androstenedione to the oestrogens oestradiol and oestrone, respectively. The
conversion from androgens involves removal of the methyl group at C-19. El and
E2 are freely interconvertible by the action of oestrogen dehydrogenases19.
Oestradiol is the predominant form of circulating oestrogen in premenopausal
women and is the most potent activator of ERs. Ovarian granulosa cells have a rich
supply of aromatase and are the source of >90% of plasma oestrogens secreted in a
cyclical pattern in women before the menopause. More than 95% of circulating
oestrogens are bound to carrier proteins, oestradiol and oestrone are bound weakly to
albumin and with high affinity to sex hormone-binding globulin (SHBG). Only
approximately 2% of oestradiol is in the free form and is generally thought to
influence tissue uptake and biological activity, although some debate still exists on
this point. As ovarian function abates with the onset of the menopause, oestrogens
are synthesised in increasing amounts by extragonadal sites. Mean plasma oestradiol
levels fall to less than 10% of the premenopausal levels. Oestrone is the predominant
postmenopausal oestrogen and is produced mainly from androstenedione and also
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Figure 1.5 Pathway of oestrogen synthesis from cholesterol
3 types of oestrogen are carried by the bloodstream to act on target












Figure 1.6 Types of circulating oestrogen in postmenopausal women
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testosterone29. Figure 1.6 demonstrates the types of circulating oestrogens in the
postmenopausal/non-pregnant female.
A significant proportion of oestrogen circulates as oestrone sulfate (E1S) which
serves as a circulating reserve for the more active primary oestrogens. Both
oestradiol and oestrone can be converted into this water-soluble conjugate. Although
it circulates at much higher concentrations, it is only biologically active after
conversion back to oestrone via estrone sulphatase19.
In premenopausal women hormone production in the ovary is cyclical and the typical
reference ranges for oestrogens depend upon the time point measured. Both






Follicular phase 184 — 532 pmol/L
Luteal phase 184 - <885 pmol/L
Pre-ovulation 411 1626 pmol/I
Post-ovtt fallen 37 130 pmol/L
80 pmol/I
Oestrone levels Oestrone levels
Follicular phase 111™ 370 pmol/L
Luteal phase 333 - 592 pmol/L
Pre-ovulation >550 pmol/L
80 pmol/i.








37 ™ 130 pmol/L
Table 1.1 Typical adult female oestrogen reference ranges30
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Oestradiol is the most potent activator of oestrogen receptors and predominantly
circulates in plasma bound to proteins. Approximately only 2% is free (not bound to
protein) and is able to enter cells. Residual oestradiol is bound weakly to albumin or
to sex hormone binding globulin with high affinity. As ovarian function abates with
the onset of the menopause, oestrogens are synthesised in increasing amounts by
extragonadal sites (including adipose tissue, liver, muscle, skin, brain and the stromal
and epithelial cells ofmany breast cancers. Mean plasma oestradiol levels fall to less
than 10% of the premenopausal levels. Oestrone is the predominant postmenopausal
oestrogen and is produced mainly from androstenedione and also testosterone29.
Figure 1.6 demonstrates the types of circulating oestrogens.
Conversion of oestradiol and oestrone into the water-soluble conjugate oestrone
sulphate also occurs and circulates at much higher concentrations than the primary
oestrogens. However it is only biologically active after conversion back to oestrone
via estrone sulphatase.
Oestrogens have a marked proliferative effect on breast epithelial tissue with both
endogenous and exogenous oestrogens stimulating breast epithelial cell mitosis,
increasing the number of cell divisions and thus the opportunity for random genetic
errors. They not only exert effects on breast and reproductive tissues but also mediate
changes upon other systems including those affecting bone, lipids and coagulation.
Exposure to exogenous oestrogen is common with the use of hormonal preparations
for the use of contraception and to a lesser extent to combat menopausal symptoms.
HRT has been associated with a 2.3% excess risk of developing breast cancer for
each year of use. The risk is higher with preparations combining oestrogen and
progesterone compared with the use of oestrogen or progesterone alone31. Its use has
diminished in recent years following the publication of the Women's Health
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Initiative study which showed that long-term HRT not only increased the risk of
breast cancer but also increased the risk of stroke, thromboembolic and
cardiovascular disease32. HRT has a positive effect on bone density and is related to a
reduced incidence of osteoporosis and bone fractures.
Tibolone, an analogue of the progestin norethynodrel, is a synthetic selective tissue
oestrogenic activity regulator (STEAR) which relieves menopausal symptoms. It is a
steroid with weak oestrogenic, progestrogenic and androgenic properties which
affects multiple tissues in different ways. Tibolone is metabolised in the
gastrointestinal tract to the 3a and 3p metabolites, which circulate in their inactive
sulphated form and become oestrogenically active when desulphated33,34. Its global
effect is predominantly oestrogenic in target organs. In breast tissue, the 30
metabolites strongly inhibit sulphatase, blocking the conversion of oestrone sulphate
to oestrone which causes a reduction of bioactive oestrogen. This induces inhibition
of proliferation and stimulates apoptosis and differentiation of breast cancer cells and
supports a potential lower risk of breast cancer with tibolone compared with other
forms of HRT35. However it has been associated with an increased risk of
postmenopausal breast cancer in some studies but results are not univocal35. Tibolone
is almost as effective as combined HRT at relieving menopausal symptoms and is as
effective as oestrogen-progestin therapy at preventing bone loss.
The Million Women UK study (appendix F) was set up to investigate the effects of
specific types of HRT on breast cancer incidence and fatal breast cancer. Results
demonstrated that current HRT users were more likely to develop breast cancer and
die from it (adjusted relative risk 1.66 and 1.22 respectively) compared with those
that had never used HRT. Incidence was significantly increased for current users of
oestrogen only HRT, oestrogen-progestagen HRT and tibolone (adjusted relative
risks 1.30, 2.00 and 1.45 respectively)32. The findings of this study were criticised as
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they were at odds with most of other studies comparing breast cancer risk in HRT
users. Data from the Danish Nurse Cohort study (appendix F) also demonstrated a
significant increased risk of breast cancer with the current use of tibolone RR 4.27
[95% CI 1.74-10.5136, The use of combined HRT in the Womens' Health Initiative
study demonstrated an estimated hazard ratio of 1.26 [95% CI 1.00-1.59] for breast
cancer37. Subsequent studies have demonstrated no increase in breast cancer risk
associated with tibolone use as demonstrated in the UK General Practice Research
Database RR0.86 [CI 0.65-1.13]38 and LIFT study relative hazard 0.32 [95% CI
0.13-0.80]39(appendix F). The higher risk demonstrated in the Million Women study
may be attributed to the preferential prescribing of tibolone to higher risk women,
patients being given combined HRT prior to entry into the study which may increase
their risk of breast cancer and the inadequacy of breast cancer screening prior to
entry into the study35.
A further study, LIBERATE (appendix F) was undertaken to demonstrate non-
inferiority in breast cancer recurrence of tibolone versus placebo in women with
menopausal symptoms who had undergone surgery for primary breast cancer within
five years. After a median follow-up of 3.1 years 15.2% ofwomen on tibolone had a
cancer recurrence, compared with only 10.7% taking placebo (p=0.001). The study
was stopped prematurely because of the 1.40 relative hazard risk of developing
breast cancer. Although tibolone relieved vasomotor symptoms and prevented bone
loss, it increased the risk of recurrence in breast cancer patients40. A Cochrane
database systemic review was recently published detailing the randomised controlled
trials comparing tibolone versus placebo, oestrogens or combined HRT by assessing
menopausal symptoms and the occurrence of safety outcomes in postmenopausal
women. Data on the long term safety of tibolone is concerning given the increase in
the risk of breast cancer in women who had already suffered from breast cancer in
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the past and in a separate trial the increase in the risk of stroke in women whose
mean age was over 60 years. The overall risk-benefit profiles for combined
preparations ofHRT are better known41.
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1.5.1 Osteoporosis, bone metabolism and the effects of oestrogen
Osteoporosis is a common bone disease amongst postmenopausal women which is
characterised by reduced BMD, micro-architectural deterioration in bone tissue and
an increased fracture risk42. It occurs due to excess bone being removed during bone
resorption compared with the amount remodelled during bone formation. Its
pathogenesis is complicated with many factors involved, although oestrogen
deficiency in postmenopausal women appears to be the most important. Predictors of
future fractures related to osteoporosis include low BMD, prior fragility fractures,
advancing age (bone mass peaks between the ages of 20 - 40 years in normal healthy
females), smoking, low body weight, a family history of osteoporotic fractures and
excess alcohol.
Bone has several functions which include maintaining blood calcium levels,
providing mechanical support to soft tissues including muscle, supporting
haematopoiesis and also providing protection to vital structures including the brain
and spinal cord43. It is a dynamic tissue which is constantly changing through a
process of remodelling which occurs through the resorption of old bone by
osteoclasts and the formation of new bone by osteoblasts. The three most important
effects on bone include the homeostatic demands for calcium, mechanical adaptation
to changes in loading and finally the influence of sex hormones. Genetic factors also
play an important role in regulating bone mineral density (BMD), skeletal geometry
and bone turnover44 as demonstrated in twin studies43. Their effects on bone
metabolism result from a combination of genetic and environmental influences.
Genome-wide linkage studies have identified several loci that show linkage with




Oestrogens and androgens play important roles in bone metabolism and homeostasis.
Sex steroids influence the remodelling of bone in adults and alongside oestrogen are
vital for maintaining bone mass in women. The closely coupled process of bone
resorption followed by bone formation is a delicate balance between osteoclasts and
osteoblasts and is responsible for renewing the skeleton while maintaining its
anatomical and structural integrity45. The purpose of remodelling is believed to not
only prevent bone aging and facilitate repair, but also to ensure appropriate blood
calcium levels necessary for correct cell function. Approximately 25% of trabecular
bone is replaced annually in adults whereas only 3% of cortical bone is replaced.
This may be explained by the high surface-to-volume ratio of trabecular bone to bone
marrow with approximately 70-85% of the bone surface being in contact with
marrow39.
Osteoclasts are multinucleated cells of haematopoietic origin which arise from
granulocyte-macrophage colony-forming units whereas osteoblasts arise from the
mononuclear cells of mesenchymal stem cells of the marrow stroma, fibroblast
colony-forming units, and are responsible for the production of osteoid and
subsequent formation of bone. Haemopoietic precursors of osteoclasts are unable to
develop without the presence of stromal-osteoblastic cells which produce factors
which mediate osteoclastic development45. Another important cell type involved in
bone homeostasis includes osteocytes which are cells ofmyeloid origin. They are the
most abundant cells in mature bone and are formed from osteoblasts. They have long
cytoplasmic processes that make contact with their neighbouring osteoblasts by tight
junctions. Osteocytes sense mechanical forces imposed on the bone, specifically
mechanical distortion, which initiates bone remodelling. Osteocytes are not only
responsible for the sensing and responding to mechanical loading of the skeleton but
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they are also involved in phosphate metabolism and the exchange of calcium
between extracellular fluid and bone28'42,46.
Under normal circumstances bone resorption and formation are closely linked within
spatiotemporal anatomic structures called the basic multicellular unit (BMU). Bone
remodelling is demonstrated in figure 1.7 and is accomplished by cycles which
involve the resorption of old bone by osteoclasts and the subsequent formation of
new bone by osteoblasts. These cells are replenished from their haematopoietic
progenitors within the bone marrow45. Osteoclast precursors are attracted from
peripheral blood by chemotactic factors. These precursors then differentiate into
mature osteoclasts in response to receptor activator of nuclear factor-K (3 ligand
(RANKL) which activates RANK receptors which are expressed on osteoclasts and
their precursors. Osteoprotegerin inhibits osteoclast formation and blocks RANK
receptors. Mature osteoclasts adhere to bone and break it down via acidification and
proteolytic digestion. They secrete hydrochloric acid and enzymes including
cathepsin K which dissolves matrix and breaks down collagen respectively. Once
resorption is complete they undergo apoptosis and osteoblasts subsequently invade
the area and start the process of bone formation by secreting osteoid which is a
matrix of collagen and protein which finally becomes mineralised. Some osteoblasts
become trapped within the bone matrix and differentiate into osteocytes. Once bone
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Figure 1.7 The bone remodelling cycle
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Increased mechanical loads stimulate bone formation and suppress resorption,
whereas unloading has the opposite effect47. The rate of remodelling is coupled
locally so that when the rate of one increases or decreases then the other usually
follows. The rate of resorption is however faster than the rate of formation and it
usually takes at least three months to rebuild bone which is resorbed in only 2-3
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weeks. Increased bone resorption therefore causes bone loss even though it is
coupled with increased formation43.
The regulation of bone remodelling is very complex and many cytokines and growth
factors are involved, it is principally under autocrine-paracrine control. Systemic
48hormones control the production of local mediators in the bone microenvironment
and include circulating hormones such as parathyroid hormone (PTH), calcitriol,
Cortisol and sex steroids: vitamin D3 is also involved. Molecules that govern bone
remodelling include proteins which belong to the tumour necrosis factor (TNF)
superfamily: osteoprotegerin, RANKL and their receptor RANK. Other molecules
include TNF-a, IL-1 and IL-6 which are important mediators involved with the
effects of oestrogen deficiency48. TNF-a is a multifunctional cytokine produced by
activated monocytes-macrophages and is one of the most potent osteoclastogenic
cytokines produced in inflammation, it also induces IL-1 synthesis. Several cytokines
and colony-stimulating factors are specifically involved in the development of
osteoclasts including IL-1, IL-3, IL-6, IL-11, TNF, granulocyte-macrohage colony-
stimulating factor, macrophage colony-stimulating factor, leukaemia inhibiting factor
and stem-cell factor. Cytokines which specifically stimulate bone resorption include
IL4, IL-10, IL-18 and IFN-y48.
There are several important factors regulated by oestradiol which are involved in
regulating the differentiation and function of osteoclasts and osteoblasts. Suppression
of osteoclastic bone resorption and stimulation of osteoblastic bone formation form
the basis for the bone-preserving effects of oestogen49. Oestrogen inhibits bone
resorption by reducing osteoclast numbers and is thought to involve lineage
allocation of monocyte/macrophage/osteoclast precursors through the effects on
regulatory cytokines including IL-1, IL-6, TNF-a and prostaglandin E (PGE). In
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osteoblasts, oestrogen stimulates the synthesis and secretion of the anabolic growth
factor IGF-1 and inhibits that of the cytokines, IL-1, TNF and IL-6 which are
involved in bone resorption50. Oestrogen deficiency results in the increased
production of IL-6 in bone marrow cells45. Interestingly IL-6 only appears to be
important for osteoclastogenesis in the pathological state and has been shown to have
no effect on the development of osteoclast precursors in marrow with sufficient sex
steroid levels i.e. in the oestrogen replete state. Oestradiol also stimulates the
synthesis and secretion of osteoprotegerin (OPG), a protein with a critical role in
inhibition of the function of osteoclasts. OPG, osteoclast differentiation factor (ODF)
and RANK regulate osteoclastic differentiation and function49. After the menopause
approximately 10% of bone is lost annually due to increased bone turnover.
Oestrogen deficiency increases the activation of BMUs which induces this imbalance
in remodelling. Bone loss related to oestrogen deficiency occurs mainly at the
expense of trabecular bone as a result of excessive osteoclast activity. This is in
contrast to the process associated with ageing, which affects primarily cortical bone
and is most likely due to a reduction in the supply of osteoblasts compared to
demand19'45.
BMD is measured using dual energy X-ray absorptiometry (DEXA). Table 1.2
demonstrates the simple diagnostic criteria for low BMD used by the World Health
Organisation (WHO)19. A decrease in 1 standard deviation (SD) in BMD leads to a
doubling of the risk of fractures51. WHO have estimated that approximately 30% of
postmenopausal women have osteoporosis and 54% have osteopenia. Osteoporosis
has been labelled a 'silent epidemic' because patients are often asymptomatic up
until the point of bone fracture19.
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WHO diagnostic criteria for osteopososis
::p" J! ?
Normal
BMD not more than 1 SD below the mean value of peak
bone mass in a normal adult
T-score > -1
Osteopenia
BMD within -1 SD and -2.5 SD of the mean value of
peak bone mass in a normal adult
T-score -2.5 - -1
Osteoporosis
BMD more than 2.5 SD below the mean value of peak
bone mass in a normal adult
T-score < -2.5
Severe osteoporosis
BMD more than 2.5 SD below the mean value of peak
bone mass in a normal adult
T-score < -2.5 with the presence of fractures
SD - standard deviation
Table 1.2 WHO criteria of BMD and osteoporosis
There is clear evidence that bone turnover markers are strong predictors of future
fractures52'53 and can be used independently of BMD measurements to assess future
risk. Increased bone turnover has a detrimental effect on bone microarchitecture and
fragility54. Biochemical bone turnover markers include enzymes and proteins
released during bone formation and degradation products produced during bone
resorption. They can be easily measured, often with autoanalysers, using a variety of
biochemical markers in either serum or urine. They can be divided into two
categories as shown in table 1.3: markers of bone resorption, which reflect osteoclast
activity and are for the most part degradation products of type I collagen; markers of
bone formation, which reflect osteoblast activity and are byproducts of collagen
synthesis, matrix proteins or osteoblastic enzymes. The International Osteoporosis
Foundation and the International Federation of Clinical Chemistry and Laboratory
Medicine have recommended that one bone resorption marker (sCTX) and one bone
formation marker (sPINP) should be used as reference markers and measured by
standardised assays in future observational and intervention studies55.
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Bone formation Bone resorption
Byproducts of collagen synthesis Collagen degradation products
Procollagen type I C-terminal propeptide8 Hydroxyproline"
Procollagen type I N-terminal propeptide8 Pyridinoline"'8
Deoxypyridinolineu,s
Matrix protein Cross-linked telopeptides of type 1 collagen
Osteocalcin8 N-terminal cross-linked telopeptide"'8
Osteoblast enzyme C-terminal cross-linked telopeptide11,8
Total alkaline phosphatase8 C-terminal cross-linked telopeptide generated by
matrix metalloproteinases8
Bone alkaline phosphatase8 Osteoclast enzymes
Tartrate-resistant acid phosphatase8
Cathepsin Ks
Table 1.3 Commonly used biochemical markers of bone turnover
Smeasured in serum
"measured in urine
Recent studies have demonstrated that markers of bone turnover appear even more
strongly associated with fracture risk reduction than BMD. They support the use of
markers of bone turnover as surrogates for fracture risk reduction, perhaps even more
so than BMD. They have the advantage over BMD in that they provide information
about mechanism of effect and changes are often observed more rapidly56.
Oestrogens slow the rate of bone remodelling and protect against bone loss.
Postmenopausal bone loss is due to oestrogen withdrawal which results in increased
bone turnover due to an increase in bone resorption and a decrease in bone formation
(osteoblast apoptosis increases). These changes are mediated via an increase in the
production of cytokines with osteoclastogenic and osteoblastogenic properties.
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Ageing also alters the cellular activity of bone marrow resulting in the likely
reduction in the formation of osteoblast precursors45. Epidemiological and
experimental studies have identified oestrogen deficiency as one of the most
important risk factor for osteoporosis. Other factors include dietaiy calcium,
parathyroid function and genetic background43.
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1.5.2 Cardiovascular disease, lipid metabolism and the effects of
oestrogen
Cardiovascular disease (CVD) is a major health problem. It is the single most
important cause of premature death in Europe and the leading cause of death in
Scotland57. In the UK (population 59 million), it is estimated that l in 4 women die
from coronary heart disease; these statistics are amongst the highest in Western
Europe. Lipoprotein disorders are also common and are a major risk factor for all
types of CVD. Cholesterol is a major component of lipid-containing atherosclerotic
plaques and raised levels of circulating lipids correspond with increased risk ofCVD.
Lipids have multiple functions and are localised primarily within three
compartments: plasma, adipose tissue and biological membranes. There are several
different types of lipid, the simplest form are fatty acids which are found primarily
within plasma. Others include triglycerides (comprises 90% of dietary lipids and are
stored primarily within adipose tissue), phospholipids (the major class of cell
membrane lipids), cholesterol and sterols58. These are assimilated from the diet and
transported and metabolised throughout the body. The majority are insoluble and are
transported in plasma as particulate complexes with proteins, known as lipoprotein.
The structure of lipoprotein is demonstrated in figure 1.8 and there are several types
including chylomicrons, VLDL(very low-density lipoprotein), IDL (intermediate-
density lipoprotein), LDL (low-density lipoprotein) and HDL (high-density
lipoprotein). The protein components of the lipoproteins are called apolipoproteins
(Apo) and are a complex family of polypeptides that promote and control lipid









Figure 1.8 Structure of lipoproteins!42}
Apolipoproteins combine with lipids to form spherical lipoproteins which possess a
hydrophobic core and a less hydrophobic coat.
Exogenous lipids
Dietary lipids are insoluble in water and undergo lipolysis before becoming
incorporated into mixed micelles which are then absorbed into enterocytes from
which they pass into the systemic circulation. This absorption occurs in a step-wise
process which includes: i) Fat emulsification by peristalytic movements within the
stomach and small intestine. This is aided by salivary and gastric lipases, ii) Lipids
cause cholecystokinin to be released from the duodenum and upper jejunum which
stimulates the release of pancreatic enzymes including amylase, lipase, co-lipase and
proteases. These enzymes allow the major digestive process of lipids to occur
whereby triglycerides are cleaved to form fatty acids and monoglycerides. These are
solubilised by interacting with bile salts (released from the gallbladder) and
phospholipids to form mixed micelles which are considerably smaller than lipid
emulsion droplets, iii) Enterocytes absorb the micelles and extract monoglycerides
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and free fatty acids which are re-esterified to form triglycerides. Triglycerides (87%)
combine with cholesterol (3%) and fat-soluble vitamins, all of which are enveloped
in a coat composed of specific apolipoproteins (1%), phospholipids (9%) and free
cholesterol to form chylomicrons28, iv) Chylomicrons leave the enterocyte by
exocytoses and travel to the systemic circulating via lymphatics. They are
remodelled by the transfer of additional apolipoproteins and are acted upon by
lipoprotein lipase located on endothelium of capillary beds to release fatty acids that
can be used for energy or storage. The remnant chylomicron particle is then cleared
by the liver as shown in figure 1.942.
Endogenous lipids
The liver is the major source of plasma lipids in the fasting state and has the capacity
to acquire lipids from uptake, synthesis or conversion from other macronutrients as
shown in figure 1.9. These lipids are transported by secretion of triglyceride-rich
VLDL which differ from chylomicrons as they contain apolipoprotein B100. Once
secreted into the circulation VLDL undergo a similar metabolic process to
chylomicrons. Fatty acids are released and the particle is converted to IDL and LDL.
The latter being a source of cholesterol used for esters maintaining cell and tissue
homeostasis. There is a negative feedback mechanism which controls cholesterol
synthesis. Cholesterol down-regulates expression of the LDL receptor gene and
reduces the synthesis and activity of the enzyme for cholesterol synthesis, HMGCoA
reductase. The intracellular free cholesterol level is maintained within a narrow range
due to this negative feedback mechanism and the modulation of cholesterol
esterification42.
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ABCA1 - AP-binding cassette A1 Cholesterol ester - CE
Free fatty acids - FFA HDL - mature high-density lipoprotein
iHDL - immature high-density lipoprotein HL - hepatic lipase
HMGCoAR - hydroxyl-methyl-glutaryl-coenzyme A reductase
IDL - intermediate-density lipoprotein LCAT - lecithin cholesterol acyl transferase
LDL - low-density lipoprotein LDLR - low-density lipoprotein receptor (Apo B100
receptor)
LPL - lipoprotein lipase SRB1 - scavenger receptor B1
TG - triglyceride VLDL - very low-density lipoproteins
Figure 1.9 The absorption, transport and storage of lipids42
The pathways of lipid transport are shown; in addition cholesterol ester transfer




Excessive cholesterol accumulation within peripheral tissue is guarded against by
HDL which accepts free cholesterol from cholesterol-rich regions of the cell
membranes and then releases them to the liver and other cholesterol-requiring
tissues. This process involves a specific membrane tranporter known as ATP-binding
cassette A1 transporter and lecithin cholesterol acyl transferase42.
Atherosclerosis is a process which leads to the narrowing or complete occlusion of
the arterial lumen and leads to myocardial infarction, stroke and peripheral vascular
disease. Atherosclerotic plaques form as a result of endothelial dysfunction, intimal
lipid deposition, and the accompanying inflammatory reaction. This may occur from
excess lipoprotein levels, hypertension, diabetes and cigarette smoking58. Increased
total cholesterol and its major component fraction, LDL cholesterol have been
associated to accelerated atherosclerosis and an increased risk of coronary artery
disease. In contrast HDL cholesterol appears to have a protective and anti¬
atherogenic effect because it is involved in the mobilisation of cholesterol from
tissues and their transportation back to the liver. The risk of coronary heart disease
and other forms of atherosclerotic vascular disease increases with increased plasma
cholesterol concentrations, and in particular the ratio of total cholesterol to HDL
cholesterol. A much weaker correlation also exists with plasma triglyceride
concentration. Large scale studies have demonstrated that reducing total LDL
concentration reduces the risk of cardiovascular events including myocardial
infarction, stroke and death.
High levels of circulating triglycerides, cholesterol, LDL and Apolipoprotein B
(ApoB) are associated with an increased risk of CVD whereas high levels of HDL
and Apolipoprotein A-l (Apo A-l) are protective. HDL is an independent predictor
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of cardiovascular risk57. Atherogenic ratios can be used to predict cardiovascular
risk, often in combination with other variables including age, sex, blood pressure and
smoking status. Elevated total cholesterokHDL, LDL:HDL and ApoB:ApoA-l are
associated with an increased risk of CVD. The ratio of total cholesterokHDL
cholesterol has been shown to be the optimal predictor of cardiovascular risk when
incorporated in multiple risk factor equations59.
It is known that oestrogen affects hepatic lipoprotein metabolism by increasing the
synthesis ofVLDL leading to an increase in triglyceride levels. In addition it causes
an increased apolipoprotein B receptor to lower LDL and lastly an increased
synthesis of apolipoprotein A-l which causes a high concentration of HDL60.
Oestrogen therapy is known to have a mixed effect on serum lipid levels resulting in
a significant decrease in total cholesterol and LDL, a favourable increase in HDL and
an unfavourable increase in triglycerides61'62. Premenopausal women have much
lower rates of CVD compared to age and risk matched males however this disparity
rapidly disappears after the menopause. Additional risk factors include hypertension,
hypercholesterolaemia, diabetes, smoking, lack of exercise and obesity and the effect
of these risk factors is multiplicative. In addition to increased oestrogen levels,
premenopausal women have been shown to have lower systolic and diastolic blood
pressures as well as lower pulse pressures and mean arterial pressures than men
during the fourth decade of life. By the age of 70 years these differences narrow and,
in some cases, reverse as shown in the Framingham Heart Study63.
Tamoxifen has oestrogenic and anti-oestrogenic properties. It is known to have an
overall favourable effect on serum lipoprotein levels and in meta-analyses has a
potential cardioprotective effect which reduced the rate of myocardial
infarction64,65'66'67'68, ft exerts oestrogenic effects on lipids and decreases LDL and
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increases HDL and triglycerides69. The mechanisms underpinning this effect remain
unclear60.
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1.5.3 Thromboembolic disease, coagulation and the effects of
oestrogen
Thromboembolic disease is a major cause of morbidity and mortality in patients with
cancer. Blood circulates around the body transporting blood cells, nutrients, gases,
water, metabolic products and chemical messengers between different organs.
Complex systems have evolved to maintain its continuity, which prevent excessive
bleeding by securing haemostasis, and also prevent obstruction to flow due to
thrombosis. Injury to the vessel wall firstly causes vasoconstriction and sets off
platelet activation, adhesion and aggregation thus forming a plug which arrests
haemorrhage. This is followed by activation of the coagulation cascade which results
in the formation of a fibrin network to secure the platelet plug shown in figure 1.10.
Extrinsic pathway Intrinsic pathway
The reactions of IXa/VIIla and Xa/Va (in the green and blue boxes) occur on the platelet surface.
The dotted lines represent positive feedback effects from small amounts of thrombin. This greatly
enhances the activity of the coagulation network and results in large amounts of thrombin generation
and thus fibrin formation in the clot.
Figure 1.10 Normal haemostatic mechanism: coagulation factors of the
intrinsic and extrinsic pathways42.
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The coagulation system consists of a series of soluble inactive zymogen proteins
which when proteolytically cleaved and activated, become capable of activating one
or more components of the cascade. Coagulation factors are synthesised in the liver
and are identified by Roman numerals, activated factors are given the suffix 'a'.
Factor V is also produced by platelets and endothelial cells. Two pathways of
activation have been identified, the intrinsic and extrinsic although the latter is the
main mechanism in vivo. Coagulation is initiated by the extrinsic (or tissue factor)
pathway and amplified by the intrinsic pathway. Tissue factor is a transmembrane
protein which is expressed during endothelial cell damage, which activates factor VII
to Vila. This in turn activates factor X—>Xa which forms a complex with factor V on
the surface of platelets which converts prothrombin—^thrombin. This in turn converts
fibrinogen—^fibrin, which polymerises and is cross-linked by factor XIII to form a
stable clot. Thrombin plays an important role in what is referred to as the 'final
common pathway', it activates factors XI, VIII, V and platelets in a positive
feedback loop. Von Willebrand factor (vWF) is a protein synthesised by endothelial
cells and megakaryocytes which is also involved with coagulation and platelet
function. It acts as a carrier protein to factor VIII and deficiencies cause lower
plasma factor VIII levels. It also enables platelets to adhere to damaged vessel walls
and reduced levels cause impaired platelet plug formation42.
To prevent over-activity of the coagulation cascade once haemostasis has been
secured, natural anticoagulants are present. These include tissue factor pathway
inhibitor (TFPI), antithrombin (AT), protein C and protein S. TFPI inactivates the
tissue factor-Vila complex and factor Xa whereas AT principally inhibits thrombin
(Ila) and factor Xa but also inactivates IXa and XIa. Protein C is a vitamin In¬
dependent factor which, when activated by thrombin along-with its co-factor protein
S, degrades and inactivates factor Va and Villa. A deficiency in the function of these
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natural inhibitors results in a tendency towards thrombus formation (prothrombotic
state).
Insoluble blood clots need to be broken down to allow vessel recanalization to occur.
This occurs secondary to fibrinolysis as shown in figure 1.11. It is primarily initiated
by tissue plasminogen activator (tPA), (released by the endothelium) and also by
urokinase (synthesised in the kidney). They convert inactive circulating plasminogen
to the active enzyme plasmin which hydrolyses the fibrin clot, producing fibrin
degradation products. Within thrombi, both tPA and plasminogen bind to cross-
linked fibrin resulting in the production of plasmin which lyses developing thrombi.
CmD
PAI - plasminogen activator inhibitor, tPA — tissue plasminogen activator
Figure 1.11 Fibrinolysis42
Excessive activity of tPA is prevented by plasminogen activator inhibitor (PAI)
which occurs in plasma. Further inhibitors of fibrinolysis include a2 antiplasmin and
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a2 macroglobulin which inactivate plasmin. A decreased fibrinolytic capacity is
associated with thrombotic disease42'70.
Thrombosis occurs when haemostasis proceeds 'unchecked' resulting in vascular
occlusion. Thrombi may 'break up' into smaller clots and lodge at distant points
within the circulation, known as emboli. In arteries thrombosis usually occurs from
rupture of an atheromatous plaque which initiates the formation of a platelet nidus on
which platelets adhere and aggregate. Predisposing risk factors for arterial
thrombosis are related to the development of atherosclerosis and include male sex,
positive family history, hyperlipidaemia, hypertension, diabetes mellitus and
smoking71. Venous thromboses are more common and are associated with Virchow's
triad which suggests that there are three components to thrombus formation:
disruption of venous endothelium, disruption in the pattern of blood flow and
changes in the blood constituents (hypercoagulability). Predisposing risks for venous
thrombosis include age >40years, obesity, varicose veins, previous deep vein
thrombosis (DVT), oral contraception, pregnancy, hormone replacement therapy
(HRT), dehydration, immobility and malignancy.
There are several inherited disorders which are associated with an increased risk of
thrombosis. These include factor V Leiden, prothrombin G20210A variant, protein C
deficiency, antithrombin deficiency, protein S deficiency and dysfibrinogenaemia.
Factor V Leiden is the most common of these disorders and affects 30% of
Caucasian factor V allelles. It is associated with failure of activated protein C (APC)
when added to plasma to prolong the activated partial thromboplastin time (APTT).
It makes factor V less susceptible to cleavage by APC and is called the 'factor V
Leiden mutation'. Heterozygous patients have an approximately 5-8 fold increased
risk of venous thrombosis compared with the general population whereas those who
are homozygous have a 30 - 140 fold risk71.
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The first association between malignancy and thrombosis was reported by Armand
Trousseau in 186572. Neoplastic cells are known to activate the coagulation cascade
resulting in a hypercoagulable state. Procoagulant mechanisms primarily involve
expression of haemostatic proteins on tumour cells, production of inflammatory
cytokines and adhesion of tumour cells to endothelium. Tissue factor plays a major
role in tumour progression, metastasis and angiogenesis through signaling via its
intracellular domain73.
Increased circulating oestrogen levels are also associated with an increased incidence
of thromboembolic events. This has been demonstrated in pregnancy, the puerperium
and in women taking oral contraception and HRT. Oestrogen is associated with an
increase in plasma levels of factors II, VII, VIII, IX and X and a decrease in levels of
anticoagulants AT and tPA in the vessel walls71. These changes result in an increased
tendency to thrombosis. Tamoxifen has oestrogenic effects on coagulation and is
associated with an increased risk of venous thromboembolic events including
pulmonary embolism and deep vein thrombosis74.
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1.6 The aetiology of breast cancer
The cause of most breast cancers remains largely unknown however hormonal
influences are widely acknowledged as playing a significant constitutional role.
There exist several demonstrable risk factors which play varying and sometimes
cumulative effects on a person's risk. These include genetic, hormonal,
environmental and nutritional influences with the most important risk being
attributed to gender, increasing age, lifetime oestrogen exposure and genetic
susceptibility.
The most important risk factor is gender: women are 135 times more likely to
develop breast cancer compared with males. Only 277 male cases were reported in
the UK in 2007. This represents <1% of the total number diagnosed3.
Age is also an important risk factor which is often overlooked. Half of a woman's
cumulative risk occurs after the age of 65 years75. The level of risk for younger
women is low and in the absence of other risk factors, a woman between the ages of
35 and 55 years has only a 2.5 % chance of developing breast cancer76. The
incidence doubles approximately every 10 years until the menopause, when the rate
of increase slows dramatically77.
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1.6.1 Genetic influences
Epidemiological data has suggested that there is a genetic contribution to the
development of breast cancer with certain families having multiple members
affected. A family history of breast cancer in a first-degree relative (mother or sister)
is associated with a 1.7 increased chance of developing breast cancer. If the relative
affected is pre-menopausal there is a three-fold increased risk and if they are
postmenopausal the risk is 1.5 fold. Those with a history of bilateral cancers in a
first-degree relative are 5 times more likely to develop the disease and if the history
includes bilateral cancers in a premenopausal woman then the risk increases further
to 9 times. An increasing risk is associated with the larger the number of relatives
affected and the closer their genetic relationship78'79. Notwithstanding this, most
cancers are sporadic and although many patients have a positive family history, this
is more likely to be due to the frequent incidence of breast cancer rather than an
underlying genetic predisposition which affects <10%.
Several genes are now known to be involved with the development of breast cancer
and include BRCA1, BRCA2, p52, PTEN, ATM and CHEK2. The commonest
causative genes are BRCA 1 and 2 although these mutations remain rare. Both are
inherited in an autosomal dominant pattern and are therefore passed through the
generations via the mother or the father. BRCA1 is located on chromosome 17 and
gene carriers are at risk of developing other malignancies including ovarian and
prostate cancer. Women with this mutation have between 56-86% chance of
developing breast cancer and between 15-45% chance of developing ovarian cancer.
The BRCA2 gene is located on chromosome 13 and carriers have a similar chance of
developing breast cancer compared with BRCA1 carriage. BRCA2 is associated with
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an increased risk of developing ovarian, pancreatic, and prostate cancers and
melanoma. The Ashkenazi Jewish population are frequent carriers of this mutation.
Li-Fraumeni syndrome is associated with premenopausal breast cancer and other
tumours which often appear in childhood. It is rare and is associated with a germline
mutation in the p53 gene on chromosome 17.
Women who are heterozygous for mutations in the ATM gene are at increased risk of
developing breast cancer, as are those with germline mutations in the PTEN gene
located on chromosome 10 which causes Cowden's syndrome and is associated with
a lifetime risk of developing breast cancer between 25-50%. Other rare genetic
disorders associated with the development of breast cancer include Peutz-Jeghers
syndrome and ataxia telangiectasia9.
Breast cancers are polygenic in nature. In addition to the high and moderate risk
genes previously mentioned, there are many other susceptibility alleles associated
with lower risk which were discovered by genome wide association studies. The
majority of familial breast cancer risk appears to be associated with a combination of
multiple lower penetrance alleles. These alleles include single nucleotide
polymorphisms (SNPs) in five novel genes including TNRC9, FGFR2, MAP3K1,
H19 and lymphocyte-specific protein 1 (LSP1). The effects of the loci appear to
combine multiplicatively. The most strongly associated SNP is intron 2 of the
FGFR2 gene, a tyrosine kinase receptor, which is amplified and overexpressed in 5-
10% of breast cancers. The odds ratio for this allele is estimated to be 1.26. Several
of the loci appear to be associated with specific subtypes of breast cancer e.g. the
FGFR2 locus is strongly associated with ER positivity. The SNP rs3803662 of the
TNRC9 gene appears to be correlated with bone metastases and also ER positivity.
The discovery of breast cancer susceptibility loci has led to an improved
66
understanding of the pathogenesis for breast cancer and may in turn lead to improved
diagnostics and treatments in the future80'81.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) implemented
the P-l Breast Cancer Prevention Trial (appendix F) in 1992 to assess the value of
using tamoxifen for the prevention of breast cancer in 13,388 women at increased
risk. Results demonstrated that tamoxifen reduced the risk of invasive breast cancer
by 49% (pO.OOOOl). It reduced the occurrence of ER+ve tumours by 69%, but
showed no difference in the occurrence of oestrogen receptor negative (ER-ve)
82
tumours .
Women in the UK deemed likely to have an underlying genetic predisposition to
developing breast cancer are referred for genetics counselling and testing.
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1.6.2 Hormonal influences
There is a large amount of evidence linking oestrogen with breast development and
subsequent tumourogenesis. This is demonstrated by the complete failure of breast
development in the absence of ovarian function83. Mice studies have confirmed that
if the gene for the oestrogen receptor alpha is knocked out, no further breast tissue
development occurs and breast cancer development does not occur, even with the
addition of oestradiol therapy84.
The risk of postmenopausal breast cancer increases with higher levels of oestrogen
levels. This association is stronger for hormone receptor positive cancers. Oestradiol
is considered the most biologically active endogenous oestrogen and circulates
'unbound' or 'bound' to sex hormone-binding globulin or albumin. Unbound
oestradiol or that bound weakly to albumin may be more closely associated with an
increased risk of breast cancer because it is more readily available to breast tissue as
it crosses the plasma membrane of target cells more easily6. Adipose tissue is a major
source of oestrogen and obese women subsequently have higher levels of
endogenous oestrogen and an increased risk of developing breast cancer.
Early age at menarche has been consistently associated with an increased risk of
developing breast cancer. Studies suggest that this risk is more closely associated
with the development of premenopausal breast cancer. Each year of delay in
menarche is associated with a 9% reduction in the development of premenopausal
breast cancers and a 4% reduction in postmenopausal breast cancers. The cause of
this risk remains to be ascertained however it may be due to lifelong exposure to
endogenous hormones or due to the cyclic levels of ovarian hormones.
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Shorter menstrual cycles have been associated with a greater risk of breast cancer.
This may be explained by an associated increase in the overall number of menstrual
cycles.
An early menopause or bilateral oophorectomy at a young age is associated with
reduced risk of breast cancer due to decreased endogenous hormone levels and
decreased breast cell divisions. Overall there is a marked fall in the incidence of
breast cancer in women treated with ovarian ablation or anti-oestrogen therapy82.
Parity is inversely associated with the risk of breast cancer with nulliparous women
being at increased risk. Nonetheless, epidemiological evidence consistently indicates
that risk is also increased during the first decade after first pregnancy. A younger age
at full term pregnancy is associated with a lower lifetime risk of breast cancer. This
risk reduction takes approximately 10-15 years to become evident and is not seen
before the age of forty. The first pregnancy is associated with differentiation and
permanent changes in breast glandular epithelium. The later the first pregnancy, the
more likely mistakes in DNA have been made which may be propagated during the
cell proliferation of pregnancy. Each subsequent birth decreases breast cancer risk,
probably because of changes in breast morphology. In addition, there is evidence
demonstrating that a short time between each pregnancy reduces risk.
Induced abortion has previously been associated with an increased risk of breast
cancer in case-control studies however the Nurses' Health Study studied 105,716
women between 1993 and 2003 and concluded that neither spontaneous nor induced
abortion is associated with an increased risk of breast cancer85.
Breastfeeding has been shown to induce a protective effect against breast cancer as it
delays the recurrence of the menstrual cycle. This has been shown by the observation
between breastfeeding duration and the delayed return of ovulation during the
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postpartum period. Suppression of ovarian function has been shown to be associated
with a reduced risk of breast cancer compared with normally cycling women.
Epidemiological evidence has been inconsistent however a meta-analysis of 40
studies performed in 2000 suggested a small but significant protective effect of
breast feeding on the risk of breast cancer in non-menopausal women86. Other studies
have indicated that there is a 4% overall risk reduction for every year of breast
feeding42.
The relationship between HRT and breast cancer has been extensively studied over
the last thirty years. Randomised controlled trials have confirmed the relationship
between HRT and an increased risk of breast cancer. Risk is greater for women
taking HRT for more than five years and for those who used oestrogen and progestin
hormone combinations. Results from the Women Health Initiative Survey and
Million Women Study (appendix F) demonstrated a significantly increased incidence
of breast cancer in users of HRT. The magnitude of risk was substantially greater for
oestrogen-progestagen than for other types of HRT32,37. The Breast Cancer
Demonstration Project concluded that the risk of breast cancer increased by
approximately 1% for every year that women were administered oestrogen alone and
about 8% for every year that they took oestrogen plus progestin87. Once either type
ofHRT treatment is stopped, the risk of breast cancer falls88. Published results show
that since 2003 there has been a decrease in the incidence of breast cancer observed
in the Flemish region of Belgium which has been attributed to a fall in the
OQ t
consumption of HRT . HRT has now been classed as a group 1 carcinogen to
humans by the International Agency for Research on Cancer32'37'8' °.
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1.6.3 Environmental factors
A high versus low level of physical activity has consistently been associated with a
20-40% reduction in the risk of postmenopausal breast cancer91. Proposed
mechanisms by which physical activity may act on breast tumour development
include reducing the levels of endogenous sex hormones92, boosting the immune
system, modulating insulin and insulin-like growth factors and lowering levels of
chronic inflammation93. A recent study of 118,899 women demonstrated that >7
hours per week of moderate-to vigorous exercise within the last ten years was
associated with a 16% reduced risk of postmenopausal breast cancer94.
There is a positive association between alcohol consumption and breast cancer.
Alcohol is metabolised by the enzyme alcohol dehydrogenase into acetaldehyde, a
known carcinogen95. One large study concluded that recent consumption of three or
more alcoholic drinks per day is associated with a relative risk of 2.296. Alcohol
ingestion has been shown to directly increase plasma oestradiol levels in
postmenopausal women which may account for these findings97.
Case-controlled and prospective cohort studies have linked night shift work with
breast cancer risk. Melatonin, a hormone produced primarily by the pineal gland, has
anti-neoplastic properties including an ability to modulate the immune system with
antioxidant, antimitotic and antiangiogenic effects98. Melatonin secretion is regulated
by the hypothalamus, which receives environmental light signals from the retina via
the retino-hypothalamic tract. Artificial light alters the natural release of melatonin,
with the highest levels of melatonin physiologically occurring during the dark night
phase and relatively low levels throughout the day99. Melatonin may block the
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oestrogen receptor ERa and affect the enzyme aromatase, which produces oestradiol.
Epidemiological studies have shown that night workers have lower nightly melatonin
levels. Evidence supporting the association between sleep duration and melatonin
production is less clear. Night shift work is likely to become a recognised potential
go
public health hazard in the future .
Moderate to high-dose ionising radiation exposure is known to increase the risk
breast cancer. Radiation causes DNA damage by interacting directly with DNA
molecules and via the production of reaction oxygen species that form as a by¬
product of water radiolysis. A recent study of 2,882 women demonstrated that low-
dose radiation exposure also increases the risk of breast cancer. Women who
reported having multiple chest X-rays, 7 or more mammograms and those who had
dental X-rays without lead protection before the age of 20 years were at increased
risk with an odds ratio of 1.8100.
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1.6.4 Other risk factors for breast cancer
Increased mammographic breast density is strongly associated with an increased risk
of breast cancer. A recent meta-analysis demonstrated that the relative risk for
women with high breast density ranged from 3.25 - 6.49'01. This has led to the use of
breast density as a biomarker for breast cancer risk102. Breast density is correlated
with HRT use103 so breast density may reflect a more oestrogenic environment. It is
well established that increased breast density may result in cancers being masked on
screening mammograms and it is therefore important that this group are considered
for alternative imaging techniques which may result in earlier diagnosis.
The positive relationship between atypical hyperplasia (AH) and breast cancer is well
established. AH encompasses both atypical ductal hyperplasia and atypical lobular
hyperplasia. Normal breast tissue expresses relatively small amounts of ER on cells
yet AH has an abundance of ER. In fact ER increases during the progression from
normal to cancerous cells. In the prevention studies, tamoxifen produced a huge
reduction in progression from AH to cancer82 so ER is important in the process.
Atypical lobular hyperplasia is associated with the greatest increase in risk. The odds
ratio for the development of breast cancer with AH is 4.1l04. Women with both
proliferative breast disease and calcification have an estimated 69% increased risk
compared with those without either and women without proliferative disease have no
elevation in breast cancer risk compared with women of similar age105.
In the USA breast cancer is most likely to affect the left breast. There is on average
more breast tissue within the left breast however this has not been shown to be the
aetiology of the laterality106. Other studies have demonstrated similar results and
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many explanations for this have been hypothesised however to date there is no
supporting evidence demonstrating a cause106'107.
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1.7 Tumourogenesis
The majority of breast cancers arise within the TDLU. Tumourogenesis is thought to
occur as a result of highly diverse, multiple genetic changes which appear to develop
from pre-existing benign lesions. It involves a spectrum of changes which occur over
a long period of time. These include the progression from normal breast epithelium
to benign proliferative lesions to atypical proliferative lesions and then to carcinoma
in situ and finally invasive neoplasms108. The expression of ER increases with this
slow progression.
Of the many different types of benign breast conditions, only a few have significant
premalignant potential. The most recognised include atypical hyperplasias and
carcinomas in situ. Prognosis of pre-malignant conditions has been estimated from
epidemiological studies which have shown that women with a history ofAHs and in
situ carcinomas have approximately 5-10 increased relative risk of developing
invasive disease. Future therapies may have the potential to target specific genetic
10R
defects thus preventing the development of invasive disease .
1.7.1 Pre-invasive cancer
There are two main categories of non-invasive cancer which are distinguished by
their cell types and histological patterns. Ductal carcinoma in-situ (DCIS) is the
commonest and lobular carcinoma in-situ (LC1S) is comparatively rare.
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1.7.2 Microinvasion
Microinvasion is defined as an invasive carcinoma with no focus measuring >lmm.
It is usually found in DCIS or less often LCIS where small foci of tumour cells
invade through the basement membrane into surrounding stroma. It is associated
with a good prognosis although the impact of multifocal microinvasive disease
remains to be determined1.
1.7.3 Invasive breast cancer
Infiltrating ductal cancer accounts for the majority (85%) of invasive cancers
whereas lobular tumours account for the remainder. Tumour cells arise within the
TDLU and invade through the basement membrane into surrounding tissue including
lymphatics and blood vessels. The commonest histological type is invasive ductal
carcinoma of no special type (NST) however many others exist including tubular,
cribriform, mucinous and papillary as shown in table 1.4. Most of these special types
express a greater amount of ER and are associated with a much better prognosis
compared with NST tumours. In contrast, tumour types that are aggressive such as
basal cancers and HER 2*+ve cancers are often ER -ve. Rare cancers include adenoid
cystic carcinoma, adenomyoepithelioma and squamous carcinomas109.
*
HER2 (human epidermal growth factor 2 also known as ErbB-2) is a transmembrane growth factor
receptor which is expressed in 20% of breast cancers. Breast cancer patients who overexpress HER2
can be treated with the humanised murine monoclonal antibody Transtuzumab which has antitumour
activity against cells which overexpress HER2.
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Table 1.4 Histopathological types of breast cancer
1.7.3.1 Tumour grade
All invasive breast carcinomas are graded excluding medullary carcinomas. The
Nottingham combined histologic grade is currently recommended. It is the result of
the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system. Grade
is determined by assessing morphological features including tubule formation,
nuclear pleomorphism and mitotic count109 and is correlated with ER. Grades of 1
(favourable) to 3 (unfavourable) are determined for each feature and are then added
together. The resulting combined score of 3-5 is designated grade 1, 6-7 is designated
grade 2 and 8-9 is designated grade 3109.
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1.7.3.2 Metastatic disease
Tumour cells spread via direct infiltration into breast parenchyma, along mammary
ducts, via tumour emboli to lymphatics and through blood to distal sites. Small
deposits of metastatic disease are known as micrometastases and are defined as
measuring between 0.2mm and 2mm in size.
Approximately 95% of lymph from the breast drains to the axilla. Axillary lymph
node involvement is considered to be the single most prognostic indicator in breast
cancer and survival is correlated directly with the number and level of axillary lymph
nodes involved. Cancerous cells may also metastasis to the internal mammary lymph
nodes but it is uncommon for these to be involved in isolation.
Metastases are often present in women prior to initial diagnosis and treatment. This
is demonstrated by the necessity of neoadjuvant and adjuvant systemic therapies
compared with tumour excision alone. Bone is the commonest site of first distant
relapse in all reported series and affects % of patients with secondary breast cancer.
Other sites commonly affected include lung, liver and brain however multiple other
sites may be involved. Solitary first relapses to the liver are relatively rare although
liver metastases have been reported in >50% of patients who have died of breast
cancer following post-mortem examination.
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1.8 The role of hormones and hormone receptors in breast
cancer
The majority of breast cancers are dependent upon oestrogen and progesterone for
their growth. Oestrogen is the major inducement driving the growth of hormone-
dependent breast cancer and endocrine therapy is therefore directed towards
inhibiting or reducing oestrogen activity.
Changes in breast morphology and physiology are mediated through binding of sex
hormones to either intracellular steroid receptors or membrane-bound peptide
receptors. Oestrogen and progesterone mediate effects on their target sites via
oestrogen receptors (ER) and progesterone receptors (PgR) respectively, both are
steroid receptors located in the cell nucleus. They have been demonstrated in
approximately 15-25% of normal breast epithelium and are expressed in varying
levels throughout the menstrual cycle. Oestrogen promotes the growth and survival
of normal and cancerous breast epithelial cells by binding and activating the ER.
Both ER and PgR function as transcription factors when they are bound to their
respective ligands6. The activated receptor in turn binds to gene promoters in the
nucleus and activates many other genes responsible for cell division, inhibition of
cell death, new blood vessel formation and protease activity. There is an increase in
the proportion of cells that express ER found at both the earliest stages of pre¬
cancerous changes and in approximately 70% of cancers110.
The expression of ER is inversely correlated with tumour proliferation rates and
cancers expressing ER and PgR are more likely to be well differentiated and have
lower degrees of proliferation and hence an overall better prognosis.
Initially it was accepted that there was a solitary ER responsible for the effects of
oestrogen and its antagonists. In the mid 1990s two distinct and functional ER
proteins were identified, ERa and ERp. Both have been extensively studied and are
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now collectively called ER. The amount of ERa is of paramount importance in terms
of response to endocrine therapy and subsequent prognosis. ER0 was initially
identified from the cDNA of rat prostate and there have now been several isoforms
cloned. Similarly, two progesterone receptors have been located which are known as
PgR-A and PgR-B, collectively known as PgR.
There is a bimodal distribution of ER with tumours being either predominantly ER
negative or strongly positive as shown in figure 1.12. A relatively small number
show intermediate values111.
% ER- Positive Tumour Cells
Figure 1.12 Frequency distribution of the percentage of cells showing
nuclear staining for oestrogen receptor among 825 primary breast cancers1
Numerous assay methods have been available to measure ER and PgR levels. Early
studies used multipoint titration analysis using dextran-coated charcoal and sucrose
density gradient centrifugation. These methods were replaced in the 1990s with
immunohistochemistry assays which are more specific, reliable and are
commercially available. They are based on ligand binding methods and the
recognition of the receptor protein by specific antibodies. The optimal method to use
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is controversial however most pathology laboratories use the manual scoring Allred
system or histo score (H score). The semiquantitative Allred scale consists of a
proportion score which represents the estimated proportion of positively stained
tumour cells (scores ranging from 0 to 5), and an intensity
score which represents the average intensity of positive tumour cells (scores
ranging from 0 to 3). The proportion and intensity scores are added to obtain a total
score resulting in overall scores of 0 or 2 through to 8 as shown in figure 1.131 .A
score between 3 and 8 is considered ER positive.
The H-score is calculated by multiplying the frequency of positivity and the intensity
of staining.
It has been demonstrated that any benefit gained from treatment is directly
in
proportional to the quantity ofER present as shown in table 1.14.
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Figure 1.13 Schematic depicting Allred Score112
Proportion Score (PS) range 0 to 5, Intensity Score (IS) range 0 to 3
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ER score Clinical responses expected
0 Endocrine treatment will not work
2-3 Associated with a small (20%) chance of response
4-6 Associated with -50% chance of response
7-8 Associated with a high (75%) chance of response
Table 1.14 Oestrogen receptor scores and related clinical responses
Endocrine treatment is also deemed worthwhile in patients with low oestrogen
receptor but high progesterone receptor values114, although such a receptor profile is
rare.
The dominant oestrogen in ER/PgR positive breast cancers is oestradiol. Plasma
oestrogen levels can be measured using sensitive assays however the extent to which
they reflect absolute tissue oestrogen levels is more complicated to assess. Tissue
samples from postmenopausal women with ER+ve tumours have shown that the
concentration of oestradiol in the tumour is about 10 fold the concentration measured
in plasma. Oestrone sulphate levels within breast cancer tissue have been shown to
be much lower compared with plasma oestrone sulphate levels115.
Despite the fall in plasma oestrogen levels at the time of the menopause,
postmenopausal breast tissue has the ability to maintain local concentrations of
oestrone and oestradiol at levels that are 2-10 and 10-20 fold higher, respectively
than corresponding plasma levels1 6'117' 1 '119. High levels of intratumoural aromatase
and the uptake of oestrogens from the circulation and or in situ oestrogen synthesis
by intratumoural aromatase may account for this120.
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There is substantial evidence demonstrating the risk of breast cancer increases with
prolonged exposure to oestrogen. Early evidence of the importance of lowering
oestrogen levels in breast cancer arose from the observation that a number of patients
who developed progression following castration achieved a further response to the
suppression of plasma oestrogen following adrenalectomy121'122. Nowadays
clinicians target endocrine treatment at those women with breast cancer who are
likely to respond i.e. those whose tumours express ER and PgR receptors. This is
accomplished by measuring the quantity of these steroid hormone receptors present
within tumours. Endocrine therapies target the ER signalling pathway either by
strategies which act on the receptor or by approaches which deprive the receptor of
oestrogen. Adjuvant endocrine therapy is effective only in patients who have ER +/-
PgR positive breast cancer. ER is the best predictor of tamoxifen benefit123 and large
studies have confirmed that both ER and PgR are important predictors of the benefits
of endocrine therapy. The incidence of response to hormone therapy increases with
increasing ER levels and those found to be ER, PgR negative respond rarely if at all
to hormonal manipulation. Approximately two thirds of all patients with breast
cancer have cancers which are ER+ve114,120 and can therefore be treated using
oestrogen suppression. The levels of ER expression vary between patients and
change throughout the course of the disease and also in response to endocrine
therapies. ERs are present more often in tumours of postmenopausal women
compared with those of premenopausal women and are contained within 90% of
male breast carcinomas. PgR is present in 45% to 60% of primary or metastatic
breast tumours.
ER and PgR should therefore be assessed in all tumour specimens as they correlate
with the response of systemic endocrine therapy. The absence of oestrogen and
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progesterone receptors and the overexpression of HER2 are related to a worse
prognosis. Paradoxically, it is important to note that not all ER +ve cancers will
respond to endocrine therapy. It is becoming increasingly clear that ER positivity is a
good prognostic marker whereas PgR positivity may be a marker of a more
aggressive tumour type6. The absence of ER in a breast tumour correlates well with
an increased response to cytotoxic chemotherapy.
There are large-scale molecular differences between ER+ve and ER-ve breast
cancers124. Research into the biology of the ER and resistance mechanisms are of
considerable interest as these results may hold the key to future therapies targeting
resistance and therefore improving outcomes. Despite the successes of endocrine
treatment, there are many patients who develop de novo or acquired resistance and
subsequently die.
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1.9 The enzyme aromatase
In postmenopausal women, aromatase is the key enzyme that catalyses oestrogen
synthesis by converting androstenedione to oestrone and testosterone to oestradiol.
Circulating androgens, mainly androstenedione, are secreted by the adrenal gland
and, to a minor extent, probably the postmenopausal ovary125'126. They are
synthesised from cholesterol via a number of different transformations as previously
shown in figure 1.5. The last step is catalysed by the action of the aromatase enzyme
(product of CYP19 gene). After the menopause, aromatase is present in peripheral
tissues including adipose tissue, liver, muscle, skin, brain and breast tumours. It is
also identified in the epithelial and stromal components of breast tissue. Breast
cancers may be able to produce hormones or growth factors which can modulate the
local environment to support tumours. The majority of post-menopausal breast
cancers express significant levels of ERa, the nuclear transcription factor that is
activated by oestrogen binding and will respond to endocrine treatment19.
The human aromatase gene (CYP19; P450arom) is expressed in many
postmenopausal tissues and is comprised of a 30-kb coding region containing nine
exons and a 93-kb regulatory region containing 10 untranslated exons. The large
regulatory region contains ten tissue-specific promotors that are alternatively used in
various cell types. Each individual promotor is controlled by regulatory sequences in
197
the DNA and transcription factors that bind to these specific sequences . Promoters
II, 1.3 and 1.7 are particularly active in breast cancer128. These regions are promoted
by various growth factors and interleukins known to be synthesised in breast
tumours, probably contributing to the high local oestrogen concentrations. Tissue
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oestrogen concentrations appear to be much higher in tumours of ER+ve women
compared with those who are ER-ve.
Circulating oestrogens are thought to arise from passive diffusion, leakage from
tissue following metabolism and excretion by the liver and kidney, respectively129.
The use of tracer techniques to measure the total amount of body aromatisation is an
estimation of the amount of oestrogen produced in the peripheral tissues and can
therefore be used as a surrogate marker. There is marked variation in tissue oestrogen
levels between postmenopausal breast tumours and this is most likely to be due to the
different degrees of expression of the aromatase enzyme. Additionally, differences
may also be secondary to local oestrogen metabolism.
In postmenopausal breast cancer the intratumoural concentrations of 17B-oestradiol
are much higher than that in the plasma due to high levels of tumour aromatase
production and a combination of tumour synthesis and selective uptake from the
plasma. The amount of ER expressed in the physiological state is higher in those
with breast cancer. Inhibiting aromatase reduces circulating oestrogen levels and
inhibits local synthesis. Studies have shown that tissue oestrogen levels in breast
cancer tissue are significantly decreased after the introduction of the third generation
aromatase inhibitors, anastrozole130 and letrozole131.
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1.10 The management of breast cancer
1.10.1 Diagnosis
Patients with breast cancer may present with a range of symptoms for example, a
palpable lump(s), asymmetrical nodularity, inflammatory changes, pain, nipple
discharge and changes in breast or nipple skin or contour. Less commonly they
present with symptoms of metastatic disease including abdominal pain, bone pain
and spinal cord compression. In the UK patients are commonly referred to specialist
breast centres and it is widely recognised that those treated at larger units with
dedicated specialists working as part of a multidisciplinary team have the best
outcomes132. It is recommended that patients attending breast clinics should receive
all necessary investigations and be informed of the results in a single clinic visit i.e.
'one stop'.
A thorough history is obtained prior to 'triple assessment' which includes clinical
examination, imaging and biopsy to aid diagnosis. Clinical examination includes
identifying the location and size of any lump or abnormality and determining if there
is evidence of involvement of adjacent tissues including skin and muscle. The
axillae, supraclavicular fossae and neck are palpated to detect possible lymph node
metastases however the correlation between clinical examination and lymph node
involvement is <50%133. Any signs ofmetastatic disease are sought.
Imaging includes breast ultrasound in patients under the age of 35 years and
mammography in those over the age of 35 years. Ultrasound is also used to guide
core biopsies in those lumps/opacities which are impalpable, small or difficult to
localise. Core biopsy is used to assess malignancy and remains the current standard
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of care for evaluating breast lumps. It provides a higher level of specificity when
compared with fine needle aspiration cytology (FNAC), (92% and 88% respectively)
as it provides more tissue and histologic architecture to better classify pathological
types but takes longer to process. It also results in higher positive predictive values of
suspicious lesions (100% and 78% respectively) and atypia (80% and 18%
respectively)134. Biopsies are obtained using a size 14 gauge disposable core biopsy
instrument which yields on average lOOmg tissue per core. Multiple biopsies are
obtained where possible and subsequently placed in 4% buffered formalin to allow
histological examination. The results are usually available within a few days and
provide information on tumour type and grade (degree of differentiation), ER and
PgR positivity, HER2 status, the presence of lymphatic or vascular invasion and if
there is in situ cancer present.
Several pre-operative investigations are routinely performed after diagnosis. They
assess the patient's overall fitness for treatment and facilitate staging. They include
blood tests (full blood count, urea and electrolytes, liver function tests, calcium), a
chest x-ray and electrocardiogram. Other investigations may be performed if there is
a clinical suspicion of metastatic disease e.g. liver ultrasound and bone isotope scan.
The results of all diagnostic procedures should be discussed with a multi-disciplinary
team to facilitate the most appropriate management plan.
Nowadays an increasing number of breast cancers are being identified by routine
screening mammography. Breast screening is targeted at women at risk e.g. those >
50 years of age and those in high risk groups e.g. younger women with a significant
genetic predisposition. The aim is to reduce morbidity and mortality by detecting
disease at an early stage and treating it before metastases have a chance to occur. At
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present, mammography is routinely used for screening however magnetic resonance
imaging (MRI) is used in younger high risk women, particularly those who carry the
BRCA1 gene135 and also when imaging women with breast implants.
In the UK, women are routinely invited to attend mammography every three years
between the ages of 50 to 70 inclusive. Those at higher risk may attend more
frequently and at a younger age. Two mammographic views are obtained:
craniocaudal and mediolateral oblique. Double reading of mammograms improves
the overall sensitivity. Studies have shown that screening can significantly reduce
absolute mortality from breast cancer by up to 40% in those who attend. Drawbacks
include anxiety associated with attendance and potential recall although only a small
number of women recalled for biopsy are found not to have cancer136. The risk of
radiation induced breast cancer following mammography is small with one extra
cancer per year after ten years in women receiving a single mammogram137.
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1.10.2 Prognosis
Prognostic factors put individual patients into risk categories and indicate the likely
future behaviour of the disease although this is not absolute. They are useful in
guiding therapeutic decisions. The most powerful prognostic factors include the
presence of disease spread or 'stage' at presentation and on the aggressiveness of the
tumour. The most widely used prognostic index in the UK is the Nottingham
Prognostic Index (NPI) which is based on three factors using the following formula:
NPI = pathological tumour size (cm) x 0.2 + lymph node stage (1,2,3) + histological
grade (1,2,3)
Patients are divided into six prognostic groups depending on their overall score as
depicted in table 1.5.
NPI Prognostic groups
<2.4 Excellent prognostic group
2.5-3.4 Good prognostic group
3.5-4.4 Moderate I prognostic group
4.5-5.4 Moderate II prognostic group
5.5-6.4 Poor prognostic group
>6.4 Very poor prognostic group
Table 1.5 Nottingham Prognostic Index
Several other factors are taken into consideration when assessing prognosis
including: age at diagnosis with younger women being associated with a poorer
prognosis; hormone receptor positivity; and HER2 status.
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Other tools used to assess prognosis include Adjuvant! Online
(www.adjuvantonline.org) which is a simple-to-use computer program designed to
produce prognostic estimates of outcome with and without therapy, based on the
estimates of individual patient prognosis. It is aimed at patients with early breast
cancer who are considering chemotherapy, hormonal therapy or both after surgery
and estimates the cancer related mortality, the reduction in risk afforded by therapy,
and the risks of side effects of the therapies138.
The Oncotype Dx breast cancer assay is a validated commercially available
multigene expression test which predicts the likelihood of chemotherapy benefit as
well as recurrence in early stage breast cancer. It is a RT-PCR assay which measures
the expression of 21 genes and is intended to be used by women with early stage,
node negative, ER positive invasive breast cancer who will be treated with
tamoxifen. It is included in the American Society of Clinical Oncology (ASCO) 2007
and the National Comprehensive Cancer Network (NCCN) guidelines as an option to
identify patients who are predicted to obtain the most therapeutic benefit from
adjuvant tamoxifen and may not require adjuvant chemotherapy139.
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1.10.3 Staging
When breast cancer is diagnosed, the extent of disease should be assessed and the
tumour staged. Staging is determined using information related to the tumour (T),
regional nodes (N) and metastases (M) whereby cases with similar prognosis are
grouped together. The TNM staging system for breast carcinoma was developed in
1959. During this era it reflected the risk of distant recurrence and death subsequent
to local therapy which included radical mastectomy and adjuvant radiation to the
chest wall. At this time there was no effective systemic therapy and the system
provided prognosis for those with newly diagnosed cancer. Its main use was to
preclude ineffectual therapies for patients who were going to die rapidly despite
aggressive treatments which would certainly impede their quality of life1.
Staging may be 'clinical' or pre-surgery and 'pathological' or postsurgical. The
system can be applied to both invasive and in situ carcinomas. The complete TNM
staging system depicted in table 1.6 is determined using information sought prior to
neoadjuvant therapy or surgery. Pathological staging is determined using information
identified following surgery and is depicted using 'p'. Post-therapy pathologic
staging is described using 'yp'. The system is updated annually by the American
Joint Committee on Cancer (AJCC) to reflect any advances in technology and or
clinical advance.
The TNM classification permits scientists and clinicians to communicate with one
another using a common 'language'. It also holds some value in determining future
outcome although other variables including hormone receptor and HER2 status and
the availability of multigene expression assays should be taken into account.
Additionally, the TNM system can be used to differentiate between prognostic
groups by assigning patients into stages from 0 - IV as depicted by the International
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Union Against Cancer (UICC) system shown in table 1.7 The stages correlate with
outcome e.g. increasing tumour size and the presence of lymph node involvement
have a negative impact on prognosis.
Neither the TNM nor UICC classifications are well suited to breast cancer as the





Tx Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis In situ disease only (DCIS, LCIS and Paget's disease ofthe nipple with no invasive cancer)
T1 < 2cm
Tlmic < 0.1cm
Tla > 0.1 -0.5cm
Tib > 0.5 - 1cm
Tic > 1 - 2cm
T2 >2 - 5cm
T3 > 5cm
T4 Any size of tumour with involvement of chest wall or skin
T4a Direct extension into chest wall
T4b Direct extension into skin, with oedema, ulceration or nodules
T4c Both chest wall and skin involvement
T4d Inflammatory breast cancer
N stage
Nx Lymph node status has not been assessed
NO No regional lymph node metastases
N1 Mobile axillary lymphadenopathy
pNlmi Micro-metastasis, > 0.2mm <2mm
pNla 1-3 positive axillary nodes
pNlb Internal mammary nodes with micro-metastasis
pNlc 1-3 positive axillary nodes and internal mammary micro-metastasis
N2a Fixed axillary lymph nodes
pN2a 4-9 positive axillary lymph nodes
N2b Internal mammary nodes clinically apparent
pN2b Internal mammary nodes positive, clinically apparent, negative axillary nodes
N3a Infraclavicular lymphadenopathy
pN3a > 10 positive axillary nodes or positive infraclavicular node
N3b Internal mammary and axillary lymphadenopathy
pN3b Positive axillary and internal mammary nodes
N3c Supraclavicular lymphadenopathy
pN3c Supraclavicular node positive
M stage
MO No evidence of metastasis
Ml Evidence of distant metastasis
DCIS - ductal carcinoma in situ, LCIS - locular carcinoma in situ.
Table 1.6 Classification of breast cancer using the TNM Staging (2009)77
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Prognostic Groups 10 year
survival
Stage 0 Tis NO MO >95%
Stage IA T1 NO MO 75-95%
Stage IB TO Nlmi MO 75-95
T1 Nlmi MO
Stage IIA TO N1 MO 45-85%
T1 N1 MO
T2 NO MO
Stage IIB T2 N1 MO 40-80%
T3 NO MO





StagelHB T4 NO MO 0-35%
T4 N1 MO
T4 N2 MO
Stage IIIC Any T N3 MO 0-30%
Stage IV Any T Any N Ml <5%
Mi = micrometastases




Surgery is determined by tumour size and margins, location and multicentricity.
Patients with early breast cancer require complete removal of the primary tumour by
either wide local excision or mastectomy. The original mastectomy performed by
Halsted until the latter half of last century has been replaced by more conservative
surgery. Wide local excision is now the most common operation performed for those
with early breast cancer and involves the removal of the tumour mass with a
surrounding margin of normal tissue (0.5-lcm). This is combined with breast
irradiation for the majority of those with Tl-2 tumours.
Breast reconstruction is discussed with patients requiring mastectomy.
Reconstruction can be performed at the time of surgery or at a later date. Latissimus
dorsi and transverse rectus abdominus myocutaneous flaps are used for
reconstruction often in combination with a silicone implant or tissue expander.
Breast lymphatic drainage is of paramount clinical significance as it is the most
common site of local metastases. For surgical purposes, the axilla can be divided into
three levels depending on their relationship with the pectoralis minor muscle. Level I
contain the majority of nodes and, by definition, lies below and lateral to the
inferolateral border of the pectoralis minor muscle. Level II contains 4 or 5 nodes
and is located posterior to the pectoralis minor muscle. There are usually only 2-3
modes located in level III which lie superior to the upper border of the pectoralis
minor. Tumour metastasises to the axilla in a progressive manner from levels I to III.
Axillary surgery may involve axillary clearance or more commonly sentinel lymph
node biopsy. The advantage of the former is that it obviates the need for adjuvant
radiotherapy however associated morbidity includes arm stiffness, pain,
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lymphoedema and potential effects on quality of life. Sampling involves taking a
minimum of four nodes from the lower axilla. If these are positive for tumour,
patients require axillary radiotherapy or less commonly axillary surgical clearance.
The technique of sentinel lymph node biopsy assumes that breast cancer spreads in a
progressive manner from level I - III nodes. It involves identifying the first node
which drains the tumour. This is usually obtained using a combination of blue dye
which is infiltrated around the nipple area and also the injection of radiolabeled
colloid injection around the nipple. A small incision is made over the axillary
hairline and the first blue node or one with a radioactivity count >10 times greater
than the background level is excised.
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1.10.5 Early breast cancer
Early breast cancer is defined as disease which can be removed by surgery, i.e. Tl-3,
N0-1, MO tumours. Local treatment is used to control local disease and involves
breast conserving surgery/mastectomy and radiotherapy. Systemic treatment is used
to combat any micrometastases and includes chemotherapy, endocrine therapy and
HER 2 treatment. The choice is determined by the risk of recurrence which involves
both patient and tumour factors: menopausal status, tumour size, type, grade, lymph
node involvement, the presence of tumour markers including ER, PgR, HER2 and
gene expression. Discussion between the multidisciplinary team (surgeon,
pathologist, oncologist, radiotherapist and nursing staff) enables the optimum
treatment regimen to be selected after discussion with the patient.
Wide local excision is the most common type of surgery performed for early breast
cancer as previously discussed. Unless contraindicated, patients receive adjuvant
radiotherapy which uses ionising radiation to destroy cancer cells. Energy released
within the tissues from X-ray beams cause tissue damage to DNA molecules.
Patients attend a treatment planning consultation and at this stage the treatment area
is pre-marked. Regimens vary between departments however a common course
includes 2 Grays of radiotherapy given daily over a five week period. Irradiation of
lymph nodes is recommended if there is nodal tumour involvement. An effort is
made to reduce the amount of radiation delivered to lung and cardiac tissues and the
overall aim of radiotherapy is to deliver sufficient treatment intensity whilst reducing
any adverse effects.
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Endocrine therapy includes the use of tamoxifen and the newer AIs, anastrozole,
letrozole and exemestane which are licensed for use in women with postmenopausal
tumours only. These treatments will be discussed in depth in section 1.10. The
prognosis for patients with early breast cancer is excellent following treatment, with
<10% developing local recurrence after 10 years of follow-up3.
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1.10.6 Locally advanced breast cancer
Locally advanced breast disease is characterised by signs suggesting skin or chest
wall infiltration or clinically involved matted axillary nodes. It arises due to tumour
position within the breast, as a result of neglect or due to biological aggressiveness
which includes inflammatory cancer and the majority of those with peau d'orange.
The mainstay treatment has been radiotherapy as surgery in the form of mastectomy
is often not possible and results in higher rates of local recurrence. Intensive
neoadjuvant chemotherapy and endocrine therapy can cause shrinkage of the tumour
rendering it operable and often breast conservation is possible at this stage.
Standard chemotherapy regimens have increased the initial rate of control and result
in a reduction in local recurrence. Hormonal treatment reduces the risk of
locoregional failure, distant metastases and mortality in those with hormone receptor
positive tumours.
The prognosis for patients with locally advanced breast cancer depends on the
biology of the underlying disease. Overall five year survival is approximately
50%141.
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1.11 Endocrine treatment of breast cancer
There have been several significant advances in the management of breast cancer
over the last decade. The emergence of hormonal treatments since Beatson's historic
Lancet publication in 1896 reporting breast cancer regression after oophorectomy,
has revolutionalised the options available to patients however their side effects
remain a major challenge. The clinical rationale behind endocrine therapy is to
deprive tumour of oestrogen, which is the major established mitogen for human
i 142
breast cancer in vivo .
Endocrine therapy can be used in the premenopausal and postmenopausal setting and
is commonly used in adjuvant, neoadjuvant and metastatic care. Tamoxifen and other
anti-oestrogens competitively block the binding of oestrogen to its receptor whereas
oophorectomy, gonadotrophin-releasing hormone (GnRH) agonists and AIs reduce
the level of serum oestrogen137. Table 1.8 lists common endocrine treatments.
Endocrine treatments of breast cancer




Aroinatase inhibitors anastrozole, letrozole, exemestane
Oestrogen down-regulators fulvestrant
Oestrogens oestradiol, diethylstilboestrol
Progesterones medroxyprogesterone acetate, megesterol acetate
Table 1.8 Endocrine therapies137
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1.11.1 Tamoxifen
Tamoxifen is a synthetic, non-steroidal, triphenylethylene which has been used to
treat women with breast cancer for the last forty years. Because of its agonist and
antagonist effects, it is known as a SERM. It is converted to its active metabolite 4-
hydroxy-N-desmethyltamoxifen (endoxifen) by the enzyme cytochrome P450.
Tamoxifen competes for the binding of oestradiol to the ER, but still allows the
dimerisation of tamoxifen-receptor complexes, which can interact with the oestrogen
responsive elements at the nuclear level143. This results in a block in the Gi phase of
the cell cycle and a decrease in tumour growth144. It acts as a competitive antagonist
of oestrogen in breast tissue and inhibits the growth of ER+ve breast cancer. It is also
a partial oestrogen agonist and stimulates endometrium explaining its association
with endometrial thickening, polyps, fibroids, hyperplasia and an increased rate of
endometrial cancers. This agonist property is also responsible for the increase in
thrombogenicity and favourable impact on bone mineralisation and lipids (as a result
of a decrease in the atherogenic fractions of cholesterol)145. It is known to activate
the coagulation system with an associated significant increased risk of venous
thromboembolic events, pulmonary emboli and stroke82'146'147. Tamoxifen is
generally a well tolerated drug but is associated with additional side effects including
hot flushes, vaginal dryness, vaginal bleeding, weight gain and loss of libido which
may have a considerable impact on quality of life. Overall, menopausal symptoms, a
modest increase in blood clots and endometrial cancer in postmenopausal women are
the most important side effects noted in all studies.
Tamoxifen remains an important component of endocrine therapy despite clinical
trials which demonstrate that AIs are more effective and better tolerated alternatives
102
in postmenopausal women. Over the last few decades, tamoxifen was known as the
standard adjuvant endocrine treatment for ER+ve breast cancer and remains so for
hormone sensitive premenopausal women. Patients have been traditionally
prescribed five years of adjuvant tamoxifen (20mg daily). It has been shown to offer
both substantive and persistent benefits in terms of reducing disease recurrences and
breast cancer-related mortality in women with early ER+ve disease67. Research has
shown that extended treatment with tamoxifen beyond five years does not yield any
great benefit in disease free survival or reduction in time to recurrence148'149,150,151'152.
This may be explained by breast cancer cells becoming resistant to the anti-
oestrogenic effects of tamoxifen over time.
The need to explore alternative endocrine treatments for breast cancer is driven by
the toxicity profiles of treatment and also the emerging resistance to tamoxifen.
Therapy is commonly given as a sequence of treatments to minimise the
development of resistance to one particular drug.
Pharmacogenomics addresses the relationship between a patient's genetic makeup
and their response to an individual drug. Recent studies have shown significant
variations in the enzyme cytochrome P450 which converts tamoxifen to its active
compound.
Despite the effects of anti-oestrogen therapies, intrinsic (de novo) or acquired
resistance to the drugs inevitably develops. Future research will hopefully predict
which patients may or may not benefit from specific therapies and may facilitate the




AIs were initially used in the treatment of postmenopausal women with metastatic
breast cancer and were intended to have the benefits of tamoxifen without the
adverse side-effects154. The superiority of the third-generation AIs in advanced stage
disease led to their efficacy in the adjuvant setting being proven for women with
early stage disease. They have additionally been investigated as neoadjuvant and
preventative treatments.
AIs interfere with the body's ability to convert androgens into oestrogen in
postmenopausal women by suppressing the cytochrome P450 aromatase enzyme and
thereby prevent oestrogen biosynthesis. This mode of action differs from that of
tamoxifen which competes with the natural ligand for binding to the ER155. AIs may
be divided into two classes, steroidal (type 1) and non-steroidal (type 2), based on
their chemical structure. Anastrozole and letrozole are non-steroidal drugs which
bind reversibly to the enzyme at the cytochrome P450 moiety. Both drugs are
triazoles which have a flat aromatic ring, enabling a good fit with the substrate-
binding site of the enzyme. Exemestane is a steroidal AI which competes with the
natural substrate for aromatase and binds irreversibly to the enzyme at the active site,
acting as a suicide inhibitor. It leads to irreversible inhibition of aromatase by
covalently binding to the enzyme156 and produces metabolites which mimic
1 S7
androstenedione .
Aromatase inhibitors and inactivators differ in their mechanism of action. The









Figure 1.14 Structure and classes of aromatase inhibitor19
The antiepileptic drug and first generation AI aminoglutethimide was shown to
inhibit the peripheral conversion of adrenal androgens to oestrogens by the enzyme
aromatase, using radioisotope techniques158. To demonstrate this, tracer compounds
including 3H-labelled androstenedione and I4C-labelled oestrone were administered
by intravenous injection. Thereafter, urine was collected for four days with
measurement of the isotope ratio in the oestrogen metabolites159.
The first and second generation AIs inhibit up to 84-92% of aromatase in vivo.
Moreover, the third-generation drugs achieve >97% aromatase inhibition14'160'161'162
as shown in table 1.9.
Aminoglutethimide attained 81.4% of plasma oestrogen suppression compared with
letrozole which suppressed levels to 98.0% as shown in table 1.7159.163.164 Letrozole
has been shown to be the most potent suppressor of oestradiol, the most bioactive
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oestrogen, compared with other AIs163'165. The clinical significance of these findings
remains to be defined165.
Each successive generation ofAI has been developed with higher specificity for the









''■''A...''. indicated) % %
First generation
Aminoglutethimide 250mg qid 90.6 81.4
Second generation
Fadrozole 2mg bd 92.6 n/a




Letrozole 2.5mg od 98.9 98.0
Anastrozole lmg od 97.3 93.5
Exemestane 25mg od 97.9 93.2
Abbreviations: od- once daily, bd- twice daily, qid- four times daily
Table 1.9 Efficacy of aromatase and oestrogen suppression by three
generations of AIs164
Preclinical pharmacology may not always be translated to the in vivo setting in
humans and the effects of an individual drug depend on several factors including
pharmacokinetics, tissue penetration and cellular uptake. AIs act on the aromatase
enzyme CYP19 and genetic variability in the expression of the CYP19 gene may be
related to the activity of the aromatase enzyme167. The effects of AIs at the tissue
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level, in particular with respect to local effects in the normal breast as well as breast
tumour tissue, is still incompletely understood168.
Third-generation AIs can reduce levels of circulating oestrogens to undetectable
values (with standard assays) in postmenopausal women, thereby removing very
efficiently the growth stimulus for hormone-sensitive tumours169.
Anastrozole
Anastrozole was the first 3rd-generation AI to enter into clinical trials and was
launched in 1995. The dosing is lmg daily and it is rapidly absorbed after oral
administration with peak plasma concentrations reached after approximately two
hours. Its estimated half life is approximately 40-50 hours170. Plasma oestrogen
levels may need up to four weeks to recover following termination of treatment171. It
is currently recommended as adjuvant early and advanced breast cancer treatments in
postmenopausal women. It can also be used for two to three years following two to
three years of tamoxifen.
Letrozole
Letrozole dosing is 2.5mg daily and is administered orally. It is rapidly absorbed and
its estimated half life is approximately 48 hours170. Plasma oestrogen levels may
need up to four weeks to recover following termination of treatment171. It is
recommended as either upfront or extended adjuvant therapy for postmenopausal
women have already received tamoxifen as first or second line treatment of adjuvant
disease. It may also be used neoadjuvantly in an attempt to reduce the size of
tumours enabling breast conserving surgery.
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Exemestane
Exemestane dosing is 25mg daily and is also administered orally. It is rapidly
absorbed, with maximum plasma concentrations reached within two hours of a single
dose. It undergoes extensive metabolism and has a mean half life of approximately
24 hours170'172. Unlike anastrozole or letrozole, it induces aromatase degradation in a
dose responsive manner without affecting mRNA levels173. Exemestane is used for
adjuvant treatment of early breast cancer or after completion of two or three years of
tamoxifen treatment or in postmenopausal women with advanced breast cancer
whose disease has progressed following treatment with tamoxifen.
All three of these drugs may also be used to treat postmenopausal patients in whom
other anti-oestrogen therapy has failed.
The two classes of AIs demonstrate a lack of complete cross-resistance171'17 .
Patients who fail to respond to one type of drug may still have a 25-30% chance of
achieving clinical benefit from the other. This may be explained by the differing
pharmacological characteristics between steroidal and non-steroidal compounds. In
addition, the binding kinetics vary, with non-steroidal compounds binding reversibly,
while the steroidal compounds bind irreversibly. Other possible causes include the
differing endocrine efficacy which is seen in vivo between the non-steroidal
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compounds .
AIs are not co-administered with tamoxifen because tamoxifen in a low oestrogen
environment may be seen as oestrogenic176'177 and there is no greater efficacy when
the agents are used together. Previous studies demonstrated a 27% reduction of
plasma anastrozole levels when it was administered concomitantly with tamoxifen178.
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1.12.1 Pre-menopausal use of Als
AI therapy is currently not recommended for premenopausal women with breast
cancer because it is generally ineffective. It causes a reduced feedback of oestrogen
to the hypothalalmus and pituitary which in turn results in an increase in
gonadotropin secretion. This stimulates the ovary, leading to an increase in androgen
substrate and aromatase179. Ovarian suppression may be achieved using GnRH
agonists, LHRH (luteinsing hormone releasing hormone) agonists, oophorectomy or
radiation. These modalities may be used to prevent the increased hormone levels
caused by Als in pre-menopausal women. Interestingly, results from the ABCSG-12
trial (appendix F) suggested no benefit to the use of an AI plus ovarian suppression
when compared with tamoxifen plus ovarian suppression180.
Other phase III clinical trials include SOFT (Suppression ofOvarian Function Trial)
(appendix F) which aims to evaluate the benefits of tamoxifen plus ovarian
suppression, tamoxifen alone and exemestane plus ovarian suppression in
premenopausal women with hormone positive breast cancer after surgery. The
IBCSG 25-02 (TEXT) trial (appendix F) aims to assess the role of tamoxifen and
exemestane plus GnRH analogue as adjuvant therapy for premenopausal women
with breast cancer. The results of these trials are awaited.
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1.12.2 Neoadjuvant use of Als
Neoadjuvant endocrine therapy is emerging as an alternative to neoadjuvant
chemotherapy in postmenopausal women with large operable or locally advanced
breast cancers. In this group, the likelihood of breast conservation with a
cosmetically acceptable outcome is often limited and neoadjuvant endocrine
treatment improves the chances of breast conservation by downstaging tumours. It
also treats any micrometastases in a timely manner. Initially, small non-randomised
studies suggested that third generation Als might be more effective than tamoxifen as
first-line endocrine agents in postmenopausal women with advanced and early breast
Letrozole
Larger, randomised trials include the P024 study which studied postmenopausal
women with large, operable or locally advanced ER and/or PgR+ve untreated breast
cancers. Patients were randomised to letrozole or tamoxifen. Objective response rates
by palpation, mammography and ultrasound were all significantly higher in the
letrozole group. Overall objective response rate was 55% for letrozole compared
with 36% for tamoxifen p<0.001. There was also a higher rate of breast conserving
surgery for patients randomised to letrozole (45% versus 35% p=0.022)182. A further
multicentre trial demonstrated that letrozole improved operability and breast




Two large randomised trials compared anastrozole with tamoxifen prior to surgery:
the IMPACT and PROACT studies (appendix F). The objective response rates in
IMPACT showed no significant differences between the groups (anastrozole vs
tamoxifen vs combination). Nevertheless, a significantly higher number of women
experienced sufficient tumour regression to be suitable for breast conservation
following treatment with anastrozole (46%) compared with tamoxifen (26%)
p=0.03185. The PROACT study randomised a small subgroup of patient to
concomitant chemotherapy. Only women treated with endocrine therapy alone who
required mastectomy or had locally advanced disease at the onset received a
significantly better objective response rate in the anastrozole group (49%) versus the
tamoxifen group (36%) p=0.04186.
Exemestane
Only one study randomised postmenopausal women with ER+ve breast cancer to
receive neoadjuvant exemestane or tamoxifen alone. Results demonstrated that
exemestane was superior in terms of clinical overall response (76% versus 40%)
p=0.05) and also breast conservation surgery (36% versus 20%) p=0.05187.
The ACOSOG Z1031 study (appendix F) demonstrated no difference in clinical
response or breast conservation rate between women randomised to anastrozole,
letrozole or exemestane. Each were effective at promoting breast conservation188.
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1.12.3 Als as preventative therapy
AIs have shown encouraging results when used in breast cancer prevention. The
ATAC trial (shown in table 1.8) demonstrated a further reduction of 40% in the
frequency of de novo primary breast cancers in those taking anastrozole compared
with tamoxifen189. Anastrozole and exemestane are currently under investigation as
preventative agents in phase III randomised trials. The IBIS II study190 was set up in
2003 and aims to compare anastrozole versus placebo in postmenopausal women at
increased risk of developing breast cancer and who are not taking hormone
replacement therapy. Additional data is expected from the NSABP B-35 trial which
will test the preventative effects of anastrozole in women with DCIS191. The MAP.3
trial randomised women at increased risk of breast with exemestane plus placebo or
exemestane plus celecoxib for five years. The results are not yet available191.
It is expected that third-generation AIs will provide better protection against breast
cancer compared with the two SERMS, tamoxifen and raloxifene which are currently
approved. However until further results become available they are not yet routinely
used as primary prevention. Newer agents including bisphosphonates and metformin
have shown promise in observational studies192.
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1.12.4 Als in the adjuvant setting
Several large, multicenter, randomised phase 3 trials have compared the efficacy and
toxicity of Als and tamoxifen. They include trials whereby postmenopausal women
were randomly assigned a drug after a new diagnosis of breast cancer i.e upfront
adjuvant therapy and an AI after previous tamoxifen therapy as shown in tables 1.10
- 1.11. These trials demonstrated that Als are superior to tamoxifen in a number of
settings:
(1) Used upfront as first-line adjuvant treatment (ATAC, BIG 1-98, TEAM,
MA.27)
(2) After 2-3 years of tamoxifen (IES, ITA, ARNO)
(3) As extended adjuvant treatment after 5 years of tamoxifen (MA-17)
A recent meta-analysis of randomised trials of Als compared with tamoxifen either
as initial monotherapy or after 2-3 years of tamoxifen demonstrated that Als produce
significantly lower recurrence rates compared with tamoxifen, either as initial
monotherapy or after 2-3 years of tamoxifen193.
113














1.anastrozole5y s ortamoxifen5y s 2.anastrozole+ tamoxifen5yrs
9,366
100months
HR=0.85 [95%CI 0.76-0.94] p=0.003
No difference HR=1.00 [95%CI 0.89-1.12] p=0.99
Arthralgia A=35.6%vsT 29 4 OR1.32[95%CI.19-1.47] p<0.0001 Fracturerat A=11.0%vsT=7.7% OR1.49[95%CI.25-1.77] p<0.0001
IschaemicCVev nts A=4.1%vsT 3 4 OR1.23[95%CI0.95-1.60] p=0.1
DVT A=1.6%vsT 2.4 OR0.64[95%CI 0.45-0.93]p=0.02 VTE A=2.8%vsT 4 5 OR0.61[95%CI 0.47-0.80]p=0. 004
BIG1- 98195
1.letrozole5yrsr tamoxifen5yrs 2.letrozoleyrs—► tamoxifen3yrs 3.tamoxifen2yrs—► letrozole3yrs
8,010
25.8months
HR=0.81 [95%CI 0.70-0.93] p=0.003
HR=0.86 [95%CI 0.70-1.06] p=0.16
Arthralgia L=20.3%vsT=12.3% p<0.001 Fracturerat L=5.7%vsT 4 0 p<0.001
Cardiacevent L=4.1%vsT 3 8 p=0.61






HR=0.97 [95%CI 0.88-1.08] p=0.60
No difference HR=1.00 [95%CI 0.89-1.14] p>0.99
Jointdisorders E=36%vsT—>E=31% p<0.0001 Fracturerates E=5%vsT->E=3%p<0.0001 Osteoporosis E=10%vsT—>E=6% p<0.0001









No difference OS=91%for eacharm
Osteoporosis LesscommonwithE
Hypercholesterolemia LesscommonwithE Hypertriglyceridaemia LesscommonwithE
Similar
























2-3yrsoftamoxifen, thenrandomised anastrozolefo2-3 yrsortcontinue tamoxifen.Total duration5vrs
448
64months
HR=0.57 [95%CI 0.38-0.85] p=0.005
HR=0.56 [95%CI 0.28-1.15] p=0.1
Musculoskeletaldi ord rs andbo efractur s A=9.9%vsT 6 7 p=0.2
Cardiovasculardise se A=7.6%vsT 6 2 p=0.6





2yrsoftamoxifen,hen randomisedt anastrozoleor tamoxifenfor3yrs. Totaldura ion5yrs
3,224
28months
HR=0.60 [95%CI 0.44-0.81] p=0.0009
OShigher (97%)inA groupvsT group (96%) p=0.16
Bonepain A=16%vsT=19 OR1.25[95%CI.00-1.56] p=0.0546 Fracturerat A=2%vsT l OR2.14[95%CI1.14- .17] p=0.015
Myocardialinfarction A<1%vsT OR1.50]95%CI0.17-17.9] p=1.0
Thromboses A<1%vsTOR 0.25[95%CI.04- 0.92]p=0.034 Embolism A<1%vsTOR 0.22[95%CI.0 - 1.07]p=0.064
IES200'201
2-3yrsoftamoxifen, thenrandomised exemestanefor2-3 yrsorcontinuewith2- 3yrsoftamoxifen. Totaldura ion5yrs
4,724
30.6 months
HR=0.68 [95%CI 0.56-0.82] pO.OOl
HR=0.88 [95%CI 0.67-1.16] p=0.37
Arthralgia E=5.4%vsT 3 6p=0.005 Osteoporosis E=7.4%vsT 5 7p=0.023
CVDotherthan myocardialinfarct E=42.6%vsT 39 2 p=0.016
Thromboembolic disease E=1.3%vsT 2 4 p=0.007
(ii)Extendedth rapy
MA.17
5yrsoftamoxifen, thenrandomised letrozolef r5yrs placebofor5yrs
5,187
30months
HR=0.58 [95%CI 0.45-0.76] pO.OOl
HR=0.82 [95%CI 0.57-1.19] p=0.3
Arthralgia L=25%vsplacebo=21% PO.OOl Fracturerat L=5.3%vsplacebo=4.6% p=0.25
Myocardialinfarction L=0.3%vsplacebo=0.4% Therewernosignificant differencesbetweenratof cardiovasculardisea ein eachgroupp=0.76
Thromboembolic event L=0.4%vs placebo=0.2% p-valuenotgi en
ARNO95trial/BCSG8=ARimidexNOlvadexustianB stanColorectalncerStu yGroup,IEnt rgroupe eme neu y,TAIt l tamoxifenanastrozolestudy,MA.17=NationalC c rIn ti utdy A-anastrozole,CVDcardiovasculardise eEexemest nHRhaz dr tiL-Ietroz l ,OoddsiTt mox f n,ve us,yar Table1.11(i)Sequentialherapy:Effectsofsequentialt rapywi htamoxi enfoll w dbAl (ii)Extendedtherapy 115
Upfront adjuvant therapy in women with newly diagnosed postmenopausal
breast cancer:
ATAC trial
The ATAC trial was the first large, double-blind, randomised controlled, multicenter
trial of an adjuvant AI to be published. It compared anastrozole with tamoxifen in
women diagnosed with early breast cancer that had completed primary treatment
(surgery +/- radiotherapy +/- chemotherapy) and were suitable to receive adjuvant
endocrine therapy. The main objectives were to establish whether anastrozole is at
least as effective and as well tolerated as tamoxifen. It ran between July 1996 and
March 2000. Patients were randomised to receive 5 years of anastrozole plus
placebo, tamoxifen plus placebo or anastrozole and tamoxifen combined. Eighty
three per cent of patients were ER+ve, 7% were ER-ve and 10% were unknown.
After 68 months follow-up, anastrozole significantly prolonged disease-free survival,
reduced distant metastases and reduced contralateral breast cancers. In addition,
fewer withdrawals occurred with anastrozole189. Follow-up at 100 months showed no
difference in overall survival .
BIG 1-98 Collaborative Group Study
The purpose of this double-blind study was to compare letrozole with tamoxifen in
the adjuvant setting. The analysis compared two groups assigned to receive letrozole
initially with the group assigned to receive tamoxifen initially. The study included
ER+ve postmenopausal women with breast cancer and ran between March 1998 and




The TEAM study compared adjuvant tamoxifen and exemestane in early
postmenopausal ER+ve breast cancer. Patients were assigned treatment between
January 2001 and January 2006. There were two experimental arms, exemestane
alone and sequential therapy (tamoxifen followed by exemestane). The primary
endpoint was DFS and no difference was seen between the groups196.
MA.27 study
The MA.27 study is the first ever head-to-head comparative trial of anastrozole
versus exemestane. Exemestane was not superior to anastrozole but comparable in its
anticancer effects and likely better in terms of its side-effect profile. The DFS rate
was 91% in both arms. The results suggest that exemestane may be a better choice of
AI at risk of osteoporosis and dyslipidaemias197.
Sequential adjuvant therapy with Als following tamoxifen in women with
postmenopausal breast cancer
ITA trial
The Italian Tamoxifen/Arimidex trial assessed switching patients from tamoxifen to
anastrozole. Women randomised included ER+ve postmenopausal women with
breast cancer. Primary endpoints included DFS and secondary endpoints included
safety and overall survival. The study ran between March 1998 and December 2002.
Results confirmed a significant benefit in the switch group however overall survival
was not significantly different. Results suggested switching to an AI is a valuable
option for women being treated with tamoxifen198.
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ARNO 95 and ABCSG 8 trials
This was a combined analysis of two studies. Patients had to complete 2 years' of
adjuvant tamoxifen prior to being randomised to anastrozole. The trial randomised
patients between January 1996 and August 2003. Results demonstrated a 40%
decrease in the risk of an event in the anastrozole group as compared with the
tamoxifen group199. A meta-analysis of these studies combined with the ITA
demonstrated significant improvements in DFS and overall survival in the
anastrozole switch group compared with patients randomised to tamoxifen alone.
These results suggested that postmenopausal women should be switched to
anastrozole after completing 2-3 years of adjuvant tamoxifen204.
IES study
This trial investigated the idea that switching to exemestane after 2-3 years of
tamoxifen is more effective that continuing on tamoxifen for the duration of adjuvant
therapy. The trial randomised patients between April 2000 and February 2006. DFS.
The mature 55.7 month follow-up results confirmed an absolute benefit of 3.3% in
favour of exemestane and also that switching to exemestane resulted in improved
survival relative to women remaining on 5 years of tamoxifen200'201'205.
Extended adjuvant therapy with tamoxifen or Als
MA-17 study
Most breast cancer recurrences in women receiving five year of adjuvant tamoxifen
occur after five years. This study assessed extending tamoxifen therapy beyond 5
years using an AI verus placebo. The study randomised patients between August
1998 and September 2002. Letrozole significantly improved DFS202'206.
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Adjuvant third generation AI treatment has been shown to be superior at decreasing
breast cancer recurrence risk compared with adjuvant tamoxifen treatment. They
have proven to be between 15-25% more effective than tamoxifen in terms of
reducing the relative risk of breast cancer recurrence65,176'207. ASCO released
guidelines in 2004 recommending that AIs be used as adjuvant therapy for
postmenopausal women with ER+ve, invasive breast cancer208. The major clinical
trials to date have indicated a significant benefit of adjuvant AI treatment over
tamoxifen in terms of disease-free survival (DFS), distant DFS and contralateral
z"c 1 Hfi
breast cancers ' ' . However they have failed, up to this point, to show any
advantage in terms of overall survival177. ASCO recommend that postmenopausal
women with receptor-positive breast cancer receive an AI in order to lower the risk
of tumour recurrence. Optimal adjuvant hormonal therapy for postmenopausal
women with hormone receptor +ve breast cancer should include AI therapy at some
point during adjuvant treatment, either as up-front therapy or as sequential treatment
after tamoxifen according to their 2010 guidelines. The optimal timing and duration
of endocrine treatment remain unresolved. Careful consideration of adverse effect
profiles and patient preferences in deciding whether and when to incorporate AI
therapy is advised209. As previously stated, the side-effect profiles of tamoxifen and
AIs differ. To date, the long term consequences of AI therapy are not well
established but they have been shown to increase the risk of developing osteoporosis.
There is currently no data on the use of tamoxifen after an aromatase inhibitor in the
adjuvant setting.
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1.12.5 Als in the advanced breast cancer setting
Third generation Als are now replacing tamoxifen as first-line agents for advanced
breast cancer (ABC), as they have superior efficacy and in some cases, tolerability
advantages. They were first assessed as second-line agents against megestrol acetate
in the treatment of metastatic breast cancer and thereafter they were compared with
tamoxifen in the first-line setting. Large scale trials demonstrated an advantage in the
objective response rates, clinical benefit rate and overall survival for third generation
AIs210'211. The median time to progression was similar in the AI groups when
compared with megestrol acetate except for exemestane which showed a significant
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benefit (4.7 months for exemestane versus 3.8 for megestrol acetate) . In a study
comparing the effectiveness of letrozole with anastrozole in ABC, no significant
differences were seen in overall response rate, time to disease progression, or median
overall survival in the ER+ve group, suggesting that the two non-steroidal AIs are
clinically equivalent213. The EFECT trial demonstrated that fulvestrant and
exemestane were equally active and well-tolerated in postmenopausal women with
ABC who had experienced progression or recurrence during treatment with a non¬
steroidal AI. These results reinforced the idea that there is incomplete resistance
between the non-steroidal and steroidal AIs174.
All metastatic patients receiving endocrine therapy eventually progress but often they
will benefit from a new second-line endocrine agent that lacks the cross-resistance
with first-line agents214.
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1.13 Long-term safety and tolerability of aromatase inhibitors
Postmenopausal women are not only at risk of dying from breast cancer, they are
also susceptible to other major health problems which affect this age group including
bone fractures and CVD215. Third generation AIs may alter these risks and may
translate into different safety and tolerability profiles. This is of great important
given the number of patients who will receive AIs in the future and due to the long
duration of treatments. Adverse events associated with AIs include hot flushes,
vaginal dryness, loss of libido, fatigue, arthralgias, joint stiffness and loss of bone
mineral density (BMD) with subsequent increased risk of fractures208.
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1.13.1 Effects of Als on bone
Concern over the long-term effects of adjuvant AI therapy on bone health is well
established. Third generation Als reduce oestrogen levels by >90% and this results in
an increase in the rate of bone remodeling. This results in an overall acceleration of
bone loss and probably to an increase in the rate of fractures.
Findings from a subgroup of 249 patients in the ATAC trial demonstrated that the
biochemical markers of bone formation and resorption increased during treatment
with anastrozole and this increase in bone remodeling was also reflected by a
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decrease in BMD measurements from lumbar spine and hip X-rays . Factors
associated with fractures in the ATAC trial included older age, the use of
anastrozole, geographical location (higher incidence in the US and Scandinavia) and
the absence of use of statins216. Other studies have found increased frature rates after
letrozole217 and exemestane196'218 as shown in tables 1.10 and 1.11.
There may be a difference between changes in the rates of bone turnover caused by
the different third generation Als which may reflect differences in potential fracture
risk.
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1.13.2 Effects of Als on quality of life related to bone health
Oestrogen deprivation is associated with arthralgias. The incidence of arthralgia has
been reported to affect more women treated with Als compared to those treated with
tamoxifen219. It is not surprising that women treated with Als often experience joint
pain and musculoskeletal aches, given the extent to which they suppress oestrogen,
and this may lead to cessation of treatment.
The term arthralgia encompasses a wide range of symptoms. Joint pain may emanate
from a wide variety of locations including bone, ligaments, joint capsule, articular
surfaces and periosteum. If inflammation is present there may be a surge of
inflammatory markers including prostaglandins and bradykinins which activate
peripheral nociceptor receptors, which in turn, increase the sensitivity to pain. This
may result in normal day-to-day stimuli causing painful symptoms220. Oestrogen
influences inflammation and neural processing of nociceptive input and do not have
any specific known effects on articular surfaces221. In particular oestrogen has tissue-
specific effects on inflammatory cytokines. The effects of oestrogen deprivation
caused by aromatase inhibition may therefore explain the exaggerated nociception
which occurs in many of these women222.
Oestrogen deficiency has been shown to be associated with an increase in pain
sensitivity. Oestrogen is known to affect nociceptive input at the levels of the central
nervous system which may be related to symptoms such as arthralgia and breast pain
described by patients taking Als221. It has direct effects on opioid pain fibres in the
central nervous system223. The specific effects of aromatase depletion on nociceptive
fibres are less well established compared with the effects of oestrogen. However
*
aromatase has been located in dorsal horn cells in some species224 which may act to
convert androgens to oestrogen. In addition, there is data suggesting that there is an
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inverse link between the proportion of circulating oestrogen and the sensitivity to
pain e.g. during pregnancy when oestrogen levels are elevated, women have
exaggerated pain thresholds.
Clinical trials have consistently demonstrated a link between AIs and higher rates of
musculoskeletal complains versus patients taking placebo or tamoxifen. Table 1.13
demonstrates the results of recent large scale trials comparing the musculoskeletal
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Table 1.13 Clinical trials demonstrating the musculoskeletal effects of
AIs
A diagnosis of breast cancer, together with treatment, is likely to affect the quality of
life (QOL) ofmost patients which in turn may affect drug compliance.
QOL can be assessed using a number of methods. Firstly any adverse events (AEs)
can be reported by the clinician or alternatively the patient can self report events
using validated QOL instruments. There are several questionnaires which have been
developed for use in oncology. The validated Functional Assessment of Cancer
Therapy-Breast + Endocrine Subscale (FACT-B+ES) questionnaire is tailored for
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patients with breast cancer and includes specific questions relevant to endocrine
therapy including menopausal symptoms. The questionnaire includes 49 questions
which are graded on a 5-point scale from 0 (not at all) to 4 (very much). It was
validated by Fallowfield et al in 1999 in 268 women with breast cancer who received
adjuvant endocrine therapy and has been shown to be reliable and demonstrated
consistency and sensitivity225.
Adjuvant hormonal treatment is currently recommended for a minimum duration of 5
years which can be extended for another 3-5 years in those treated with sequential
therapy following 2-3 years of tamoxifen. It is vital that the QOL of that survival is
maximised, given the long duration of treatment. In published clinical trials and in
clinical practice, AEs constitute the main reason for non-adherence to endocrine
treatments226. Some toxicities are resolved by simply switching to another drug
whereas others may resolve with conservative treatment or with the addition of
further agents. This may allow the patient to remain on therapy without
compromising their QOL226.
It is hypothesised that different AIs will result in different toxicities due to the varied
mechanisms of action of each drug. It is understood that musculoskeletal symptoms
may be related to bone loss and it is of great interest to determine if increases in bone
turnover markers are associated with increased rates ofmusculoskeletal side-effects.
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1.13.3 Effects of Als on lipids
AIs do not improve lipid profiles as tamoxifen does, and there has been a suggestion
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that there is an increased risk ofCVD with their use . This is of critical importance
as women diagnosed with postmenopausal breast cancer are likely, at the time of
diagnosis, to have a significant risk of developing CVD which may then be added to
by the direct and indirect effects of breast cancer treatments228. Studies comparing
the incidence of cardiovascular events between women treated with AIs versus
tamoxifen have reported a small increase in the incidence in the AI group as shown
in tables 1.10 and 1.11. It is not clear whether this finding is simply due to the
tamoxifen-associated cardioprotective effects which are lost or ifAI therapy directly
causes an adverse effect. Obesity is also an established risk factor for CVD and
studies have associated the use of adjuvant endocrine therapy for breast cancer with
weight gain229'230'231. In addition, whether any increased CVD risk is related to lipid
dysfunction is unclear. The BIG-98 study showed elevated lipid levels in the 43.6%
of the letrozole group versus 19.2% of those taking tamoxifen, p-value not available.
Lipid disorders affected 8.1% of those taking anastrozole versus only 1.4% on
tamoxifen in the ITA study. Letrozole is the only AI that has placebo-controlled
cardiovascular data from a large trial, MA. 17. It demonstrated no significant
differences between the groups. Studies so far have shown differences between the
classes of AIs and their effects on lipid metabolism and it has been suggested that
these differences are a function of the steroidal nature of exemestane. Exemestane
and its metabolites mimic androstenedione and may have a protective effect on
lipids, especially triglycerides, by reducing serum hormone-binding protein and
ApoA levels227.
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1.13.4 Effects of Als on coagulation
For the individual patient with breast cancer, the absolute risk of venous
thromboembolism (VTE) is dependent upon the interaction between a number of
patient and cancer specific factors. These include age, obesity, immobility, medical
co-morbidities, site and stage of cancer, chemotherapy regimens, and
hospitalization232. In addition, the use of oestrogen-related compounds such as
tamoxifen is known to have pro-thrombotic effects233 and between 1-2% of women
taking tamoxifen develop DVT as a result of tamoxifen's oestrogenic properties.
Thrombosis is currently the second leading cause of death in patients with
malignancy232 and underlying malignancy is responsible for up to 25% of all cases of
symptomatic venous thromboemboli73.
In theory, Als should have either no significant effect or reduce the risk of
thrombembolism as they significantly reduce circulating oestrogen levels. Large
scale clinical trials have shown that Als cause less thromboembolic events in
postmenopausal women compared with tamoxifen. Both anastrozole and exemestane
are associated with significantly fewer venous and arterial vascular events when
compared with tamoxifen189'200.
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SECTION 2: ALIQUOT STUDY
128
2.1 ALIQUOT INTRODUCTION
There is concern over the long-term effects of adjuvant AI therapy on bone and
cardiovascular health. Studies have shown a higher fracture rate when AIs are
compared with tamoxifen therapy and an increased incidence of cardiovascular
events when compared with a healthy population.
The aim of this study was to compare whether there is a significant difference
between the nonsteroidal AIs in their effects on bone turnover, quality of life and
lipid parameters in a series of healthy postmenopausal women with ER+ve operable
breast cancer.
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2.2 ALIQUOT MATERIALS AND METHODS
2.2.1 Study design
ALIQUOT (Anastrozole versus Letrozole, an Investigation of Quality Of Life and
Tolerability) was a prospective, open-label, randomised pharmacodynamic study
involving 185 postmenopausal women with invasive ER+ve breast cancer. Patients
were randomised as part of their adjuvant endocrine therapy to receive either 3
months of letrozole followed by 3 months of anastrozole or 3 months of anastrozole
followed by 3 months of letrozole. Some patients received adjuvant AI therapy
immediately following surgery, while other patients had already received adjuvant
tamoxifen and then received AIs in the extended adjuvant setting.
All patients were treated in the Edinburgh Breast Unit, UK. Following informed
consent, each patient was randomised to receive 3 months of anastrozole (1 mg) or
letrozole (2.5 mg) orally once daily in this crossover study as shown in figure 2.1.
Each drug was administered for 3 months, and after completion of the study period,
patients in the immediate adjuvant group were either switched to tamoxifen or
continued on anastrozole or letrozole. All those having extended adjuvant therapy
continued on letrozole unless they expressed a specific preference for anastrozole, as
letrozole is approved for extended therapy.
The cross-over design was chosen to remove interpatient variability. The drug
carryover effect after 3 months is minimal because the half-life of both anastrozole
and letrozole is between 40 to 50 hours only234'235. Within one month of stopping an
AI, little drug remains. Thee months is certainly more than adequate to ensure that
the results obtained for each drug represent values for that drug and that there is no
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significant carryover effect165. Randomisation for ALIQUOT was 1:1, anastrozole:
letrozole.
The primary endpoints were the effects of anastrozole and letrozole on bone turnover
markers and lipid parameters. Secondary endpoints included the effects of these
drugs on quality of life with particular reference to bone health.
Randomisation Crossover
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Figure 2.1 ALIQUOT Cross-over study design
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2.2.2 Ethical Approval
The study was approved by the Lothian Research Ethics Committee and the Lothian
NHS Trust Research and Development Department. It was carried out in accordance
with the Declaration of Helsinki and in keeping with Good Clinical Practice.
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2.2.3 Patient selection
Patients were recruited from the Edinburgh Breast Unit, Western General Hospital,
Edinburgh. Postmenopausal women who had recently undergone surgery and been
identified as having ER+ve breast cancer suitable for adjuvant treatment with
tamoxifen alone were identified at the multi-disciplinary team meeting. Study
participation was discussed at this meeting alongside all aspects of future
management. Each patient had to satisfy the inclusion / exclusion criteria as shown in
appendix A. Entry into the study was then discussed with potential patients at the
time they received their pathology results and proposed management. Patient
information sheets were given to patients as shown in appendix B. Patients were
given plenty of time to ask any questions during and at the end of the clinic
consultation. If they were interested in participating, a checklist to ensure suitability
was performed. All patients were given a minimum of 24 hours to consider entering
the trial prior to recruitment. Patients were asked to return to a specialised research
clinic if they wished to participate in the study. At this time, informed consent was
obtained using a standard consent form which was approved by the local ethics
committee. Baseline QOL questionnaires and blood and urine samples were collected
for analysis.
A smaller number of patients were identified at the long-term follow-up clinic when
patients were approaching the completion of five years of adjuvant tamoxifen
therapy and were adjudged to be appropriate for extended adjuvant therapy with an
AI.
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2.2.4 Oestrogen receptor testing
All patients eligible for the study were ER+ve. For trial entry, each patient had to
score >4 on the ALLRED scoring chart however the majority were oestrogen rich
and scored >7. A standard immunohistochemical scoring system was used to assess
the quantity of oestrogen and progesterone receptor present.
2.2.5 Collection of clinical data
A clinical research folder (CRF) was completed for every patient. The following data
were collected: date of entry into study; patient demographics; tumour characteristics
including ER status; date and type of surgery; adjuvant treatments received;
randomisation drugs and start date; previous hormone treatment; past medical
history; current medications; height, weight and body mass index.
In addition the person who initially discussed the trial was recorded. Copies of the
consent forms and pathology reports were filed in each CRF. QOL questionnaires
and adverse events were recorded at each visit. All data were collected prospectively.
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2.2.6 Collection and storage of blood and urine specimens
Blood and urine samples for bone marker measurements and blood samples for lipid
measurements were collected following an overnight fast, at the same time of day
and on the same day of the week at the beginning and end of each 3 month period of
drug treatment. Further samples were obtained after 9 months. The timing of samples
was scheduled to minimise diurnal and diet-related effects. Plasma samples were
separated by centrifugation and stored at -80°C until analysed. The second voided
urine of the day was collected for measurement of urinary bone markers and stored at
-80°C.
Patient details were encoded to ensure anonymity. A detailed chronological log book
of all samples collected was recorded, ensuring easy and accurate identification of
specimens.
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2.2.7 Bone turnover marker analysis
Several bone turnover markers were measured as shown in table 2.1. Procollagen
type 1 N-terminal propeptide (PINP) and bone specific alkaline phosphatase (ALP)
are markers of bone formation. The cross linked C and N telopeptides of type 1
collagen, serum C-terminal telopeptides (sCTX) and urinary N-terminal telopeptides
(uNTX) are markers of bone resorption. Increases in uNTX and sCTX indicate bone
resorption, while increases in PINP and ALP indicate bone formation. Parathyroid
hormone (PTH) is a calcium regulating hormone and is also referred to as a regulator
of bone remodelling46. It was previously described as having bone resorbing
properties but has since been shown to have anabolic effects too. The normal
reference ranges for postmenopausal women are shown for the bone turnover
markers in table 2.1. No available postmenopausal ranges are available for PTH and
therefore only the normal range has been given in table 2.1.
Blood and urine samples were analysed at the Academic Unit of Bone Metabolism,
Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Sheffield. Urinary
NTX was measured by an automated Vitros Eci chemiluminescence immunoassay
(Ortho Clinical Diagnostics) and was expressed as a ratio to urinary creatinine which
was measured by a dry slide method (Citros 250, Ortho Clinical Diagnostics). Serum
CTX was measured by an enzyme-linked immunoassay (Crosslaps®, Nordic
Bioscience Diagnostics). Intact PINP was measured by radioimmunoassay (Orion
Diagnostics Oy). Bone ALP was measured by the Ostase® assay, a paramagnetic
chemiluminescent method on an Access® autoanalyser (Beckman Coulter Inc.).
Serum PTH was measured by enzyme linked immunoassay (Biomericalnc).
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Bone markers associated with bone formation normal reference ranges / unit
PINP236 16-96 ng/ml
Bone ALP237 3.8-22.6 pg/1
Bonemarkers associated with bone resorption
sCTX238 0.104- 1.008 ng/ml
uNTX239 26- 124 nmolBCE/mmolCr
Regulator of bone remodelling
PTH238 8.3 - 63.0 pg/ml
s - serum u - urinary BCE - bone collagen equivalents Cr - creatinine
Reference ranges shown are for postmenopausal women with the exception of PTH which is the adult
reference range.
Table 2.1 Markers of bone turnover and bone metabolism hormone
The PINP interassay CV was 5.7% and the intra-assay CV was 5.2%. The bone ALP
interassay CV was 2.3% and the intra-assay CV was not calculated as bone ALP was
run on an autoanalyser. Intra-assay sCTX CV was 3.2% and interassay CV was
3.0%. Interassay uNTX coefficient of variations (CV) was 6.2 % and the intra-assay
CV was not calculated as NTX was run on an autoanalyser. The serum PTH
interassay CV was 7.2% and the intra-assay CV was 3.7%.
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2.2.8 Quality of life assessment
FACT-B+ES (version 4) questionnaires were completed by patients prior to
hormonal treatment and at regular intervals both during and after treatment i.e
baseline, 3, 4 and 12 months, as shown in appendix C. Any adverse events or side
effects offered by patients on direct questioning were also recorded. It is well known
that there is a weak correlation between the aforementioned methods and it is for this
reason that we chose to record both. Due to the different mechanisms of actions of
each AI class, it is expected that there would be associated different toxicities. AIs
are known to result in a significantly higher incidence of musculoskeletal symptoms
(including arthralgia, bone loss and fractures) compared with tamoxifen177. This
study therefore set out to identify if there was any differences in the degree of
musculoskeletal side-effects between the AIs. In addition a correlation between bone
turnover markers and bone/joint side-effects was sought.
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2.2.9 Lipid analysis
The lipid transport system has evolved to transport fat from sites of origin to sites of
utilisation via plasma. The major types of lipids that circulate in plasma were
measured including cholesterols, triglycerides and lipoproteins. The proteins that
mediate this circulation are apolipoproteins which were also measured. The lipids
and lipoproteins measured are shown in table 2.2 alongside their normal reference
ranges. LDL increases and HDL decreases after the menopause but these changes
have not been taken into account when formulating the normal reference ranges.
Atherogenic lipids
(associated with an increased
risk of atherosclerosis
Normal reference ranges / unit
Triglycerides30 < 1.7 mmol/1
Cholesterol30 <5.0 mmol/1
Low-density lipoprotein cholesterol (cLDL)30 < 3.0mmol/l




High-density lipoprotein cholesterol (cHDL)30 >1.0 mmol/1
Apoprotein Al (ApoAl)240 1.20- 1.76 g/l
Table 2.2 Plasma lipids
Cholesterol acts as the substrate for steroid hormones. Triglycerides are hydrolysed
by lipases to generate free fatty acids used for energy utilisation. Lipoproteins
transport triglycerides from intestine and liver to sites of utilisation, they also
transport cholesterol to peripheral tissues.
Triglycerides, total cholesterol, low-density lipoprotein (LDL), apolipoprotein B
(ApoB), high-density lipoprotein (HDL), and apoplipoprotein A1 (ApoAl) were
measured at baseline and after 3 and 6 months of AI. At this point patients who had
not received any other form of hormone therapy were switched to tamoxifen and
further lipid measurements obtained at 9 months. High levels of circulating
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triglycerides, cholesterol and LDL are associated with an increased risk of CVD
whereas high levels of HDL and apoA-1 lipoproteins are protective against CVD
(due to their ability to facilitate transportation of lipids from the intima).
Plasma lipids were collected in EDTA tubes. Patient number 1 - 60 specimens were
immediately centrifuged after collection. They were then transported on ice to the
Centre for Cardiovascular Science, Queen's Medical Research Institute, Royal
Infirmary of Edinburgh where they were stored at -80°C until analysis. Patient
number 61-182 specimens were immediately centrifuged and stored at the Breast
Research Facility, Western General Hospital, Edinburgh. They were subsequently
transported to the Centre for Cardiovascular Science at completion of the study
where they were analysed alongside the samples from patients 1-60. Lipid
parameters were analysed at the Centre for Cardiovascular Science, Queen's Medical
Research Institute, Edinburgh.
Total cholesterol, triglyceride and HDL cholesterol were measured on an Olympus
AU2700 automated analyser using the manufacturer recommended reagents
(Beckman Coulter Ltd, High Wycombe, UK). The percentage coefficient of
variation for all three analyses was <5% across the working range.
Calculated LDL cholesterol was determined using the Friedewald Equation:
LDL cholesterol = total cholesterol - HDL cholesterol - (0.45 x triglycerides)
All units mmol/1241
ApoAl and ApoB concentrations were measured using immunoturbidimetric
immunoassay kits (A.Menarini Diagnostics, Winnersh-Wokingham, UK) adapted for
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use on a Cobas Fara Centrifugal Analyser (Roche Diagnostics Ltd, Welwyn Garden
City, UK). These methods are based on the reaction of a sample containing either
ApoAl or ApoB and the appropriate specific antiserum to form an insoluble complex
which can be measured turbidimetrically at 340nm. The between batch percent
coefficient of variations for the ApoAl assay for low medium and high quality
control material was 4.02, 3.66 and 4.64 respectively. While the between batch
percent coefficient of variations for the ApoB assay for low, medium and high
quality control material was 4.00, 3.68 and 3.53 respectively. Analyses were carried
out under blinded conditions.
Atherogenic ratios can be used to predict cardiovascular risk, often in combination
with other variables including age, sex, blood pressure and smoking status. The ratios
of total cholesterokHDL, LDL:HDL and ApoB:ApoA-l were calculated. These are
associated with an increased risk of cardiovascular disease when elevated.
2.2.10 Adverse event monitoring
The incidence, type and grade of adverse events (AEs) and serious AEs were
recorded during treatment in accordance with the National Cancer Institute's
common terminology criteria for adverse events (version 3.0). Side effect profiles




2.3.1 Bone turnover markers
2.3.1.1 Patients
Ninety-four postmenopausal women with ER+ve breast cancer were suitable for
adjuvant or extended adjuvant treatment with an AI and were eligible to provide
blood and urine samples for analysis. Very few patients enrolled were on drugs likely
to have an effect on bone metabolism. Patients were either due to start endocrine
therapy as their first treatment after surgery and were therefore tamoxifen-naive
(n=52) or were finishing 5 years of tamoxifen and beginning extended adjuvant
therapy (n=42).
All patients included had histologically confirmed invasive cancer that was ER+ve
(ALLRED score >4). Postmenopausal status was defined as amenorrhea for 1 year
and/or luteinising hormone with follicular stimulating hormone levels in the
postmenopausal range. Postmenopausal women who had early invasive breast cancer
(Tl-3, NO-1, MO) and who were able to give informed consent were considered
eligible. Of note, the only post chemotherapy patients were those who had completed
5 years of tamoxifen. All premenopausal women; women receiving concurrent or
previous chemotherapy (within the last four years); women taking concomitant
hormonal therapy, including hormone replacement therapy; women taking drugs
likely to affect bone metabolism, including steroids and bisphosphonates; and
patients unable to give informed consent were excluded from entry into the study.
Each patient was randomised (1:1) to receive 6 months of AI therapy, which
included 3 months of anastrozole followed by 3 months of letrozole or 3 months of
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letrozole followed by 3 months of anastrozole. Patients with no prior exposure to
tamoxifen were thereafter commenced on 20mg tamoxifen daily for four and a half
years.
Eighty four patients had complete sample measurements and were included in the
analysis. Patient disposition is shown in the CONSORT diagram in appendix G.
Forty-six patients were randomised to letrozole followed by anastrozole, and 48 were
randomised to anastrozole followed by letrozole. Ten patients were excluded from
analysis due to technical problems with samples. One patient was later removed from
the analysis, as she was found to be taking medication likely to affect bone turnover.
The median age of patients was 63 years (range, 40 to 87). Table 2.3 shows
additional demographics and it can be seen that both groups were similar except for a
difference between the median ages and for the number of patients who had
undergone hysterectomy. Patients who received five years of prior tamoxifen were
slightly younger and there were a larger number of women who had undergone
hysterectomy in this group. The type of statistical analysis performed on the data is








































0.03 X2 - test




0.09 Fisher's Exact Test
Table 2.3 Bone marker patient demographics
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2.3.1.2 Statistical analysis
The statistical analysis was conducted by an independent statistician. Hormone
therapy for each patient was coded to maintain the blind assessment and avoid bias.
A repeated measures analysis of variance was conducted, with baseline variables
accounted for, since measurements were of the same patient over a series of time
points. Whether the patients had taken tamoxifen for 5 years was also included in the
model. Bone ALP and PTH were log transformed to achieve Normality prior to
analysis.
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2.3.1.3 Effect of prior tamoxifen treatment
Baseline results
There were significant differences at baseline between the tamoxifen-nai've group
and patients who had received prior tamoxifen for PINP levels (47.94 versus
37.3ng/l, p=0.005) and sCTX levels (0.67 versus 0.49ng/l, p=0.0003) as shown in
table 2.4. Lower baseline levels of bone turnover markers were seen in all parameters
for those patients who received prior tamoxifen although only the aforementioned
were statistically significant.
Changes over time
Results are presented as mean percentage change from baseline for each group as
shown in figures 2.2 - 2.6. Patients who received prior tamoxifen had a greater
increase in levels of PINP (figure 2.2), ALP (figure 2.3), sCTX (figure 2.4) and
uNTX (figure 2.5) after 3 and 6 months of an AI compared with the tamoxifen naive
patients. PTH (figure 2.6) is an indirect measure of overall bone turnover, and greater
reductions between the two groups reflect the increased bone turnover in patients
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Table 2.4 Bone marker results - baseline absolute values






















Figure 2.2 Mean percentage change in PINP from baseline
Difference between no previous tamoxifen and previous tamoxifen at 3 months p=0.0044**
Difference between no previous tamoxifen and previous tamoxifen at 6 months p=0.0003***



























Figure 2.3 Mean percentage change in ALP from baseline
Difference between no previous tamoxifen and previous tamoxifen at 3 months p=0.004**











3 months 6 months
Time
Figure 2.4 Mean percentage change in sCTX from baseline
Difference between no previous tamoxifen and previous tamoxifen at 3 months p<0.0001***












3 months 6 months
Time
Figure 2.5 Mean percentage change in uNTX from baseline
Difference between no previous tamoxifen and previous tamoxifen at 3 months p=0.03

























3 months 6 months
Time
Figure 2.6 Mean percentage change in PTH from baseline
Difference between no previous tamoxifen and previous tamoxifen at 3 months p=0.45
Difference between no previous tamoxifen and previous tamoxifen at 6 months p=<0.0001***
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2.3.1.4 Differences between anastrozole and letrozole
There were no significant differences at baseline between those patients who initially
received anastrozole compared to those who received letrozole as seen in figure 2.4.
Both AIs had major effects on all bone markers, although there were no significant
differences between the drugs at the 3- or 6-month time points for any of the
parameters measured (all p>0.1). This was independent of the drug sequencing.
Absolute changes from baseline as shown in table 2.4 and mean percentage changes
from baseline are shown in figures 2.7 - 2.11. Both anastrozole and letrozole
markedly increased bone turnover markers.
Changes over time
There were significant increases in both bone formation and bone resorption between
baseline and 3 months and 3 and 6 months for PINP, bone ALP and sCTX (all
p<0.0001), and uNTX (p=0.04). PTH showed no change. The group who had
previously received tamoxifen had significantly greater increases (all p <0.0006) in
markers of bone resorption together with significantly larger rises in markers of bone
formation at all time points compared with the tamoxifen-naive group. The
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Time
Figure 2.7 Mean percentage change in PINP over time
Difference between anastrozole and letrozole at 3 months p=0.97







3 months 6 months
Time
Figure 2.8 Mean percentage change in ALP over time
Difference between anastrozole and letrozole at 3 months p=0.53
Difference between anastrozole and letrozole at 6 months p=0.51
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3 months 6 months
Time
Figure 2.9 Mean percentage change in sCTX over time
Difference between anastrozole and letrozole at 3 months p=0.48
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3 months 6 months
Time
Figure 2.10 Mean percentage change in uNTX overtime
Difference between anastrozole and letrozole at 3 months p=0.75




3 months 6 months
Time
Figure 2.11 Mean percentage change in PTH over time
Difference between anastrozole and letrozole at 3 months p=0.25
Difference between anastrozole and letrozole at 6 months p=0.74
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2.3.1.5 Effects of Als followed by tamoxifen
Tamoxifen had major effects on the markers of bone resorption when administered
after Als, sCTX (p=0.0004) and uNTX (p=0.0009), as shown in table 2.5. In both
cases, no difference was seen between the anastrozole and letrozole group. Only a
limited number of patients had data for this analysis, so some degree of care must be
taken in the interpretation of the results. There was no influence on mean percentage
change following tamoxifen by the sequence of the previous Als (all p>0.5).
Drug (mean percentage change, 95% CI)





































-10.20 (-21.69 to 0.87) 0.0009
Table 2.5 Comparison of anastrozole, letrozole and tamoxifen following
aromatase inhibitor
The bold results show where there is a significant change from baseline.
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2.3.1.6 Bone turnover discussion and conclusion
Anastrozole and letrozole are potent third-generation AIs that cause profound
suppression of plasma oestrogen levels in postmenopausal women173'243. There is
evidence that letrozole is a more potent inhibitor of aromatase, and that at clinically
used doses, letrozole reduces oestrogen levels to a greater degree than
anastrozole165'244. These results demonstrate that six months of treatment with
letrozole and anastrozole induces a significant increase in bone turnover, and that this
is further augmented in patients who have already received 5 years of adjuvant
tamoxifen therapy. Despite the greater ability of letrozole (2.5 mg) to lower
circulating oestrogen levels compared with anastrozole (1 mg)165, the effects on bone
metabolism are similar at clinically used doses. These effects increase with time, and
greater bone turnover is evident at 6 months compared with 3 months, although there
is no difference between the drugs. There is therefore unlikely to be any difference
between these drugs in fracture rate or the rate of osteoporosis. In postmenopausal
women, AI therapy has been associated with increases in bone turnover and bone
loss at an average rate of 1% to 3% per year245. Consequently, an increase in fracture
incidence is also observed when compared with that seen during tamoxifen use245. In
the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial, the fracture rate
for anastrozole was 11% at a median follow-up of 68 months, versus 7.7% for
tamoxifen176. This increased fracture rate with anastrozole did not continue after
treatment had stopped, suggesting that this is a short-term effect that could be
managed with DEXA scans and bisphosphonates when needed177. Similarly, in the
subset analysis restricted to the monotherapy arms of the Breast International Group
(BIG) 1-98 trial, the fracture rate for letrozole was 8.6% at a median follow-up of 51
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months, compared with 5.8% for tamoxifen246. The fracture rates increased in both
groups with the length of follow-up as shown in table 1.8.
Oestradiol levels have been reported to be virtually undetectable in patients taking
AIs, and this partly explains the high rate of bone loss and greater risk of fractures.
Deterioration in bone health is a major concern for patients taking AIs long-term. In
our study, there was no difference between letrozole and anastrozole with regard to
their effects on bone metabolism. Our findings are similar to those in the Letrozole,
Exemestane and Anastrozole in healthy Postmenopausal women (LEAP) study,
which also reports that the third-generation AIs, whether steroidal or nonsteroidal,
are similar with respect to their effects on bone247.
Postmenopausal women with hormone-sensitive breast cancer receiving adjuvant AI
therapy are at risk of Al-associated bone loss, but it is important to note that this
bone loss is manageable, and AI therapy should not be withheld for fear of bone loss.
The American Society of Clinical Oncology ( ASCO ) recommends BMD
assessments in all women beginning adjuvant AI therapy. While most women will
have normal BMD, routine screening may identify women who are at increased risk
for bone loss and are candidates for bisphosphonate therapy248. Bisphosphonates are
synthetic analogues of pyro-phosphate that adsorb on to bone surfaces and become
incorporated within the bone matrix. The drug is released when osteoclasts resorb
bone containing this compound. It inhibits signalling pathways that are necessary for
osteoclast function and therapy therefore results in a fall in bone resorption35.
Randomised clinical trials such as the Zometa-Femara Adjuvant Synergy Trial (Z-
FAST in the United States and ZO-FAST in Europe) support the use of zoledronic
acid (4 mg), a bisphosphonate, every 6 months to prevent Al-associated bone
loss249'250. In addition to calcium and vitamin D supplementation, oral
bisphosphonates are recommended to patients who start AI therapy with a T-score
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<-2.0. Bisphosphonates can also be recommended for any patient who is receiving
AI therapy and has any two of the following risk factors: T-score <-1.5, age >65
years, family history of hip fracture, personal history of fragility fracture after age
50, or oral corticosteroid use >6 months251.
It is evident that both anastrozole and letrozole cause a significant increase in the
bone turnover markers studied here, and that these effects increase over time. Since
both drugs have similar effects on bone metabolism and turnover, there is a clear AI
class effect on bone health in postmenopausal women with hormone-sensitive breast
cancer. Tamoxifen has been reported to have some beneficial effects on bone
turnover and fracture risk in postmenopausal women252'253'254'255 but the results here
suggest that these positive effects do not carry over once tamoxifen therapy is
discontinued. Patients who had previously received tamoxifen showed significantly
greater increases in the bone turnover markers PINP, bone ALP, sCTX and uNTX
and when switched to an AI, compared with patients who had not been treated with
tamoxifen. These results are in keeping with those from the ATAC trial, which
suggested that bone resorption and formation are likely to be suppressed by about
30% and 15%, respectively, in patients treated with tamoxifen compared with an
untreated population216. Tamoxifen inhibits bone turnover, explaining its bone-
preserving properties. Bone turnover rates increased in patients who had recently
stopped tamoxifen as a result of a 'rebound' increase in their rate of bone turnover.
The introduction of an AI is likely to further increase this rate of bone turnover and
this explains our results.
Bone remodelling is regulated by hormones including PTH. PTH causes increased
bone resorption and increased bone formation. PTH levels were lower in patients
treated with prior tamoxifen because tamoxifen has a beneficial effect on bone
turnover levels and PTH levels will be suppressed as a result of negative feedback.
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Prior tamoxifen therapy has also been shown to have a major effect on how AIs
affect bone. This study has shown that prior treatment with tamoxifen followed by
treatment with an AI results in a major increase in bone turnover markers which is
likely to result in bone loss. Major increases in bone turnover are likely to occur
when tamoxifen is withdrawn and then added to this are the effects that occur when
anastrozole or letrozole is started. These findings are similar to those seen in the IES
bone substudy: in those patients who were on tamoxifen for 2 to 3 years and then
switched to exemestane, there was a significant decrease in BMD compared with
baseline within 6 months at both the lumbar spine (2.7%; p<.0001) and hip (1.4%;
p<.0001)201. Thus, any benefit that tamoxifen has on bone density appears to be lost
rapidly after tamoxifen treatment ends and AIs begin. This is not significantly
different from the effects of withdrawal of HRT. Therefore, patients who take
anastrozole or letrozole after tamoxifen need the same bone monitoring as any
patient taking anastrozole or letrozole alone.
In conclusion, these results indicate that the effects of anastrozole and letrozole on
bone turnover are similar and increase with time. However prior tamoxifen treatment
has a major effect on how AIs affect bone. The effects of AIs are amplified when
introduced after previous tamoxifen treatment. This suggests a rebound increase in
bone turnover resulting from tamoxifen withdrawal and the introduction ofAIs. Any
benefits on bone health from tamoxifen appear to be rapidly lost after introducing
AIs.
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2.3.2 Quality of life and bone health
Oestrogen is an important component of bone homeostasis and causes stimulation
and inhibition of bone proliferation and resorption. Oestrogen deprivation is
associated with increased bone turnover and overall bone loss. It is suggested that
any bone or joint symptoms might be related to bone loss and it is of interest to
determine if an increase in bone turnover is associated with an increased rate of
musculoskeletal side-effects. Any side-effects which compromise QOL are
important.
2.3.2.1 Patients
A total of 166 patients were eligible for analysis of joint pain/stiffness symptoms.
Forty two patients reported joint pain or stiffness as shown alongside bone turnover
parameters in table 2.6.
The mean PINP marker for patients with joint symptoms was 55.6ng/l compared
with 50.2ng/l for those with no symptoms. These results were statistically significant
p=0.03. The mean sCTX bone turnover marker was 0.76ng/l for the 42 women who
reported joint symptoms. This figure was lower at 0.70ng/l for those who did not
report joint symptoms. These results showed borderline statistical significance
p=0.05.
When the patients were separated into groups depending on which drug they had
taken, there was no statistically significant difference demonstrated, although the size
of the measurements were very similar (tables 2.8 and 2.9) This is explained by the
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smaller numbers in each group which resulted in an increase in the size of the
confidence intervals.
These results suggest that PINP and sCTX are increased in patients who report
increased joint symptoms. There was no significant difference between the other
bone turnover parameters (ALP, uNTX or PTH) when comparing the group who
reported joint pain/stiffness with the group who reported no joint symptoms.








50.2 (47.8, 52.6) 55.6 (51.4, 59.8) 0.03
transformed
(ug/l)
2.60 (2.57,2.63) 2.62 (2.57, 2.68) 0.47
sCTX
(ng/ml)
0.70 (0.67, 0.73) 0.76 (0.71,0.82) 0.05
uNTX
(nmolBCE/mmolCr)
56.2 (52.9 59.5) 57.3 (51.6 63.0) 0.74
pfpj_j transformed
(Pg/ml)
3.96 (3.91,4.00) 3.98 (3.91,4.05) 0.57
Note thatpatients appear twice in this comparison (once per drug).
Mean and 95% CI given, results adjustedfor baseline. Repeated measures analysis performed to take into
account repeatedpatient measurements.
Table 2.6 Comparison of bone markers by presence of joint pain/stiffness
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2.3.2.2 Comparison of bone markers and joint symptoms by drug
There was no evidence to suggest that that the presence of joint symptoms was







No report of joint pain/stiffness 64 (77.1%) 60 (72.2%) 124
Report of joint pain/stiffness 19(22.9%) 23 (27.8%) 42
Total 83 83 166
Table 2.7 Reports of joint pain/stiffness by drug
The bone turnover marker PINP was significantly increased in patients who reported
joint symptoms compared with those who did not (60.9ng/l versus 50. lng/1 p=0.004)
in the anastrozole group as shown in table 2.8. There was no difference in those
taking letrozole as shown in table 2.9 and no significant difference between the two
drugs (p=0.10).
Anastrozole






PINP (ng/1) 50.1 (46.9, 53.3) 60.9 (54.6, 67.1) 0.004
ALP ,rans,ormell(ng/l) 2.61 (2.57,2.65) 2.65 (2.57, 2.72) 0.45
sCTX (ng/ml) 0.71 (0.67, 0.75) 0.77 (0.69, 0.85) 0.19
uNTX
(nmolBCE/mmolCr)
57.5 (53.4,61.7) 58.6 (50.9, 66.3) 0.82
PTHtransformed
(pg/ml)
3.95 (3.89, 4.02) 4.04 (3.93,4.15) 0.17











PINP (ng/1) 49.9 (46.7,53.1) 52.4 (47.2, 57.6) 0.42
ALP ,rans,ormed(gg/l) 2.59(2.54,2.64) 2.61 (2.53,2.68) 0.67
sCTX (ng/ml) 0.69 (0.65, 0.73) 0.76 (0.69, 0.83) 0.10
uNTX
(nmolBCE/mmolCr)
55.2 (50.5,59.9) 55.1 (47.4, 62.81) 0.99
PTH "rans^orme^
(pg/ml)
3.96 (3.91,4.01) 3.93 (3.84, 4.02) 0.56
Table 2.9 Comparison of bone markers by presence of joint pain/stiffness
while on letrozole
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2.3.2.3 Effects of prior tamoxifen
There was no evidence to suggest any relationship between the reporting of joint
symptoms and prior treatment with tamoxifen as demonstrated in table 2.10.
No prior tamoxifen Prior tamoxifen Total
n (%) n (%) N
No report of joint pain/stiffness 62 (75.6%) 62 (73.8%) 124
Report of joint pain/stiffness 20 (24.3%) 22 (26.2%) 42
Total n 82 84 166
Table 2.10 Reports of joint pain/stiffness by prior tamoxifen
x2 test p=0.79
PINP was elevated in patients who reported joint symptoms and had not been
exposed to prior tamoxifen (56.2ng/l) when compared to those who did not report
joint symptoms (44.9ng/l) p=0.002 as shown in table 2.11.
There was a significant interaction between the report of joint symptoms and prior
tamoxifen (p=0.009), suggesting that the behaviour of PINP is not consistent with
regards to each variable, such that where there is no prior tamoxifen, the PINP
measure is higher when there is a report of joint symptoms than without, but the
PINP measure is lower when there are joint symptoms than without, where there is
prior tamoxifen.
sCTX was significantly lower in patients who were tamoxifen naive as shown in
Tables 2.12 and 2.13 (p=0.006). This had no bearing on the report of joint
pain/stiffness in those previously exposed to tamoxifen, however there was a
difference between those who were tamoxifen naive (no symptoms 0.63ng/l versus
symptoms 0.74ng/l p=0.016).
163
uNTX levels were significantly different between those with previous tamoxifen and
those without (p=0.01), but this has no bearing on the report ofjoint pain/stiffness.
No prior tamoxifen
No report of joint pain
/stiffness (n=62)




PINP ng/1 44.9 (41.8,48.1) 56.2 (50.2, 62.2) 0.002
ALP ,ransrormci1 ng/| 2.57(2.52,2.61) 2.61 (2.52,2.69) 0.41
sCTX ng/ml 0.63 (0.59, 0.67) 0.74 (0.66, 0.82) 0.016
uNTX
nmolBCE/mmolCr
51.7 (47.1, 56.3) 53.2 (45.1,61.3) 0.74
PTH ,ranslormed pg/ml 4.02 (3.96,4.08) 3.99 (3.89,4.09) 0.61
Table 2.11 Comparison of bone markers by presence of joint pain/stiffness
without prior tamoxifen
Prior tamoxifen
No report of joint pain
/stiffness (n=62)




PINP ng/1 55.9 (52.6, 59.1) 54.6 (49.3,59.8) 0.67
ALP ,r"ns,"rn,ed (fg/l 2.64 (2.59,2.68) 2.64 (2.57,2.71) 0.95
sCTX ng/ml 0.78 (0.73, 0.82) 0.77 (0.70, 0.84) 0.60
uNTX
nmolBCE/mmolCr
60.7(56.1,65.3) 60.8 (53.1,68.6) 0.98
pTH transformed pg/m, 3.88(3.82,3.94) 3.97 (3.87,4.07) 0.13
Table 2.12 Comparison of bone markers by presence of joint pain/stiffness
with prior tamoxifen
164
2.3.2.4 Effects by visit intervals
More patients reported joint symptoms at visit 2 (month 6) compared with visit 1







No report of joint pain/stiffness n (%) 67 (80.7%) 57 (68.6%) 124
Report of joint pain/stiffness n (%) 16(19.2%) 26 (31.3%) 42
Total 83 83 166
Table 2.13 Reports of joint pain/stiffness by order
The bone turnover markers PINP, sCTX and ALP were significantly increased at
visit 2 (p=0.0025, 0.01, 0.003 respectively) as shown in tables 2.14 and 2.15. There
was no suggestion that this was related to the presence or absence ofjoint symptoms.
Visit 1
No report of joint pain
/stiffness (n=67)




PINP ng/1 46.6 (43.6, 49.6) 51.6 (45.4, 57.8) 0.15
ALP translormed U2/I 2.55 (2.51,2.59) 2.58 (2.50,2.66) 0.56
sCTX ng/ml 0.67 (0.64, 0.71) 0.70 (0.62, 0.79) 0.52
uNTX
nmolBCE/mmolCr
54.0 (49.7, 58.3) 54.78 (46.2, 63.4) 0.87
pTH transformed pg/m| 3.96 (3.91,4.02) 4.03 (3.92,4.14) 0.27
Table 2.14 Comparison of bone markers by presence of joint pain/stiffness
after visit 1
Visit 2
No report of joint pain
/stiffness (n=77)




PINP ng/1 54.5 (51.2, 57.7) 57.9 (53.0, 62.8) 0.25
ALP ,ransformed pg/l 2.66 (2.62, 2.70) 2.65 (2.59, 2.72) 0.81
sCTX ng/ml 0.73 (0.69, 0.78) 0.80 (0.74,0.86) 0.09
uNTX
nmolBCE/mmolCr
58.8 (54.1,63.4) 58.8 (51.9, 65.8) 0.98
PTH ,n,"s'onnedpg/ml 3.95 (3.89,4.01) 3.95 (3.86,4.04) 0.97
Table 2.15 Comparison of bone markers by presence of joint pain/stiffness
after visit 2
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2.3.2.5 Correlation between bone markers and frequency of joint
pain (BRM1)
The FACT-ES questionnaire investigates physical wellbeing, social and family
wellbeing, emotional and functional wellbeing, endocrine symptoms and additional
concerns. The endocrine section as shown in appendix C asks the patient to indicate
how often they experience pains in their joints. This is referred to as BRM1.
There was a statistically significant correlation between PINP in women who had not
been exposed to tamoxifen prior to commencing an AI and BRM1. Women taking








No Yes A L 1 2 No Yes
PINP -0.11 -0.02 0.03 -0.16 -0.07 -0.16 -0.04 -0.283 0.12
ALPtrani,formcd -0.201 -0.17 -0.04 -0.18 -0.232 -0.19 -0.20 -0.13 -0.20
sCTX -0.12 -0.01 -0.01 -0.18 0.07 -0.13 -0.09 -0.15 0.03
uNTX 0.003 0.04 0.04 -0.05 0.04 -0.03 0.03 -0.08 0.10
p'jpjj transformed -0.10 -0.11 -0.05 -0.05 -0.16 -0.04 -0.18 0.07 -0.25
A = anastrozole L = letrozole
p=0.01 2p=0.05 3 p=0.02
The bold results show where there is a significant change
Table 2.16 Correlation of BRM1 and bone markers
Due to the large number of hypothesis tests in the section on joint pain and bone
turnover markers, multiple testing may be an issue. There are several ways to deal
with this problem, one of which is to calculate a per comparison significance level
across the entire section. In this section, there are 83 significance tests, 45 alone in
table 2.16. The adjusted p-value calculated using Bonferroni's correction is less than
0.0006, so that for any test to be considered significant, the p-value would need to be
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less than 0.0006. In this section, no test reaches this threshold, implying that there is
no significant difference in any analysis however larger sample sizes may
demonstrate statistical significance in future trials.
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2.3.2.6 Bone turnover markers and musculoskeletal symptoms
Discussion and conclusions
In summary, the bone turnover markers PINP and sCTX were increased in women
with an increased incidence ofjoint symptoms suggesting that women with increased
joint pain may have increased bone turnover. There was no evidence to suggest that
the type ofAI had any effect on the presence ofjoint symptoms. As mentioned in the
results section, it is important to acknowledge that multiple tests were performed and
therefore the nominally significant p-values need to be considered as possibly
spurious when multiple testing is taken into account. The combination of QOL with
bone markers had too few cases to provide clinically meaningful information and this
is a major limitation of the study which was not powered to investigate any
relationship between these two variables. These results correlating bone turnover
markers and bone and musculoskeletal pain should therefore be considered as
hypothesis generating and it will be interesting to see if these results are confirmed in
future larger scale trials.
Musculoskeletal symptoms have been shown to affect 47% of women taking AIs in
early stage breast cancer256 however the aetiology of these symptoms remains
unclear. Arthralgias and myalgias may result from increased bone turnover and could
potentially be a marker of oestrogen suppression. Increased bone turnover results
from a complex process of cytokine and growth factor production, some of which are
involved with inflammation and may cause musculoskeletal symptoms.
Oestrogen has direct anti-nociceptive effects and therefore its withdrawal may in
addition increase pain sensation to underlying musculoskeletal pathologies. This may
be independent of the effects of increased bone turnover resulting from oestrogen
deprivation. The absence of circulating oestrogen binding to ER in joint tissue may
also induce pathophysiological changes leading to joint pain. Previous studies have
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not shown an association between systemic inflammatory cytokine levels and AI
associated musculoskeletal symptoms. One study did however detect a lower
concentration of multiple cytokines before AI initiation in women who developed
40
musculoskeletal symptoms compared with controls . Patients with metastatic breast
cancer treated with AI therapy report a much lower incidence of AI associated
musculoskeletal symptoms (16%) and this may be explained by patients with 'active
cancer' having higher levels of circulating cytokines before initiation of therapy257
MRI studies have demonstrated the development of tenosynovitis in patients treated
with AIs258, suggesting that localised inflammation may be involved with
musculoskeletal symptoms.
These current studies have suggested an association between bone turnover markers
and musculoskeletal symptoms. One explanation is that multiple oestrogen-
dependent inflammatory mediators resulting in increased bone turnover may be
associated with the development of a localised inflammatory process resulting in
pain although the precise mechanism may be multi-factorial.
One major limitation of this study is that the patients recruited had cancer and
potentially other conditions rather than well patients with no other conditions such as
those included in the LEAP study. Other limitations include the relatively small
number of subjects investigated especially the group included in QOL and
musculoskeletal symptoms. In addition, there was no control/placebo group therefore
we are unable to state that the changes detected were definitely a result of
tamoxifen/AI. The groups were not aged-matched however there was no significant
difference in ages in each group. Compliance may also have been a limitation as
there is no way of knowing whether the patients adhered strictly to the regimen. Both
studies would have benefitted from having age-matched and cancer-free control
groups.
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Clinical trials have shown that Als generally have more favourable adverse events
compared to tamoxifen. Results from ATAC demonstrated that discontinuation rates
due to adverse events were significantly higher in the tamoxifen compared with
anastrozole group (14.3% vs. 11.1% respectively p=0.0002)176. The MA.17 trial
demonstrated that more patients discontinued letrozole compared with the placebo
group (4.9% vs. 3.6% p = 0.019202. However a 138 patients taking exemestane in the
IES study discontinued therapy compared with 121 taking tamoxifen. A further 164
patients taking exemestane refused to continue therapy compared with 116 in the
tamoxifen group200. AI associated musculoskeletal symptoms respresent an important
toxicity and results from the major trials shown in table 1.12 demonstrate that there is
an increased incidence compared with tamoxifen. This in turn may affect drug non¬




Ninety-four postmenopausal women with ER+ve breast cancer were suitable for
adjuvant or extended adjuvant treatment with an AI and were eligible to provide
samples for analysis. Patient disposition is shown in the CONSORT diagram in
appendix G. Very few patients enrolled were on drugs likely to have an effect on
lipid metabolism.
2.3.3.2 Statistical analysis
The statistical analysis was conducted by an independent statistician. Hormone
therapy for each patient was coded to maintain the blind assessment and avoid bias.
Baseline data were analysed using analysis of variance methods. For the post-
treatment data, analysis of the variables was conducted using mixed models and
repeated measures. Estimates of effect size (and 95% CI) have been calculated from
the least square means, with baseline values entered into the model as covariates.
Triglycerides were log transformed to achieve Normality at baseline.
I7l
2.3.3.3 Effect of treatment on lipid profile
Results are presented as percentage change from baseline for each group.
Anastrozole versus letrozole:
There was little evidence to suggest a difference between the two drugs. Only cLDL
at 6 months appears to show any difference. Letrozole caused a significant increase
ofcLDL from baseline compared to anastrozole. This is shown in table 2.17.
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Atherogenic





Triglyceride1"8 3 months -5.52 +4.74 0.21
rnmol/1 6 months +5.39 -0.32 0.51
p-value 0.20 0.55
Cholesterol 3 months +0.64 +5.06 0.19
mmol/l 6 months -0.83 +4.17 0.18
p-value 0.67 0.90
cLDL 3 months +4.74 +6.87 0.69
mmol/l 6 months -2.71 +8.60 0.04
p-value 0.17 0.75
ApoB 3 months -1.17 +5.05 0.27




HDL 3 months +1.36 +0.92 0.92
mmol/l 6 months +4.45 +3.20 0.76
p-value 0.93 0.62
ApoAl 3 months -6.74 -1.90 0.27
g/1 6 months +0.24 -3.27 0.37
p-value 0.09 0.75
Table 2.17 Mean percentage changes in lipids from baseline
The bold results show where there is a significant change from baseline. A positive mean with all
positive confidence limits indicates a significant percentage rise from baseline, while a negative mean
with all negative confidence limits indicates a significant fall from baseline
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2.3.3.4 Effects of prior tamoxifen
Prior tamoxifen versus no tamoxifen in system
anastrozole versus letrozole:
Tables 2.18 show a comparison of anastrozole versus letrozole in relation to prior
tamoxifen use (absolute values).
Drug Prior tamoxifen No prior p-value
tamoxifen (drug)
Atherogenic lipids Mean (95% CI)
Triglyceridel"g""'sl"n,"xl anastrozole -0.02 (-0.24, 0.20) 0.51 (0.37, 0.66) 0.0001
mmol/L letrozole 0.08 (-0.13, 0.29) 0.52 (0.38, 0.67) 0.001
p-va!ue (tamoxifen) 0.20 0.86
Cholesterol anastrozole 5.56(5.00,6.12) 5.66 (5.28,6.03) 0.78
mmol/L letrozole 5.72 (5.17, 6.27) 5.95 (5.57, 6.32) 0.50
p-value (tamoxifen) 0.52 0.11
cLDL anstrozole 3.37 (2.86,3.88) 3.36(3.01,3.71) 0.96
mmol/L letrozole 3.54 (3.04, 4.05) 3.66 (3.32, 4.01) 0.70
p-value (tamoxifen) 0.44 0.07
ApoB anastrozole 0.78 (0.64, 0.91) 0.94 (0.85, 1.03) 0.04
g/L letrozole 0.84 (0.71, 0.97) 0.95 (0.86,1.04) 0.19
p-value (tamoxifen) 0.23 0.90
Atheroprotective lipids
HDL anastrozole 1.68(1.49, 1.86) 1.40 (1.28, 1.52) 0.0155
mmol/L letrozole 1.66 (1.47, 1.84) 1.43 (1.31, 1.55) 0.0453
p-value (tamoxifen) 0.74 0.52
ApoAl anastrozole 1.52 (1.37, 1.66) 1.36(1.26, 1.46) 0.08
g/L letrozole 1.48 (1.34, 1.63) 1.40(1.29, 1.49) 0.32
p-value (tamoxifen) 0.53 0.37
Table 2.18 Comparison of final measurements by tamoxifen status
The bold results show where there is a significant change from baseline. A positive mean with all
positive confidence limits indicates a significant percentage rise from baseline, while a negative mean
with all negative confidence limits indicates a significant fall from baseline
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Triglycerides (mmol/l)
Both anastrozole and letrozole resulted in a fall in the levels of triglycerides in
patients who had recently stopped tamoxifen as shown in figure 2.12. Anastrozole
=-0.02 (-0.24, 0.20) and letrozole =0.08 (-0.13, 0.29) compared with those with no
recent tamoxifen exposure. Anastrozole =0.51 (0.37, 0.66) and letrozole =0.52 (0.38,
0.67), p-values 0.0001 and 0.001 respectively.
ApoB (g/l)
There were significantly lower levels of ApoB in patients who had recently stopped
tamoxifen and were then treated with anastrozole, than those with no recent
tamoxifen exposure (0.78 (0.64, 0.91) versus 0.94 (0.85, 1.03), p=0.04), as shown in
figure 2.13.
HDL (mmol/l)
Patients treated with anastrozole had significantly higher levels ofHDL in those who
had recently stopped tamoxifen as shown in figure 2.14. Anastrozole: 1.68 (1.49,
1.86) versus letrozole 1.40 (1.28, 1.52), p=0.02. Levels on letrozole were also higher
for patients who had recently stopped tamoxifen than for those with no recent
tamoxifen exposure (letrozole: 1.66 (1.47, 1.84) versus 1.43 (1.31, 1.55) (p=0.045).
ApoA1 (g/l), cholesterol (mmol/l) and cLDL (mmol/l)
There were no significant changes for ApoAl, cholesterol or cLDL as shown in
figures 2.15-2.17.
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Figure 2.12 Triglycerides (mmol/L)
No previous tamoxifen versus previous tamoxifen
Anastrozole p<0.001***, letrozole p<0.001***
Frsviom ^ ©nit ~o?rc
■ no
Drug
Error bars: 95% CI
Figure 2.13 ApoB (g/L)
No previous tamoxifen versus previous tamoxifen







Error bars: 95% CI
*
Figure 2.14 HDL (mmol/L)
No previous tamoxifen versus previous tamoxifen
Anastrozole p=0.02*, letrozole p=0.045*
Figure 2.15 ApoA1 (g/L)
No previous tamoxifen versus previous tamoxifen
Drug
Error bars: 95% CI










Error bars: 95% CI
Figure 2.16 Cholesterol (mmol/L)
No previous tamoxifen versus previous tamoxifen





Error bars: 95% CI
Figure 2.17 cLDL (mm/L)
No previous tamoxifen versus previous tamoxifen




The mechanisms by which tamoxifen and AIs affect lipids and lipoproteins are
unclear. It is known that oestrogen affects hepatic lipoprotein metabolism by
increasing the synthesis of very low-density lipoproteins, leading to an increase in
triglyceride levels. In addition it causes an increased apolipoprotein B receptor to
lower LDL and lastly an increased synthesis of Apo A-l which causes a high
concentration of HDL60.
The effects of long term AI treatment on lipid metabolism are a concern. Previous
studies have suggested an unfavourable effect of letrozole on serum lipid profiles
resulting in an increase in total cholesterol, cLDL and ApoB levels as well as similar
unfavourable changes in the atherogenic risk ratios cholesterokHDL cholesterol and
LDL cholesterokHDL cholesterol259. Studies investigating the effects of anastrozole
on lipids have shown beneficial increases in HDL and favourable decreases in
triglycerides repeatedly. The effects on total cholesterol or cLDL are
variable260'261'262.
This study demonstrated no major differences between these two drugs although
letrozole increased cLDL at 6 months p=0.04 compared with anastrozole. This could
be a spurious result given the number of analyses however anastrozole did reduce
cLDL after letrozole so there is some consistency. This may relate to the lower
oestradiol levels caused by letrozole.
Patients treated with tamoxifen who then switch to anastrozole or letrozole had a
significant beneficial change in their lipid profile. This may be of value when
planning drug sequencing. Triglycerides and ApoB levels (anastrozole only) were
significantly lower in patients who had recently stopped tamoxifen. HDL levels were
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significantly greater in those with no recent tamoxifen exposure. Tamoxifen has
oestrogen-like properties and is known to favourably affect lipid profiles. Oestrogen
has been reported to reduce total cholesterol and cLDL and to increase HDL, while
the effects on triglycerides are unclear263. The ATENA substudy studied the duration
of the beneficial tamoxifen effects on Iipidaemic profiles following deprivation of
treatment. Long-term tamoxifen results in a significant decrease in total cholesterol
and LDL. These lipids could therefore be expected to rise adversely after tamoxifen
therapy is completed. Tamoxifen withdrawal demonstrated an overall trend for
increasing cholesterol and LDL and decreasing triglycerides, as early as 6-12 months
after tamoxifen withdrawal264. These changes were also demonstrated in our study
however they were not statistically significant.
One major limitation of this study is that the patients recruited had cancer and
potentially other conditions rather than well patients with no other conditions such as
those included in the LEAP study. Other limitations include the relatively small
number of subjects investigated. In addition, there was no control/placebo group
therefore we are unable to state that the lipid changes detected were definitely a
result of tamoxifen/AI. The groups were not aged-matched however there was no
significant difference in ages in each group. Compliance may also have been a
limitation as there is no way of knowing whether the patients adhered strictly to the
regimen. Both studies would have benefitted from having age-matched and cancer-
free control groups.
Although lipid parameters are important risk factors, the relationship between
hormone-related changes in these factors and the development of CVD is unclear260.
The ATAC study demonstrated no statistical difference in the incidence of ischaemic
cardiovascular events176 although ischaemic cardiovascular events were reported
more frequently with anastrozole compared to tamoxifen, i.e. a similar incidence of
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ischaemic cardiovascular events. The ITA trial reported a statistically significant
difference between the effects of anastrozole versus tamoxifen on lipid metabolism.
Dyslipidaemia was detected in 9.3% of patients treated with anastrozole versus only
4.0% receiving tamoxifen198. The LEAP trial directly compared the safety profiles
between exemestane and the non-steroidal AIs anastrozole and letrozole in 90
healthy postmenopausal women. Results demonstrated no significant differences
between anastrozole and letrozole on their effects on LDL:HDL ratios, triglycerides
and non-HDL concentrations however exemestane significantly decreased total
cholesterol at 3 months (-5.5%)247. While oestrogen withdrawal has the potential to
alter lipid profiles detrimentally, studies have shown that this does not occur with
anastrozole261. Perhaps therefore anastrozole is less potent and certainly the clinical
evidence points to anastrozole being less effective as seen in ATAC compared with
BIG1-98246. The beneficial effects of tamoxifen may explain the higher incidence of
lipid disorders demonstrated in the ITA trial which showed that switching from
adjuvant tamoxifen to anastrozole was associated with a higher incidence of lipid
disorders'98. Studies have shown that anastrozole has fewer thromboembolic and
ischaemic cerebrovascular events compared with tamoxifen and does not
demonstrate androgenic, progestogenic or oestrogenic effects. The BIG 1-98 study
reported 5.4% of hypercholesterolemia in the letrozole arm compared with 1.2% in
the tamoxifen arm in patients with baseline values within normal limits, who then
had an increase of 1.5 times the upper limit of normal65. These were not fasting
samples and the subsequent lipid substudy did not confirm the numbers of
hypercholesterolaemia seen in those who had fasted. More women in the letrozole
group had grade 3,4 or 5 cardiac events (2.1% vs. 1.1%) p<0.001 compared to
tamoxifen however this may reflect the favourable effects on lipid parameters of
tamoxifen which are well known. Big 1-98 also reported an increased number of
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cardiovascular-related deaths with letrozole compared to tamoxifen74'265- MA-17
trial compared letrozole with a placebo after prior tamoxifen therapy. It showed that
266
after 36 months of letrozole there was no significant change in lipid profile . This
raises the possibility that changes seen in lipids are a result of previous tamoxifen
treatment.
Women diagnosed with early breast cancer are at risk from cardiovascular disease
and nearly all adjuvant treatments are associated with a degree of cardiovascular
toxicity e.g. radiotherapy, chemotherapy, HER-2 therapy and tyrosine kinase
inhibitors (lapatinib). In addition to these is often a decrease in exercise and
concomitant weight gain which may accompany the diagnosis of breast cancer. As
cardiovascular disease is the highest cause of mortality in postmenopausal women, it
is vital to minimise the cardiotoxic effects of adjuvant endocrine therapy.
Recommendations to reduce major cardiovascular risk factors will help to reduce
morbidity in this patient group. Hypercholesterolaemia can be successfully treated
using lipid lowering drugs. 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) reduce cholesterol synthesis, especially in the liver. They are more
effective than other lipid-lowering drugs at lowering low-density lipoprotein
cholesterol <100mg/dl. They are known to reduce cardiovascular disease events and
total mortality irrespective of the initial cholesterol concentration267. Other
recommendations to reduce risk include lifestyle modifications such as beneficial
changes to diet, exercise and weight management. Regular exercise may have a
positive effect on hepatic fat metabolism. Alcohol consumption and smoking
cessation are other areas which can be targeted. Hypertension can be specifically
treated using beta-blockers +/- angiotensin-converting enzyme inhibitors and diabetic
patients can be successfully treated using sulfonylureas or biguanides228. In addition,
preclinical studies have demonstrated that lipophilic statins, ACE inhibitors and
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metformin exhibit antineoplastic activity in several experimental models of breast
9<CQ 9AQ 970
carcinogenesis ' ' . Statins (inhibitors of HMG-CoA reductase) are widely used
to lower lipid concentrations for prevention of coronary artery disease. Recent
observational studies have suggested a reduction in breast cancer risk associated with
statin use. The evidence is however inconsistent and further evidence is required
before statins can be included in large-scale prevention studies192.
These results demonstrate little evidence to suggest a difference between the two
available non-steroidal AIs and their effects on lipids. Patients who had recently
completed tamoxifen and commenced anastrozole or letrozole showed beneficial
changes in their lipid profile compared to patients with no recent exposure to
tamoxifen.
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SECTION 3: ALEX STUDY
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3.1 Introduction
There are two distinct groups of AIs: non-steroidal and steroidal. Each have a
different mechanism of action and it is therefore likely that each will have differing
side-effect profiles. The ALEX study evaluated the impact of the non-steroidal AIs,
anastrozole and letrozole and the steroidal inactivator, exemestane on bone, lipid,
coagulation and quality of life profiles in postmenopausal women with ER+ve breast
cancer. The effects of tamoxifen after prior AI therapy was also assessed in the lipid
and coagulation groups.
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3.2 ALEX Material and methods
3.2.1 Study Design
ALEX (Anastrozole versus Letrozole versus Exemestane) compared the effects of
AIs in a series of postmenopausal women with hormone sensitive breast cancer. This
was a prospective, open-label, randomised pharmacodynamic study. Bone markers,
lipid and coagulation parameters were measured in 120 postmenopausal women with
invasive ER+ve breast cancer. QOL questionnaires were also collected. Patients were
randomised as part of their adjuvant endocrine therapy to receive either 4 months of
anastrozole or 4 months of letrozole or 4 months of exemestane. Patients were then
switched to tamoxifen and further samples were collected at 12 months, as shown in
figure 3.1.
All patients were treated in the Edinburgh Breast Unit, UK. Following informed
consent, each patient was randomised to receive 4 months of anastrozole (1 mg) or
letrozole (2.5 mg) or exemestane (25mg) orally once daily. Patients received
adjuvant AI therapy within one month of surgery. Thereafter they were switched to
tamoxifen and further samples collected at 12 months.
3.2.2 Ethical approval
The study was approved by the Lothian Research Ethics Committee and carried out
in accordance with the Declaration of Helsinki and in keeping with Good Clinical
Practice.
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Figure 3.1 ALEX Study Design
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3.2.3 Patient Selection
One hundred and twenty postmenopausal women with ER+ve breast cancer suitable
for adjuvant therapy with an AI were enrolled. Patients were recruited within one
month of surgery and were hormone treatment naive. All patients were identified for
trial entry at the multi-disciplinary team meeting using inclusion/exclusion criteria as
shown in appendix D. Patient information sheets are shown in appendix E.
Women known to be hyperlipidaemic or taking lipid-lowering medications were
excluded as were those taking HRT within one month prior to recruitment. All
patients included had histologically confirmed invasive cancer that was ER+ve
(ALLRED score >4). Postmenopausal status was defined as amenorrhea for 1 year
and/or luteinising hormone with follicular stimulating hormone levels in the
postmenopausal range. Postmenopausal women who had early invasive breast cancer
(Tl-3, NO-1, MO) and who were able to give informed consent were considered
eligible. All premenopausal women; women receiving concurrent or previous
chemotherapy; women taking concomitant hormonal therapy, including hormone
replacement therapy; women thought to be at risk of carrying HIV, Hepatitis B or C,
women with a history of jaundice, hypothyroidism, diabetes or with known or
suspected alcohol abuse and patients unable to give informed consent were excluded
from entry into the study.
Randomisation was 1:1:1, anastrozole:letrozole:exemestane for patients 1-77 and
1:1:2 for the patients 78-120. This was to increase the numbers on exemestane to allow
a comparison between steroidal versus non-steroidal AIs. After 4 months of AI patients
were commenced on 20mg tamoxifen daily.
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3.2.4 Oestrogen receptor testing
All patients eligible for the study were ER+ve as per the ALIQUOT study.
3.2.5 Collection of clinical data
Data were collected using the same method as the ALIQUOT study. A CRF was
filled out for every patient. All data were collected prospectively.
3.2.6 Collection and storage of blood and urine samples
Fasting blood and urine samples were obtained at the beginning of the study, after 3,
4 and 12 months. Samples were obtained at the same time of day and on the same
day of the week. The timing of samples was scheduled to minimise diurnal and diet-
related effects.
Plasma samples were separated by centrifugation and stored at -80°C until analysed.
The second voided urine of the day was collected for measurement of urinary bone
markers and stored at -80°C.
Patient details were encoded to ensure anonymity. A detailed chronological log book
of all samples collected was recorded, ensuring easy and accurate identification of
specimens.
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3.2.7 Bone turnover marker analysis
Samples were analysed using the same methods as the ALIQUOT study as shown on
page 136.
3.2.8 QOL analysis
Patient information was collected using the same methods as the ALIQUOT study as
shown on page 138.
3.2.9 Lipid analysis




Coagulation and natural anticoagulants were analysed in citrated plasma at the
Department of Haematology, Royal Infirmary of Edinburgh, UK using the ACL-
TOP which is an automated, random access coagulation instrument utilising
coagulometric, chromogenic and immunological measurements. Analysis was carried
out under blind conditions to avoid bias. The analytes measured are shown in table









Major inhibitor of fibrinolysis which prevents
lysis of clot.




Binds to Factor VIII and enhances haemostasis.
High levels increase the risk of thrombosis.
0.42- 1.22 iu/ml
Factor VIII Clotting factor. Factor VIII and vWF circulate
together.
0.5 -1.5 iu/ml
Fibrinogen An acute phase protein which determines blood









Antithrombin (AT) A major naturally occurring anticoagulant. 0.8 - 1.2 iu/ml
Protein C A vitamin K-dependent glycoprotein which is
anticoagulant. It requires the co-factor, protein S,
for full activity.
0.67- 1.38 iu/ml
Protein S total A vitamin K-dependent glycoprotein. ~ 60%
circulates bound and is inactive. The remaining
40% is the active uncomplexed moiety.
0.64 - 1.54 iu/ml
Protein S free An active natural anticoagulant. 0.61 - 1.43 iu/ml
Table 3.1 Plasma coagulation factors measured271
Plasma levels of plasminogen activating inhibitor (PAI) antigen and vWF antigen are
both markers of increased thrombogenesis. Elevated factor VIII and fibrinogen levels
are also associated with increased thrombosis. Fibrinogen was measured using
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coagulometric (turbidimetric) measurements whereby the amount of time required
for a plasma specimen to clot is measured. This technique assesses coagulation
endpoint by measuring change in optical density. Resistance to activated protein C
was measured as a ratio and is a further marker of thrombogenesis. Activated protein
C resistance (APCR) is an inherited cause of venous thrombosis and results from the
factor V Leiden mutation71.
Plasma antithrombin (AT), protein C, protein S total and protein S free are natural
inhibitors of coagulation and were measured using chromogenic (absorbance)
measurements which employs the colourimetric principle of measuring absorbance
of light by a solution. Recurrent venous and occasionally arterial thrombosis are
associated with an autosomal dominant deficiency of AT71. Protein C and S are
inhibitors of coagulation cofactors V and VIII. Protein C is a vitamin K-dependent
serine protease which is activated by the binding of thrombin to an endothelial cell
surface receptor, thrombomedulin. It is able to destroy activated factors V and VIII,
thus preventing thrombin generation and its action is enhanced by another vitamin In¬
dependent protein, S. Protein C also enhances fibrinolysis. Protein S is a co-factor
for protein C71.
The interassay CVs and the intra-assay CVs were <10% on all quality controls.
Coagulation factors measured at baseline and after 3 and 4 months of each AI. After
4 months of AI patients were commenced on tamoxifen therapy and further
coagulation factors were measured at 12 months.
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3.2.11 Adverse events monitoring
The incidence, type and grade of AEs and serious AEs were recorded during
treatment in accordance with the National Cancer Institute's common terminology
criteria for adverse events (version 3.0). Side effect profiles and adverse were
recorded at each visit and also during telephone interviews with patients.
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3.3 ALEX RESULTS AND DISCUSSION
3.3.1 Bone turnover markers
3.3.1.1 Patients
Fasting blood and urine samples were collected from 120 patients as shown in the
CONSORT diagram in appendix H. An additional 42 patient sample sets were added
to the population from the ALIQUOT study (hormone naive group only). Overall
bone turnover markers were measured in 162 postmenopausal women. Data from
155 patients were available for analysis. Samples were obtained from patients at the
same time of day and the same day at entry, after 3 and 4 months of each drug.
3.3.1.2 Specimen analysis
Bone marker were analysed using the same methods as the ALIQUOT study as
described on page 138.
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3.3.1.3 Statistical analysis
Analysis of variables was performed using mixed models and repeated measures.
Bone ALP and PTH were log transformed to achieve Normality prior to analysis.
Percentage change was analysed by the method analysis of covariance, where the
baseline values are included as a covariate. Some variables were log-transformed to
achieve Normality. This is indicated in the tables where appropriate by (t). Where
data were unavailable at three months, four month data have been substituted to
create a 'post-treatment' variable. Tukey's correction has been used to adjust for
multiple comparisons.
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3.3.1.4 Differences between anastrozole, letrozole and
exemestane
Results are presented as percentage change from baseline for each group.
Anastrozole, letrozole and exemestane significantly increased bone turnover. These
effects are summarised in table 3.2.
Exemestane showed a greater rise by percentage change in bone turnover markers
compared with anastrozole and letrozole however there were no significant
differences between the drugs. These changes are shown in figures 3.2-3.6.









PINP ng/1 7.65 (0.51,14.79) 11.28 (4.34,18.22) 17.82 (10.31, 25.32) 0.15
ALP(t) pg/1 2.59 (0.84, 4.33) 2.59 (0.90, 4.30) 3.04 (1.19, 4.89) 0.92
sCTX ng/ml 11.99 (5.35,18.63) 15.72 (9.27, 22.17) 13.72 (6.73, 20.72) 0.73
uNTX (t)'
nmolBCE/mmolCr
-1.03 (-4.49,2.42) -1.44 (-4.93,2.05) 3.53 (-0.36, 7.43) 0.14
PTH (t)2 pg/ml -1.94 (-3.74, -0.13) -0.14 (-1.90, 1.61) 0.27 (-1.64, 2.19) 0.21
n = 52, 52, 45 respectively
2
n = 46, 48, 41 respectively
The bold results show where there is a significant change from baseline. A positive mean with all
positive confidence limits indicates a significant percentage rise from baseline, while a negative mean
with all negative confidence limits indicates a significant fall from baseline





Error bars, 95% CI
Figure 3.2 PINP mean percentage change per drug
No statistically significant difference detected between the drugs p=0.15
Earnestan*
Drug
Eiroi hars 95% CI
Figure 3.3 Bone ALP mean percentage change per drug




Error bars. 95% CI
Figure 3.4 sCTX mean percentage change by drug
No statistically significant difference detected between the drugs p=0.73
Drug
Error bars 95% CI
Figure 3.5 uNTX mean percentage change by drug




Error tars 95% CI
Figure 3.6 PTH mean percentage change per drug
No statistically significant difference detected between the drugs p=0.21
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3.3.1.5 Differences between non-steroidal and steroidal Als
Differences between non-steroidal and steroidal Als are demonstrated in figures 3.7-
3.11. Exemestane resulted in a greater increase in PINP compared to the non¬
steroidal Als however this showed borderline significance (p=0.07). Exemestane
resulted in a statistically greater increase in uNTX compared to non-steroidal Als
(p=0.05). PINP, bone ALP and CTX all had significantly higher than zero percentage
changes, regardless of drug or drug type. These results are summarised in table 3.3.





PINP ng/1 9.52 (4.55,14.49) 17.81 (10.32, 25.31) 0.07
ALP (t) pg/1 2.59 (1.38, 3.81) 3.04 (1.20, 4.88) 0.69
sCTX ng/ml 13.91 (9.28,18.53) 13.72 (6.74, 20.70) 0.97
uNTX (t)J
nmolBCE/mmolCr
-1.23 (-3.71, 1.24) 3.53 (-0.35, 7.41) 0.05
PTH (t)4pg/ml -1.02 (-2.28, 0.25) 0.26 (-1.66,2.18) 0.27
n = 104, 45 respectively
4
n = 94, 41 respectively
Table 3.3 Percentage changes from baseline between non-steroidal and
steroidal Als








Enor bars 95% CI
Figure 3.7 PINP mean percentage change from baseline
Non-steroidal versus steroidal Als






Error bars: 95% CI
Figure 3.8 ALP mean percentage change from baseline
Non-steroidal versus steroidal Als
No statistically significant difference detected between the classes of drug p=0.69
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Drug
Error bars: 95% CI
Figure 3.9 sCTX mean percentage change from baseline
Non-steroidal versus steroidal Als
No statistically significant difference detected between the classes of drug p=0.97
Drug
Error bars: 95% CI
Figure 3.10 uNTX mean percentage change from baseline
Non-steroidal versus steroidal Als


















Figure 3.11 PTH mean percentage change from baseline
Non-steroidal versus steroidal Als
No statistically significant difference detected between the classes of drug p=0.27
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3.3.1.6 Bone discussion and conclusions
This study demonstrated that each AI significantly increased bone turnover markers
however the effects at these clinically used doses were very similar. The steroidal AI,
exemestane had a greater effect on bone turnover compared with non-steroidal AIs,
anastrozole and letrozole however this difference was not marked.
Due to their oestrogen depriving properties, AIs are associated with osteoporosis and
an increased fracture risk. Oestrogen inhibits bone resorption by directly suppressing
early osteoblastic and osteoclastic precursors in the bone marrow through the
initiation of receptor activator of nuclear factor-kappa B ligand (RANKL) production
by osteoblastic precursors. Previous studies have shown that oestrogens stimulate the
production of osteoprotegerin, the potent anti-osteoclastogenic factor that blocks the
binding ofRANKL. Oestrogen also regulates the production ofmany bone-resorbing
cytokines by osteoblasts and bone marrow stromal cells, progenitor cell
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differentiation, and inhibits apoptosis in both osteoblasts and osteocytes ' ' .
The two classes of AIs differ in both their structure and in their interaction with
aromatase. The steroidal exemestane is structurally similar to the androgen substrate
androstenedione rendering it more androgenic. In addition, the primary metabolite of
exemestane is 17-hydroxyexemestane, which is also androgenic and binds tightly to
the androgen receptor. Androgens positively influence bone density and strength.
Their predominant effect appears to be on the osteoblast because androgens primarily
increase bone formation rather than decreasing bone resorption275. Positive
correlations between endogenous androgen levels and BMD in pre and
postmenopausal women and also in men have been reported276'277. Studies have
shown that low oestrogen concentrations have caused an increase in androgen
receptor sensitivity in bone. In comparison, the non-steroidal AIs, anastrozole and
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letrozole have no demonstrable androgenic effects278. This may partly expain the
differences between the two classes of drug and their effects on bone.
One major limitation of this study is that the patients recruited had cancer and
potentially other conditions rather than well patients with no other conditions such as
those included in the LEAP study. Other limitations include the relatively small
number of subjects investigated. In addition, there was no control/placebo group
therefore we are unable to state that the changes detected were definitely a result of
tamoxifen/AI use. The groups were not aged-matched however there was no
significant difference in ages in each group. Compliance may also have been a
limitation as there is no way of knowing whether the patients adhered strictly to the
regimen. Both studies would have benefitted from having age-matched and cancer-
free control groups.
All three AIs are associated with an increased fracture rate compared to tamoxifen or
placebo in adjuvant trials. After a median follow-up of 68 months, the ATAC trial
reported an increase in the numbers of fractures associated with anastrozole (11%
fracture rate) compared with tamoxifen (7.7% fracture rate). The incidence of hip
fractures was low in both groups however those taking anastrozole had a
significantly higher rate of vertebral fractures compared with tamoxifen (1.5% versus
0.9% respectively)189. Similarly in the BIG-1-98 study, comparing letrozole with
tamoxifen, letrozole was reported to have a higher (5.7%) fracture rate compared
with tamoxifen (4.0%) after a median follow-up of 25.8 months206. The recent
publication of the TEAM trial results has also confirmed a significantly higher
incidence of fractures and osteoporosis in women treated with exemestane
monotherapy (5% and 10% respectively) compared with those treated with
tamoxifen (3% and 6% respectively) after a median follow-up of 60 months196. The
TEAM sub-study evaluated the effects of exemestane and tamoxifen on markers of
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bone turnover. Exemestane significantly increased bone turnover markers and
tamoxifen significantly decreased them. PINP was increased by 36.7% after 3
months of exemestane compared with -18% in the tamoxifen group. These changes
increased at 6 and 12 month time points279. The earlier IES study demonstrated a
3.1% fracture rate in women treated with exemestane compared with a 2.3% rate
with tamoxifen200.
The type of fracture associated with AI use is of interest. In the ATAC study of
anastrozole, there were 45 vertebral fracture cases in the anastrozole group and 27 in
the tamoxifen group. There were only small differences in the rate of hip and forearm
fractures. It is likely that larger changes in bone turnover are required to reduce non-
vertebral fractures. Tamoxifen is known to increase BMD of the spine, but not the
forearm or total body BMD280.
AI induced bone loss is preventable and treatable using bisphosphonates alongside
dietary and lifestyle changes. Early detection using baseline bone mineral density
tests are recommended prior to commencing an AI. Bisphosphonates can be
administered to prevent the bone loss associated with AIs as demonstrated in the
Zometa-Femara Adjuvant Synergy trials (Z-FAST, ZO-FAST and E-ZO-FAST)281
and the Austrian Breast and Colorectal Cancer Study Group trial180. In addition, 80%
of breast metastases develop in bone, which further increases the risk of fracture
through osteoclast-mediated destruction of surrounding bone282.
Current guidelines to minimise AI associated bone loss include healthy lifestyle
changes e.g. weight-bearing exercises, smoking cessation and dietary supplements
including calcium and vitamin D. Vitamin D supplementation is advisable in women
with low vitamin D levels who are at higher risk of bone loss when receiving AIs283.
In conclusion, treatment with exemestane resulted in a greater change in bone
turnover markers compared with the non-steroidal AIs, although these differences
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were not marked. This may be explained by the androgenic properties of exemestane.
Increased changes in bone turnover markers are indicative of increased bone loss
however at clinically used doses, there is unlikely to be any difference between the
classes ofAIs in the rates of osteoporosis or fractures.
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3.3.2 ALEX Quality of life and bone turnover
3.3.2.1 Baseline data
The results shown in figures 3.12-3.16 demonstrate a comparison between the joint
pain scores and bone markers at baseline, before any confounding effect of drug was
possible. Joint pains (BRM1) were scored as follows (also shown in appendix C):
0 = 1 have pains in my joints - not at all
1=1 have pains in my joints - a little bit
2 = 1 have pains in my joints - somewhat
3 = 1 have pains in my joints - quite a bit
4 = 1 have pains in my joints - very much
Scores of 3 and 4 were combined, due to small numbers. outliers
LMIM at baseline
Figure 3.12 Baseline PINP and joint pain scores (BRM)
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Figure 3.14 Baseline PTFI and joint pain scores (BRM)
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Figure 3.16 Baseline uNTX and joint pain scores (BRM) ° = outliers
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3.3.2.2 Post-drug data
Sample sizes for drug versus joint pain scores (BRM) classes were very small as
shown in table 3.4 and therefore confidence intervals were very large.
BRM (joint pain scores) Total no.
0 1 2 3 4
of patients
Drug A 7 7 6 6 4 30
E 15 10 3 3 6 37
L 7 8 4 5 2 26
Nil 50 25 12 5 5 97
Total patients 79 50 25 19 17 190
Table 3.4 Joint pain scores (BRM) per drug
A = anastrozole, E = exemestane and L = letrozole
If 'no drug' is compared with 'any drug' (which is the same as using 'visit' as a










Table 3.5 BRM according to no drug versus drug
Visit 1 - baseline Visit 2 - 4 months Visit 3 - 12 months
The bold results show where there is a significant difference
From this, it would appear that only 'visit' has an influence on the bone markers; that
is, the bone markers PINP and sCTX are usually higher at the second visit than the
first, regardless of BRM score.
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3.3.2.3 Discussion and conclusions
Baseline data
There was some evidence to suggest that there is a linear relationship between joint
pain scores and sCTX (p=0.033), and between joint pain scores and log ALP
(p=0.049). These relationships were not strong.
All data
Sample size became problematic once drug was included in the models. There are
fewer than 10 patients in each anastrozole/BRM and letrozole/BRM combination,
and particularly few in the higher BRM scores. Using 'visit' as a surrogate for 'no
drug' versus 'any drug' only the presence of a drug had any significant effect on bone
markers (PINP p=0.053 and sCTX p=0.03).
Recent studies have detected a positive relationship between vasomotor menopausal
symptoms and bone turnover markers. Several studies have found that mean BMD is
lower among women with vasomotor symptoms compared with women without
symptoms. Vasomotor symptoms including hot flushes and night sweats may be
markers for risk of adverse bone health284. In addition data from the ATAC trial has
demonstrated that the development of AI associated joint pain might predict
• 285
improved breast cancer outcomes . There is currently no available published data
demonstrating a relationship between bone symptoms and bone turnover markers.
Results from the ALIQUOT study suggested there might be a relationship between
PINP and sCTX with musculoskeletal symptoms. From the ALEX results it would
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appear that joint pain score is not predictive of bone markers in most cases, and
where it is, the relationship is not strong. Further studies are required to establish if
these findings can be demonstrated in larger populations ofwomen taking AIs.
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3.3.3 ALEX Lipids Results
3.3.3.1 Patients
Of the 120 patients randomised in this study, 117 patients had evaluable lipid
samples after either 3 or 4 months of AI treatment. 96 patients were switched
thereafter to tamoxifen and had evaluable lipids measurements at 12 months. Patient
disposition is shown in the CONSORT diagram in appendix H. Overall, patient








Age yrs (median) 61.0 59.9 60.6
Height cm (median) 162.5 161.0 162.0
Weight kg (median) 66.0 67.5 66.5
BMI kg/m2 (median) 25.3 26.4 25.7
Prior HRT n (%>) 20 (59%) 13 (38%) 22 (45%)
Hysterectomy n (%) 4(12%) 4 (12%) 10(20%)
Bilateral oophorectomy
n(%)
1 (3%) 1 (3%) 4 (8%)
Table 3.6 Patient baseline demographics
3.3.3.2 Statistical analysis
Percentage change was calculated as (post-treatment - baseline)/baseline, where a
negative value indicated a fall from baseline. A repeated measures analysis was
performed, since measurements were of the same patients over a series of time
points. Estimates of effect size (and 95% CI) have been calculated from the least
squares means, with baseline values entered into the model as covariates. Each
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variable's mean and 95% CI have been adjusted for the presence of the other
variables. Tukey's correction has been used to adjust for multiple comparisons.
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3.3.3.3 Differences between anastrozole, letrozole and exemestane
Lipid measurements were similar at baseline in the three groups. The changes from
baseline to 4 months for each lipid/lipoprotein measured in shown in table 3.7.
Exemestane caused a significant fall in triglycerides (-11.53% p=0.0015), cholesterol
(-5.48% p=0.03) and HDL (-7.90% p=0.008) from baseline however only
tryglycerides showed a significant difference between the drugs at any time point as
shown in table 3.7. There were borderline significant changes between drug types for
ApoAl (p=0.08). No other drug on its own achieved a significant change from
baseline. There was no significant change in LDL or Apo B in either of the three
drugs. The period (3 or 4 months) did not have a significant effect on the overall
results.
Exemestane caused a significant increase in the atherogenic risk ratios, chokHDL
(+4.70% p=0.004), LDL:HDL (+9.04% p<0.0001) and ApoB:ApoA-l (+8.77%
p=0.0005), from baseline compared to anastrozole and letrozole as shown in table
3.7. This was mediated by the fall in the levels of atheroprotective HDL and ApoAl.
Anastrozole resulted in moderate non-significant alterations in lipid profile. The
atherogenic triglycerides (-3.91%), cholesterol (-5.32%), cLDL (-6.42%) and Apo B
(-5.39%) decreased and there was a minor fall in the atheroprotective HDL (-1.67%)
and ApoAl (-0.34). The atherogenic risk ratios chokHDL and LDL:HDL fell by -
2.85% and -3.97% respectively whereas there was a minor increase in the
ApoB:ApoAl ratio,+0.18%.
No significant changes were demonstrated for letrozole.
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Drug: mean percentage change (95% CI)
Anastrozole Letrozole Exemestane p-value
Atherogenic
lipids/lipoproteins
Triglycerides -3.91 +2.29 -11.53 0.04
mmol/1 (-12.70,+4.88) (-6.12,+10.70) (-18.57, -4.50)
p=0.0015
Cholesterol -5.32 +0.15 -5.48 0.31
mmol/1 (-11.52,+0.88) (-5.82,+6.13) (-10.49, -0.46)
p=0.03
cLDL -6.42 -0.72 -1.30 0.50
mmol/1 (-14.14,+1.30) (-8.15, +6.72) (-7.53, +4.94)
Apo B -5.39 +3.07 +0.60 0.34
g/1 (-14.02,+3.25) (-5.22,+11.36) (-6.42, +7.61)
Atheroprotective
lipids/lipoproteins
HDL -1.67 -0.37 -7.90 0.20
mmol/1 (-8.81,+5.48) (-7.24, +6.50) (-13.67. -2.14)
p=0.008
ApoA-1 -0.34 7.37 -7.70 0.08
8/!
Atherogenic
(-10.66,+9.98) (-2.52, +17.27) (-16.07, +0.66)
risk ratios
ChokHDL -2.85 +0.47 +4.70 0.01
(-6.85,+1.15) (-3.37, +4.30) (+1.50,+7.91)
p=0.004
LDL:HDL -3.97 -0.20 +9.04 0.0008










Table 3.7 Percentage change from baseline to 4 months
(results are presented as percentage change from baseline for each group, figures in bold reflect
statistical significance)
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3.3.3.4 Differences between non-steroidal and steroidal Als
The results showed greater statistical significance when the drugs were grouped into
non-steroidal versus steroidal classes as demonstrated in table 3.8. Exemestane
showed a significant fall from baseline in triglycerides (-11.53% p=0.0015),
cholesterol (-5.45% p=0.03) and HDL (-7.90% p=0.007) as shown in figures 3.17 -
3.19. There was a significant difference between the groups for triglycerides
(p=0.02) and a borderline significant difference for HDL (p=0.07). There were
borderline significant differences between the drug types for ApoA-1 (p= 0.046). No
effect of period was seen. There were significant differences between the lipid ratios
and drug types as shown in figures 3.20-3.22. Exemestane caused a significant
increase in chohHDL (4.69% p=0.005) LDL:HDL (9.02% p<0.0001) and
ApoB:ApoA-l (8.76% p=0.0005) ratios which are associated with an increase risk of
cardiovascular disease.
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Table 3.8 Mean percentage change from baseline to 4 months (non¬
steroidal versus steroidal group)




Figure 3.17 Triglyceride results for non-steroidal versus steroidal drugs
Difference between the drug type p=0.02*
Cholesterol
Figure 3.18 Cholesterol lipid results for non-steroidal versus steroidal drugs




Error bars: +/- 95% CI
Figure 3.19 HDL lipid results for non-steroidal versus steroidal drugs
Difference between the drug type p=0.07
Ratio of cholesterol to HDL
a> -
Al
irror bars: +/- 95% CI
Figure 3.20 Cholesterol:HDL lipid results for non-steroidal versus steroidal
drugs
Difference between the drug type p=0.008**
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Error bars: +/- 95% CI
Figure 3.21 LDLHDL lipid results for non-steroidal versus steroidal drugs
Difference between the drug type p=0.0003***
Ratio of ApoB to ApoA1
fo- 4 * j >
liiiilillli
Al
Error bars: +/- 95% CI
Figure 3.22 ApoB:ApoA-1 lipid results for non-steroidal versus steroidal
drugs
Difference between the drug type p=0.01*
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3.3.3.5 Effects of tamoxifen
Tamoxifen change from baseline following treatment with Als
As expected, cholesterol, LDL and chohHDL, LDL:HDL, ApoB:ApoA-l ratios were
significantly lower in each group following introduction of tamoxifen. There is no
evidence suggesting that the change from baseline following treatment with
tamoxifen is influenced by the type ofAI that the patient was on prior to tamoxifen.
Lipid changes caused by tamoxifen use (after previous AI therapy)
Tamoxifen increased HDL by a statistically significant amount following exemestane
+15.52% p=0.01 compared with anastrozole or letrozole (+0.59, +1.89%) p=0.009 as
shown in table 3.9. This may reflect the significant decrease in HDL caused by the
introduction of exemestane presumably because exemestane was producing greater
changes from baseline. Some of the effect is therefore exemestane withdrawal.
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Drug: mean percentage change (95% CI)












Cholesterol -8.69 -2.28 -7.88 0.30
mmol/1 (-15.71, -1.66) (-8.08,3.51) (-14.62,-1.14)
LDL -14.31 -12.58 -10.72 0.80
mmol/1 (-22.85, -5.77) (-20.68, -4.48) (-17.69, -3.75)
Apo B -8.40 -6.89 1.93 0.18
g/1
Atheroprotective
(-17.69, 0.90) (-15.69, 1.90) (-5.75,9.60)
lipids/lipoproteins
HDL 0.59 1.89 15.52 0.009
mmol/1 (-8.03, 9.21) (-6.38, 10.16) (8.39, 22.66)
p=0.01
ApoAl 5.41 12.06 25.09 0.07
g/1
Atherogenic
(-7.71, 18.54) (-0.60, 24.72) (14.05, 36.13)
risk ratios
ChoLHDL -7.57 -9.62 -13.90 0.19
(-13.09, -2.05) (-18.42,-9.39) (-14.82,-4.41)
LDL:HDL -12.33 -14.46 -21.45 0.14








Table 3.9 Lipid changes caused by tamoxifen use (after previous Al
therapy)





Several large clinical AI trials have demonstrated a small but significant increase in
cardiovascular events compared with tamoxifen64'65'66. Data from BIG 1-98
demonstrated an increased incidence of hypercholesterolaemia and cardiac events in
postmenopausal women taking letrozole, compared with tamoxifen286. However
these adverse events were rare and were outweighed by the superior control of
recurrence afforded by letrozole compared with tamoxifen286. These results are
shown in table 1.8 and 1.9. Exemestane has a minor androgenic effect due to
significant suppression of the sex-hormone-binding globulin. This may have a
protective effect on lipids, especially triglycerides. It causes an increase in
gonadotropins287.
The impact of the third generation AIs on lipid metabolism and subsequent
cardiovascular damage has been difficult to compare in previous phase 3 trials as
most collaborators have chosen the alternative treatment, tamoxifen as the
comparator. To date there are no published studies comparing the effects of adjuvant
anastrozole, letrozole and exemestane on serum lipid profiles in postmenopausal
women with early breast cancer.
Our results demonstrated significant differences between the steroidal and non¬
steroidal AIs. Exemestane caused a significant fall and hence beneficial effect on
serum triglycerides and cholesterol. These changes were also observed in the
EORTC trial which demonstrated that exemestane and tamoxifen had opposite
effects on triglyceride levels: exemestane lowered while tamoxifen increased
triglyceride levels over time287. The mechanism for this is unclear but oestrogen
appears to have a negative effect on triglycerides which are a major risk factor for
coronary artery disease and are a greater risk factor in women compared with men288.
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Of interest exemestane had a negative effect on the atheroprotective lipoproteins
HDL and ApoA-1 which resulted in an unfavourable increase in each of the three
risk ratios chokHDL, LDL/HDL and ApoB:ApoA-l. Exemestane is an irreversible
inhibitor of the aromatase enzyme. It is a steroidal compound which mimics the
natural substrate of aromatase, androstenione and permanently inactivates aromatase,
unlike letrozole and anastrozole. Its androgenic effects have been considered of
possible positive value. Many tissues including the breast have androgen receptors.
Its degree of androgenicity is unclear but it is likely that some of its effects and
particularly the effects not seen with letrozole and anastrozole are in relation to its
androgenicity. The different effects of exemestane may therefore be due to its
irreversible nature and also to its androgenic effects which make it different from the
non-steroidal AIs.
One major limitation of this study is that the patients recruited had cancer and
potentially other conditions rather than well patients with no other conditions such as
those included in the LEAP study. Other limitations include the relatively small
number of subjects. In addition, there was no control/placebo group therefore we are
unable to state that the changes detected were definitely a result of tamoxifen/AI use.
The groups were not aged-matched however there was no significant difference in
ages in each group. Compliance may also have been a limitation as there is no way of
knowing whether the patients adhered strictly to the regimen. Both studies would
have benefitted from having age-matched and cancer-free control groups.
Previous studies demonstrated that letrozole significantly increased the amount of
plasma total cholesterol, cLDL, apolipoprotein B and the atherogenic risk ratios total
cholesterokHDL and LDL:HDL259 and therefore had an unfavourable effect on
serum lipid profiles. Other studies have suggested that AIs do not have adverse
effects on lipid metabolism. The MA. 17 lipid sub-study found that five years of
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letrozole did not alter serum cholesterol, HDL, LDL, or triglycerides266. The steroidal
AI exemestane has previously demonstrated stabilising effects on triglycerides and
HDL287. It has been suggested that exemestane may have beneficial effects on lipid
metabolism due to its slight androgen-agonistic effect of its major metabolite289.
Results from other studies assessing lipid parameters have been variable. Large
studies investigating the non-steroidal AIs have been discussed in depth on page 179
(ALIQUOT lipids discussion). The non-significant but overall beneficial effects of
anastrozole on lipids have been previously demonstrated290. LEAP demonstrated no
significant differences between anastrozole and letrozole and their effects on
LDLiHDL ratios, triglycerides and non-HDL concentrations however exemestane
significantly decreased total cholesterol at 3 months (-5.5%) in healthy
postmenopausal women. Exemestane also significantly increased the LDL:HDL
cholesterol ratio (+17.0% at 6 months) and ApoB:ApoA-l ratio (+9.0% at 6
months)247. These results are consistent with the findings of our study. IES
randomised patients to exemestane or tamoxifen after 2-3 years of tamoxifen. A
higher rate of myocardial infarction was reported with exemestane compared with
tamoxifen but these differences were not statistically significant (1.3 vs. 0.8%)291.
Results from the TEAM study demonstrated that there was a higher incidence of
hyperlipidaemia in the exemestane group (5%) compared with the sequential therapy
group (tamoxifen followed by exemestane <1%). In addition, there was a higher
incidence of cardiac failure in the exemestane group (1%) versus the sequential
group (<1%). The TEAM Japan substudy demonstrated that anastrozole and
exemestane had no clinically significant effects on the lipidaemic profile of
postmenopausal women with breast cancer although women treated with tamoxifen
resulted in relatively favourable changes292.
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The MA-17 study demonstrated different safety profile between anastrozole verus
exemestane. There were fewer reports of dyslipidaemia in the group taking
exemestane. Elevated triglyceride levels were demonstrated in only 2% of the
exemestane group versus 3% of the anastrozole group. Hypercholesterolaemia was
found in 15% of those taking exemestane versus 18% taking anastrozole197.
Tamoxifen has oestrogen-like properties and is known to favourably affect lipid
profiles. The changes in lipids from baseline were expected, tamoxifen caused a fall
in the atherogenic ratios however the class ofAI administered prior to tamoxifen did
not affect the changes. Exemestane followed by tamoxifen therapy caused a
significant increase in HDL when the change was measured from exemestane
withdrawal. This can be explained by the withdrawal of exemestane.
In conclusion, our results are largely consistent with those of previous studies,
suggesting that the two classes of AIs have different effects of lipid metabolism.
Exemestane treatment appears to cause a beneficial fall in triglycerides and
cholesterol however, perhaps more importantly, exemestane was associated with a
detrimental fall in the atheroprotective lipoproteins and an increase in atherogenic
ratios. The results also confirm the favourable although statistically insignificant
effects of anastrozole on serum lipids. Further long-term follow-up is warranted to
establish if these effects are of clinical significance in the management of women
with breast cancer. Current studies investigating the effects of AIs on lipid profiles
are underpowered and only collection of lots of data will discover any long-term
harmful effects. If an AI is recommended then exemestane may be a better choice for
postmenopausal women with lipid abnormalities. Otherwise, tamoxifen may better




One hundred and twenty postmenopausal women with ER+ve early breast cancer
were enrolled in this study. Of these, 116 patients had evaluable blood samples.
Patient disposition is shown in the CONSORT diagram in appendix H. Overall,








Age yrs (median) 61.0 59.9 60.6
Height cm (median) 162.5 161.0 162.0
Weight kg (median) 66.0 67.5 66.5
BMI kg/m2 (median) 25.3 26.4 25.7
History of previous
HRT use n (%>)
20 (59%) 13 (38%) 22 (45%)
Hysterectomy n (%) 4(12%) 4(12%) 10(20%)
Bilateral oophorectomy n
(%)
1 (3%) 1 (3%) 4 (8%)
Table 3.10 Patient baseline demographics
3.3.4.2 Statistical analysis
The statistical analysis was conducted by an independent statistician. Hormone
therapy for each patient was coded to maintain the blind assessment and avoid bias.
Data was analysed using SPSS version 12. Analysis of variables was performed
using the method of analysis of covariance. Some variables were transformed to
achieve Normality, either the log transformation or the square root was taken.
Tukey's correction was used to adjust for multiple comparisons.
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Effect of treatment on coagulation
3.3.4.3 Differences between anastrozole, letrozole and
exemestane
The effects ofAI treatments on coagulation parameters are shown in table 3.11. For
most parameters there was little evidence to suggest significant drug effects on
coagulation variables. However exemestane significantly decreased AT from
baseline (-8.55% (-13.33, -3.79)), p=0.0006 whereas anastrozole and letrozole had no
effect. There was no significant difference between the drugs, p=0.4. Exemestane
significantly decreased protein C levels compared to anastrozole and letrozole
(15.75% (-21.48, -10.02) vs -3.80% (-10.77, 3.16) versus -3.63% (-10.50, 3.25)),
p=0.008. Exemestane and anastrozole significantly increased protein S free levels
from baseline (E 6.90% (1.98, 11.82), A 7.36% (1.37, 13.34), p=0.007. There was no
significant difference between the drugs, p=0.69. These results are demonstrated in
figures 3.23-3.35.
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Drug: Mean percentage change (95% CI)
























































































Table 3.11 Anastrozole versus letrozole versus exemestane
Mean percentage change from baseline to 4 months





Error bars. 95% CI
Figure 3.23 AT mean percentage change from baseline by drug
No statistically significant difference detected between each drug p=0.40
Error bars: 95% CI
Figure 3.24 Protein C mean percentage change from baseline by drug




Error bars 95% CI
Figure 3.25 Protein S free mean percentage change from baseline by drug
No statistically significant difference detected between each drug p=0.69
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3.3.4.4 Differences between non-steroidal and steroidal Als
The effects of steroidal versus non-steroidal Als on coagulation parameters are
shown in table 3.12 and figures 3.26-3.29. Anastrozole and letrozole combined
significantly increased vWF from baseline (6.52% (0.66, 12.38), however this
increase in vWF was not statistically different from exemestane (5.02% (-1.88,
11.91)), p=0.74.
AT decreased significantly from baseline with anastrozole and letrozole combined (-
4.54% (8.64, -0.43)), p=0.03 and also with exemestane (-8.55% (-13.31, -3.70),
p=0.0006 however there was no significant difference between the groups of drugs,
p=0.21.
Protein C levels again fell significantly with exemestane compared with anastrozole
and letrozole combined (-15.75% (-21.45, -10.05) vs -3.71% (-8.58, 1.15)), p=0.002.
There was a significant increase in protein S free from baseline in both groups,
anastrozole plus letrozole (5.70% (1.47, 9.92)), p=0.009 and with exemestane (6.90%
(1.98, 11.81)), p=0.006 however the difference between the groups was not
significant p=0.72.
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Table 3.12 Non-steroidal versus steroidal Als
Percentage change from baseline to 4 months




Error bars: 95% CI
Figure 3.26 vWF mean percentage change from baseline
Non-steroidal versus steroidal drugs







Error bars 95% CI
Figure 3.27 AT mean percentage change from baseline
Non-steroidal versus steroidal drugs





Error bars. 95% CI
E
Figure 3.28 Protein C mean percentage change from baseline
Non-steroidal versus steroidal drugs
Statistically significant difference detected between each group ofAI p=0.002**
Figure 3.29 Protein S free mean percentage change from baseline
Non-steroidal versus steroidal drugs
No statistically significant difference detected between each group ofAI p=0.72
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3.3.4.5 Effects of tamoxifen
Effects of 8 months of tamoxifen post Als from baseline
The effects of tamoxifen on coagulation parameters after treatment with Als are
shown in table 3.13. Tamoxifen treatment given after anastrozole did cause a
significant increase in vWF (10.05 (1.68, 18.41)) but this increase following
anastrozole was not different following either of the other two drugs. Fibrinogen,
AT, protein C and protein S free all showed significant changes from baseline
regardless of which drug the patient was taking during the initial trial phase.
Significant falls in fibrinogen (A-16.89, L-23.29, E-18.73) (p<0.0001) and AT levels
were seen in each group (A-12.26, L-19.59, E-16.89) (p=0.0001). Tamoxifen also
increased protein S free levels in each group (A 10.75, L 10.85, E 6.15) (p= 0.0003).
There was no evidence to suggest that any particular AI had any influence on the
post tamoxifen effects.
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Drug: mean percentage change (95% CI)
Anastrozole n=33 Letrozole n=46 Exemestane n=31 p-value
Pro-coagulants
PA1 (log) -3.49 -4.47 -0.48 0.55
(-8.98, 2.01) (-9.47, 0.52) (-5.91,4.95)
vWF (sqrt) 10.05 6.61 7.4 0.83
iu/ml (1.68,18.41) (-1.16, 14.37) (-0.95, 15.81)
p=0.02
Factor VI11 3.69 8.49 13.36 0.78
iu/ml (-15.74,23.13) (-9.45, 26.43) (-5.78, 32.52)
Fibrinogen -16.89 -23.29 -18.73 0.61
g/1 (-26.77, -7.02) (-32.25, -14.33) (-28.43, -9.03)
p<0.001 p<0.0001 p<0.0002
APCR 0.28 -0.29 -1.28 0.95
(-6.80, 7.35) (-6.48, 5.89) (-8.06, 5.49)
Anti-coagulants
AT -12.26 -19.59 -16.89 0.24
iu/ml (-18.63,-5.89) (-25.37, -13.81) (-23.26,10.52)
p=0.0001 p=0.0001 p=0.0001
Protein C -12.34 -20.77 -10.81 0.16
iu/ml (-20.73, -3.96) (-28.36,-13.17) (-19.05, -2.56)
p=0.004 p<0.0001 p=0.01
Protein S Total -11.48 -3.55 4.15 0.32
iu/ml (-25.49, 2.53) (-13.52,6.40) (-1 1.53, 19.82)
Protein S Free 10.75 10.85 6.15 0.35
(sqrt) iu/ml (5.51,15.99) (6.10,15.61) (0.91,11.39)
p=0.0003 p=0.0003 p=0.0003
Table 3.13 Effects of 8 months of tamoxifen post Als from baseline
(results are presented as percentage change for each group, figures in bold reflect statistical
significance)
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Effects of 8 months of tamoxifen post Als from 4 months
Tamoxifen significantly decreased fibrinogen levels after all three Als. Tamoxifen
also caused a significant reduction in AT following both exemestane and letrozole.
There was no evidence to suggest that non-steroidal or steroidal Als had any
influence on results when patients were taking tamoxifen (p=0.53, p=0.27
respectively). Tamoxifen significantly increased protein S free levels following all
three Als, with no evidence to suggest the drug type had any influence. These results
are demonstrated in figures 3.30 - 3.32.
Drug
Error bars: 95% CI
Figure 3.30 Fibrinogen mean percentage change post Al followed by
tamoxifen




Error bars. 95% CI
Figure 3.31 AT mean percentage change post Al treatment followed by
tamoxifen
Statistically significant difference detected between the three Als p<0.001 ***
Eaeniestane
Drug
Eiroi t.ars. 95°'o CI
***
Figure 3.32 Protein S free mean percentage change post Al followed by
tamoxifen
Statistically significant difference detected between the three Als p<0.001 ***
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3.3.4.6 ALEX Coagulation Discussion and Conclusion
Oestrogen has detrimental effects on coagulation and tamoxifen is associated with an
increased risk of thromboembolism. AIs significantly reduce the amount of
circulating oestrogen and in theory should have either no significant effects on
coagulation or should inhibit coagulation pathways. The impact of third generation
AIs on coagulation have not been directly compared in previous trials which
generally compared each AI with tamoxifen.
This study demonstrated a significant fall in the anticoagulants AT and protein C in
patients given the steroidal inactivator exemestane compared to anastrozole and
letrozole. Exemestane also caused a significantly greater increase in the
anticoagulant protein S free level. There was no significant change in coagulation
factors detected with letrozole and anastrozole and no difference between these two
drugs. Exemestane is an irreversible inhibitor of the aromatase enzyme. It is a
steroidal compound which mimics the natural substrate of aromatase, androstenione
and permanently inactivates aromatase, unlike letrozole and anastrozole. Its
androgenic effects have been considered of possible positive value. Many tissues
including the breast and bone have androgen receptors. Its degree of androgenicity is
unclear but it is likely that some of its effects and particularly the effects not seen
with letrozole and anastrozole are in relation to its androgenicity. The different
effects of exemestane may therefore be due to its irreversible nature and also to its
androgenic effects which make it different from the non-steroidal AIs.
One major limitation of this study is that the patients recruited had cancer and
potentially other conditions rather than well patients with no other conditions such as
those included in the LEAP study. Other limitations include the relatively small
number of subjects. In addition, there was no control/placebo group therefore we are
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unable to state that the changes detected were definitely a result of tamoxifen/AI use.
The groups were not aged-matched however there was no significant difference in
ages in each group. Compliance may also have been a limitation as there is no way of
knowing whether the patients adhered strictly to the regimen. Both studies would
have benefitted from having age-matched and cancer-free control groups.
Overall AIs caused a minor increase in the procoagulants and a fall in the most
clinically relevant anticoagulants predisposing to potential thrombosis. These effects
may be more concerning in those with advanced breast cancer where there is
increased tumour burden and a higher secretion of procoagulants including tissue
factors which activates coagulation293.
Anastrozole trials
The 68 month follow-up data from the ATAC study demonstrated that adjuvant
treatment with anastrozole monotherapy reduced the incidence of VTEs by 39%
when compared with those taking tamoxifen (p<0.0001)294. Results demonstrated a
2.8% incidence of VTEs and 1.6% incidence of deep venous thromboembolic events
in women taking anastrozole which is greater that the estimated risk in healthy
women176'295. The combined analysis of ABCSG 8 (Austrian Breast and Colorectal
Cancer Study Group) and German ARN09 5 (Arimidex-Nolvadex) trials (total
n=3224) showed that women taking anastrozole were significantly less likely to
develop thromboses compared with those treated with tamoxifen. Only three patients
taking anastrozole developed thromboses compared with 12 patients in the tamoxifen
arm after 28 months of follow-up, p=0.034. In addition there was a trend suggesting
fewer emboli; only two patients affected versus nine in the tamoxifen group
(p=0.064)199.
243
The ITA trial (n=448) reported a 6.0% incidence of venous disorders in the
tamoxifen group versus a 2.5% incidence in the anastrozole group198.
Of interest, anastrozole was found to have no effect on coagulation factors after
eleven days of treatment in a small population of healthy males (n=16). This may be
due to the short duration of treatment and follow-up296. Our results are consistent
with this finding, suggesting no major coagulation effects resulting from anastrozole.
Letrozole trials
The BIG 1-98 trial (n=8028) demonstrated a decreased rate of thromboembolic
events in the letrozole versus tamoxifen group. Those taking letrozole had a 1.5%
incidence of adverse thromboembolic events compared with 3.5% in those taking
tamoxifen (p<0.001)195. An updated safety analysis concluded that the risk of grade
1-5 thromboembolic adverse events in those taking letrozole was 0.9% compared
with 2.3% in the tamoxifen arm (p<0.01) and the risk of overall cardiovascular
adverse events (grade 1-5) was 1.7% versus 3.9% in the respective arms
(pco.ooi)297.
The MA-17 trial demonstrated that after 30 months of follow-up there was no
significant difference between letrozole and placebo in terms of thromboembolic
events. The rate of thromboembolism was 0.4% in the letrozole group versus 0.2% in
the placebo group202. These results are in keeping with our data which suggests that
letrozole has little effect on coagulation factors.
Exemestane trials
The IES study (n=4724) randomised women to exemestane alone or following
tamoxifen. The incidence of venous thrombembolic events was only 1.2% in patients
receiving exemestane compared with 2.4% in the tamoxifen group (p=0.004)298.
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Side-effects from exemestane were rare and some may have been due to tamoxifen
withdrawal207.
The TEAM trial (n=9779) randomised women to exemestane alone or following
tamoxifen for five years. The sequential treatment arm was associated with a higher
incidence of venous thrombosis (2%) when compared with the exemestane alone
(1%) (p=<0.0001)196. Both IES and TEAM demonstrated that exemestane was
associated with a significantly lower incidence of thromboembolic events compared
with tamoxifen.
The EORTC 10951 trial (n=382) randomised women with metastatic breast cancer to
either exemestane or tamoxifen. The incidence of deep vein thromboses was similar
in each group299. A smaller study (n=147) demonstrated that exemestane had no
effect on plasma coagulation factors in patients with early breast cancer compared
with placebo300.
Our study has demonstrated significant differences between non-steroidal and
steroidal AIs. Exemestane caused a significant fall in the anticoagulants protein C
and AT, predisposing to a potential increased risk of thromboembolic disease. Non¬
steroidal AIs caused a significant increase in vWF which is associated with a
potential increased risk of thrombosis. Previous studies have suggested that
exemestane does not appear to have long-term effects on coagulation parameters172
and therefore AI induced coagulation changes are unlikely to persist after the drug is
discontinued. The effects of tamoxifen on thromboembolism are mediated via a
reduction in known anticoagulants. Exemestane reduces significantly these same
anticoagulants and may also have greater pro-thrombotic properties compared with




The oestrogenic effects of tamoxifen are associated with an increased risk of
thromboembolic events including DVT, stroke and PE301. It has complex and
significant effects on coagulation factors.
The IBIS-1 (International Breast Cancer Intervention Study-1) found that five years
of tamoxifen in women at higher risk of developing breast cancer resulted in an
increased risk of thromboembolism compared with placebo302.
Our results demonstrated significant changes in coagulation factors consistent with
increased risk ofDVT and PE with tamoxifen. Tamoxifen therapy administered after
an AI caused a significant fall in fibrinogen, AT and protein C. There was no
evidence to suggest that the AIs had any effect on fibrinogen levels pre-tamoxifen.
Tamoxifen caused an increase in protein S free however this showed statistical
significance in the anastrozole group only. Overall, the type of AI therapy
administered prior to tamoxifen had little effect.
This study is the first to directly compare the effects of adjuvant anastrozole,
letrozole and exemestane on serum coagulation parameters in postmenopausal
women with early breast cancer. There were significant differences demonstrated
between non-steroidal and steroidal AIs and their effects on important coagulation
parameters. Exemestane caused a reduction in important anticoagulants, potentially
predisposing to an increased risk of thromboembolism. These differences were not
reflected in the results of the MA.27 trial (n= 7,576) which is the first large study to
directly compare anastrozole with exemestane. Cardiovascular effects were similar in
both groups and were infrequent197. Our study showed no differences between
anastrozole and letrozole, and generally these drugs have little thrombotic activity.
246
AIs are associated with a reduced incidence of thromboembolic events compared
with tamoxifen and are therefore better suited for use in high risk groups who have
risk factors for thromboembolism. In conclusion, tamoxifen and AIs have significant




Incorporation of an AI improves disease-free survival in postmenopausal women
with hormone receptor positive breast cancer compared with tamoxifen however, for
some women, the risks and side effects outweigh the potential benefits. AIs cause a
profound decrease in circulating oestrogen levels causing a variety of systemic
effects. These small studies revealed interesting and in some areas, unexpected
results. The most interesting finding was the effects prior tamoxifen use had on bone
turnover and the effects of adding a subsequent AI. Previous studies suggested that
prior tamoxifen use may have beneficial bone preserving effects which may reduce
increased bone turnover caused by AIs. Our findings demonstrated the opposite,
showing that there appears to be a rebound increase in turnover which is detrimental
to overall bone health from prior tamoxifen use. An attempt was made to identify a
relationship between bone markers and musculoskeletal symptoms but unfortunately
the studies were inadequately powered to demonstrate statistically significant results.
Of further interest was the different effects exemestane had on lipid metabolism
when compared with the non-steroidal AIs. These studies have demonstrated a
decrease in atherogenic ratios and exemestane use suggesting that the androgenic,
steroidal AI may be safer for use in women with dyslipidaemias. Finally exemstane
also showed a difference in coagulation parameters when compared with the non¬
steroidal AIs. Our results suggest that it is slightly more thrombogenic compared
with letrozole and anastrozole which again may be explained by its androgenic
properties. The long-term tolerability and toxicity profiles of AIs are important
considerations when trying to encourage compliance and optimise outcomes. An
enormous amount of research has already been undertaken on the effects ofAI use in
breast cancer. Despite this, there are few trials which directly compare the different
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types of AI. Future research may demonstrate further information on the effects of
increased bone turnover and musculoskeletal symptoms. The value of the current
work is that it provides important information on the effects of the different drugs




Appendix A ALIQUOT Study Inclusion / exclusion criteria
Inclusion criteria:
Operable Tl, T2 and T3, N0-N1, MO primary breast cancer.
Invasive, ER +ve tumour confirmed on core biopsy / surgical excision.
Postmenopausal women defined as a woman who has not menstruated over the
preceding 12 months or who have FSH/LH levels within the post-menopausal range.
HRT stopped < 4 weeks ago.
Patient able to give written informed consent.
Women taking drugs likely to affect bone metabolism, including steroids and
bisphosphonates were randomised to participate in the quality of life study only.
Blood and urine samples were not therefore obtained from this group.
Exclusion criteria:
Risk (in the investigator's opinion) of transmitting Human Immunodeficiency Virus
(HIV) or Hepatitis B or C, through blood or other bodily fluids.
Any evidence of severe or uncontrolled systemic disease e.g. severe renal or hepatic
impairment.
Women receiving post-operative chemotherapy.
If a patient is suitable then please contact a member of the research team.
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Appendix B ALIQUOT Study Patient Information Leaflet
Invitation to Take Part in a Research Project
Anastrozole versus Letrozole:
An Investigation into Quality of Life and Tolerability
Background Information
The purpose of this leaflet is to explain to you as openly and clearly as possible all
the procedures involved in this study before you decide to take part. The study will
be conducted at the Edinburgh Breast Unit and has been funded by an educational
grant by Novartis Pharma. 185 women will be invited to take part in this study.
Please read this leaflet carefully and feel free to ask your medical team any questions
you have however simple they may seem. Their names and telephone numbers are
found at the end of this leaflet. You may also wish to discuss the study with family
and friends or your general practitioner.
Current drugs used in the treatment ofbreast cancer
There are many different treatments for breast cancer, including hormone drugs that
remove or reduce the effect of the female hormones produced by your body. They
appear to work because most breast cancers require female hormones to grow. The
most common of these hormones are called oestrogens. Currently the drug
tamoxifen, which is known as an anti-oestrogen, is the most commonly used and is a
very effective drug in the treatment of hormone sensitive breast cancer. This drug
works by reducing the amount of oestrogen available to cancer cells and by doing
this it deprives the cancer cells of the oestrogen they need and so it can stop breast
cancer cells from growing. It also increases the number of cells dying in a cancer and
when given alone to women with breast cancer it can shrink the cancer. It is usually
given for 5 years.
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A new class of drugs called aromatase inhibitors have been developed and these
drugs have been shown to be effective against hormone sensitive breast cancers.
These drugs stop you from making oestrogen and so deprive the cancer of the
oestrogen it needs to grow. The most commonly used of these new aromatase
inhibitors are anastrozole and letrozole.
Studies of these new aromatase inhibitors have demonstrated that they are very
active treatments in postmenopausal woman with hormone sensitive breast cancers
but their long-term effects when given for 5 years have not yet been established.
Purpose ofthe Study
It may be that in future these new aromatase inhibitors will be prescribed instead of
tamoxifen or after tamoxifen for the treatment of breast cancer. All drugs have side
effects. Studies comparing tamoxifen suggests that the aromatase inhibitors have
different side effects to tamoxifen. What we want to know is whether there are
differences in side effects between the two commonly used aromatase inhibitors,
anastrozole and letrozole. You will receive each of these drugs for three months so
that in total you will receive six months of these two new aromatase inhibitors. It is
important before these drugs are introduced for long term use over 5 years in some
women that we know which of the two drugs patients prefer and which is best
tolerated by patients.
To date there have been no studies directly comparing these two drugs when given
for long periods after surgery for breast cancer. The aim is to compare how each of
these drugs affects common symptoms by using a questionnaire and to determine
which of these two drugs patients prefer.
By reducing the levels of oestrogen your body produces the aromatase inhibitors also
affect bones and might increase the rate of osteoporosis and fracture when given over
many years. It may also affect the level of cholesterol in your blood. You will not
be at risk of these problems because you are only taking these drugs for 6 months but
what we aim to do by collecting samples of blood and urine is to test what effects
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these two drugs have on hormone production and the effects they might have on
bones.
Why have I been chosen to takepart?
You have been invited to take part in this study because we know at the time of your
original surgery when the tumour was removed, it was oestrogen sensitive.
You are about to complete 5 years of hormone treatment after surgery for your breast
cancer. If you agree to take part in the study you will receive aromatase inhibitors for
six months after finishing your tamoxifen. You will receive three months of each of
the two drugs. You will start treatment after you have signed the consent form. After
six months of aromatase inhibitors - three months of letrozole and three months of
anastrozole - you will then stop treatment. If you do not want to take part in the
study you will receive no further treatment after your five years of tamoxifen.
What are the benefits of takingpart?
There is some evidence that the aromatase inhibitors add to the effects tamoxifen in
hormone sensitive tumours but there have been no studies of their long-term use.
You will be given six months of drug treatment after stopping tamoxifen with these
newer and potentially more effective drugs. There may however be no advantages to
taking the aromatase inhibitors for only six months but equally it is highly unlikely
there will be any disadvantages.
What extra tests will I have to have by being involved in the study?
If you do decide to take part you will be asked to take either:-
3 months of letrozole tablets followed by three months of anastrozole or
3 months of anastrozole followed by three months of letrozole.
There will be 3 extra visits to hospital at baseline, three months after starting the
tablets.
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When you enter the study and at three and six months we will take 20ml (four
teaspoons) of blood and a small sample of urine to measure how these aromatase
inhibitors affect your hormones, lipids and bones.
You will also be asked to complete a series of questionnaires asking about how you
feel physically and emotionally throughout the study period. These questionnaires
are simple to complete and take approximately 10 minutes to complete. The first
questionnaire is completed when you enter the study. We then ask you to complete
questionnaires after one and three months of each of the two aromatase inhibitors.
We will also ask you specifically about any side effects you experience with either of
the two drugs and will record these. At the six month visit, you will also be asked to
state which drug of the two drugs, anastrozole or letrozole, you preferred and why
you preferred that drug.
How will my treatment be decided?
If you enter the study, you will not be able to choose which of the two drugs you
receive first. All patients in the study however will have three months of each of the
two drugs, anastrozole and letrozole. You will be aware ofwhich drug you are taking
and you will be fully informed of any potential side effects. You will take one tablet
of either anastrozole or letrozole every day. It is best to take this tablet at the same
time each day and the recommendation is that you take it in the morning. For the
remainder of the 5 years of hormonal treatment you will receive tamoxifen.
Side Effects
The side effects of aromatase inhibitors are similar to those described for tamoxifen.
The majority of people who have taken aromatase inhibitors in the past have reported
mild or moderate side effects. In studies looking at these drugs individually, only a
few women have had to stop treatment because of these side effects. The side effects
which have been reported by patients taking aromatase inhibitors include:
Tiredness, hot flushes or increased sweating, changes in weight, dizziness, itching
and skin rash, muscular pains, headache, changes in appetite, water retention, nausea
and sickness, constipation or diarrhoea, stomach upset or pain, vaginal dryness or
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bleeding. Less common side effects are chest pain, viral infections, pain in bones and
joints, shortness of breath, coughing and blood clots.
Please do not be alarmed by this list of possible side effects, you may not get any
of them.
In this study you will be carefully monitored. You can contact your GP or any
member of the study team at any time if you are worried or concerned (contact
details of who and how to contact them are provided at the end of this information
leaflet). If you decide to take part in the study we will inform your GP both of your
entry into the study and the treatment that you are taking. If any side effects are too
troublesome then you may stop the treatment straight away. Your own GP or a
member of the study team may also stop your treatment at any stage if they feel that
this is in your best interest.
Is there anything else I should know?
After the study period your follow up will be as normal.
In the unlikely event of any injury arising from your participation in the trial,
information about procedures for obtaining compensation may be obtained from your
doctor.
You may read in the newspapers, see on the television and hear on the radio alot
about these new drugs. It is important to try and not let these news items influence
how you rate the two drugs and which one gives you the least problems. If we knew
which of the drugs was better and which was better tolerated there would be no point
doing this study. The results of the study you are involved in will greatly assist




Due to finish 5 years of tamoxifen therapy
Details of study outlined
Information sheet given to patient
One Week Later
Review in Clinic
Blood and urine samples collected
Randomised to receive 3 months of anastrozole or letrozole
One Month Later
Complete further FACT-ES quality of life questionnaire
Return in stamped addressed envelope provided
Telephone interview to check for any side effects
4/
Three Month Follow Up Visit
Complete further FACT-ES quality of life questionnaire
Blood and urine samples collected
Patients receiving anastrozole change to letrozole
Patients receiving letrozole change to anastrozole
4/
One Month after starting second drug
Complete further FACT-ES quality of life questionnaire
Return in stamped addressed envelope provided
4/
Two months
Telephone interview to check if any side effects
•4/
Six Month Follow Up Visit
Further FACT-ES quality of life questionnaire completed
Blood and urine samples collected





If you decide you would like to take part in this study after you have read this
information leaflet and discussed it with friends and relatives, then please sign the
consent form in the presence of your doctor. It is important that you have time to
think about and discuss this study. If you have any questions at all about the study,
then please ask your doctor, the research nurse or the breast care nurse.
If any new information on the safety or effectiveness of the drugs used in this trial
comes to light, then we will inform you immediately.
If you require any assistance with travelling expenses for any extra visits, please let
your doctor know.
Further information
Your participation is voluntary. If you decide you do not want to take part or you
wish to withdraw from the study at any time, you are completely at liberty to do so
and your future care will not be affected. Your legal rights are not affected by you
giving consent to participate. All your medical records will be confidential although
information from the study will be analysed to assess the results in an anonymous
fashion.
Please note that all your doctors and nurses are specialised in this form of
treatment, and all of us are here to help. If you do have any questions or
queries then please do not hesitate to contact us.
258
Appendix C FACT-B+ES (Version 4) questionnaire Endocrine
symptoms
By circling one (1) number per line please indicate how true each statement has
been for you during the past 7 days.








ESI I have hot flushes 0 1 2 3 4
ES2 I have cold sweats 0 1 2 3 4
ES3 I have night sweats 0 1 2 3 4
ES4 I have vaginal discharge 0 1 2 3 4
ES5 I have vaginal itching/irritation 0 1 2 3 4
ES6 I have vaginal bleeding or spotting 0 1 2 3 4
ES7 I have vaginal dryness 0 1 2 3 4
ES8 1 have pain or discomfort with intercourse 0 1 2 3 4
ES9 I have lost interest in sex 0 1 2 3 4
ES10 I have gained weight 0 1 2 3 4
An9 I feel lightheaded (dizzy) 0 1 2 3 4
02 I have been vomiting 0 1 2 3 4
C5 I have diarrhoea 0 1 2 3 4
AnlO I get headaches 0 1 2 3 4
Taxi I feel bloated 0 1 2 3 4
ESI 1 I have breast sensitivity/tenderness 0 1 2 3 4
ES12 I have mood swings 0 1 2 3 4
ES13 I am irritable 0 1 2 3 4
BRM 1 I have pain in my joints 0 1 2 3 4
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Appendix D ALEX Study -Inclusion / exclusion criteria
Inclusion criteria:
Operable Tl, T2 and T3, N0-N1, MO primary breast cancer.
Invasive, ER +ve tumour confirmed on core biopsy / surgical excision.
Postmenopausal women defined as a woman who has not menstruated over the
preceding 12 months or who have FSH/LH levels within the post-menopausal range.
HRT stopped < 4 weeks ago.
Patient able to give written informed consent.
Exclusion criteria:
Risk (in the investigator's opinion) of transmitting Human Immunodeficiency Virus
(HIV) or Hepatitis B or C, through blood or other bodily fluids.
Any evidence of severe or uncontrolled systemic disease e.g. severe renal or hepatic
impairment.
Women with a history of hypothyroidism or diabetes.
Women with a history ofjaundice.
Women with abnormal lipid profiles, prior to randomisation.
Women taking drugs likely to affect lipid or bone profiles including:
Lipid regulating drugs; fibrates, nicotinic acid, fish oil, anion-exchange resins,
neomycin, probucol, statins.
Other drugs including beta-blockers with ISA, cyclosporin, corticosteroids,
phenytoin, retinoids, thiazide diuretics, bisphosphonates, glucosamine and St John's
wort.
Women receiving post-operative chemotherapy.
Women with known alcohol abuse or in whom you suspect alcohol abuse.
If a patient is suitable then please contact a member of the research team.
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Appendix E ALEX Study Patient Information Sheet
A study to compare the effects of
anastrozole, letrozole and exemestane in postmenopausal women with hormone
sensitive breast cancer
Patient information sheet
Invitation to take part in a research project
Background Information
The purpose of this leaflet is to explain to you as openly and clearly as possible all the
procedures involved in this study before you decide to take part. The study will be
conducted at the Edinburgh Breast Unit.
120 women will be invited to take part in this study.
Please read this leaflet carefully and feel free to ask your medical team any questions
you have, however simple they may seem. Their names and telephone numbers are
found at the end of this leaflet. You may also like to discuss the trial with family and
friends.
Current drugs used in the treatment of Breast cancer
There are many different treatments for breast cancer, including drugs which remove
or reduce the effect of the female hormones in your body. They appear to work
because most breast cancers require female hormones to grow. The most common of
these hormones are called oestrogens.
Currently the drug tamoxifen, which is known as an anti-oestrogen, is the most
commonly used drug in the treatment of breast cancer. This drug works by reducing
the amount of oestrogen available to cancer cells so it can stop a breast cancer from
growing. It has also been seen to shrink breast cancers when given alone. A new class
of drugs called aromatase inhibitors have been developed and these drugs have been
shown to be effective against hormone sensitive breast cancers. These drugs stop you
from making oestrogen and so deprive the cancer of the oestrogen it needs to grow.
These new aromatase inhibitors are anastrozole, letrozole and exemestane.
Studies looking at the effects of these new aromatase inhibitors have demonstrated
that they are active treatments in postmenopausal woman with hormone sensitive
tumours.
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Purpose of the Study
It is likely that in future these new aromatase inhibitors will be prescribed instead of
tamoxifen for the treatment of breast cancer. We know that by reducing the amount
of oestrogen you have in your body over a prolonged period could cause potential
problems. These include changes in the levels of lipids such as cholesterol in the
blood, changes in clotting, and they also are likely to affect bones because oestrogen
reduces the chances of the bones becoming thin or osteoporotic. As you will receive
the drug for only 4 months, the effects on lipids and bones will be very short lived and
you should have no long term adverse effects. It is important however before we
introduce these drugs for use over many years that we understand the effects these
drugs have on blood lipids, clotting and on bone by measuring blood lipids and
markers of bone activity before, during and after 4 months treatment with different
aromatase inhibitors.
To date there has been no study that has directly compared these 3 different aromatase
inhibitors. We hope to compare how each drug affects clotting, lipids and bones.
This will not only improve our scientific knowledge, but should also help surgeons
and oncologists decide which of the 3 drugs causes the least long term problems.
Why have I been chosen to take part?
You have been invited to take part in this study because your tumour is oestrogen
sensitive.
Your doctor has decided that the best treatment for you will be surgery followed by
drug treatment. If you agree to take part in the study you will receive one of the 3
aromatase inhibitors for 4 months after surgery. You will start treatment after you
have signed the consent form. After the study period you will switch to taking
tamoxifen for 5 years. If you do not want to take part you will simply take tamoxifen
for 5 years after surgery.
What are the benefits of taking part?
There is some evidence that the aromatase inhibitors may be superior to tamoxifen in
their action on hormone sensitive tumours. You will be being treated with both an
aromatase inhibitor and the standard 5 years of tamoxifen.
What extra tests will I have to have by being involved in the study?
If you do decide to take part you will take one tablet per day for 4 months and it will
mean 4 extra blood tests. You will also be asked to supply 3 samples of urine during
the course of the 4 months of treatment and one sample once you are on tamoxifen
one year after your operation. It will involve 2 additional trips to hospital out with
routine appointments over the 4 month study period. You will also have samples
taken at your routine one year follow up appointment. . However, you will be
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providing important information to help doctors assess how these 3 drugs work on
breast cancer cells and what effects they have blood lipids and bones.
You will also have to complete a quality of life questionnaire at the start of the study
after 4 months on the drug and at 1 year.
At the end of the 4 month period you will stop taking the aromatase inhibitor and you
will then receive tamoxifen for 5 years. The anti-oestrogen drug tamoxifen remains
the current standard treatment after surgery for the majority of women with breast
cancer. If taken for 5 years it has been shown to significantly reduce the chances of
breast cancer returning.
How will my treatment be decided?
If you enter the study, you will not be able to choose which of the 3 drugs you
receive. All patients in the study, however, will receive active treatment and you will
be randomly assigned to receive either:
anastrozole lmg daily or
letrozole 2.5mg daily or
exemestane 25mg daily
You will be aware of which drug you are taking and you will be fully informed of any
potential side effects. The treatment schedule for each drug is the same regardless of
which drug you receive. Each patient in this study will take 1 tablet of anastrozole or
letrozole or exemestane every day. It is best to take the tablet at the same time each
day and the recommendation is that you take it in the morning.
Side effects
The side effects with the 3 aromatase inhibitors are similar. The majority of people
who have taken aromatase inhibitors in the past have reported no side effects. In
studies performed looking at the three drugs individually, only a few women have had
to stop treatment because of serious side effects. The majority of side effects reported
with the aromatase inhibitors are similar to the side effects which patients report when
taking tamoxifen. The side effects which have been reported by patients taking
aromatase inhibitors include:
Tiredness, hot flushes or increased sweating, changes in weight, dizziness, itching and
skin rash, headache, changes in appetite, water retention, nausea and sickness,
constipation or diarrhoea, stomach upset or pain, vaginal dryness or bleeding. Less
common side effects are chest pain, viral infections, pains in the muscles, bones and
joints, shortness of breath, coughing and blood clots.
Please do not be alarmed by this list of possible side effects. You will probably
not have any of them.
In this study you will be carefully monitored. You can contact your GP or any
member of the study team at any time if you are worried or concerned (contact details
of who and how to contact them are provided at the end of this information leaflet). If
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you decide to take part in the study we will inform your GP both of your entry into the
study and the treatment that you are taking. If any side effects are too troublesome
then you may stop the treatment straight away. Your own GP or a member of the
study team may also stop your treatment at any stage if they feel that this is in your
best interest.
What will happen over next 4 months?
Outline of Study
Post Surgical Follow Up Clinic
Results of surgery discussed.
Study discussed with you and you meet trial personnel
Given information sheet and you have time to decide whether you
wish to enter study
Ifyou decide to enter the study,
Visit One
Informed consent obtained
Fasting blood sample taken
Give a sample of urine
Start treatment with either anastrozole, letrozole or exemestane
Complete Quality of Life Questionnaire
Visit 2
Three months after starting treatment
Fasting blood sample taken
Give a sample of urine
Continue on aromatase inhibitor
Visit 3
Four months after starting treatment
Fasting blood sample taken
Give a sample of urine
Stop aromatase inhibitor
Commence tamoxifen
Complete Quality of Life Questionnaire
Visit 4
One year after initial surgery
Fasting blood sample taken
Give a sample of urine
Complete Quality of Life Questionnaire
Continue tamoxifen
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Is there anything else I should know?
After the study period your follow up will be as normal with annual clinical
examination and mammograms for 5 years.
In the unlikely event of any injury arising from your participation in the trial,
information about procedures for obtaining compensation may be obtained from your
doctor.
What now?
If you decide you would like to take part in this study after you have read this
information leaflet and discussed it with friends and relatives, then please sign the
consent form in the presence of your doctor. It is important that you have time to
think about and discuss this study. If you have any questions at all about the study,
then please ask your doctor, the research nurse or the breast care nurse.
If any new information on the safety or effectiveness of the drugs used in this trial
comes to light, then we will inform you immediately.
If you require any assistance with travelling expenses for any extra visits, please let
your doctor know.
Further information
Your participation is voluntary. If you decide you do not want to take part or you wish
to withdraw from the study at any time, you are completely at liberty to do so and
your future care will not be affected. Your legal rights are not affected by you giving
consent to participate. All your medical records will be confidential although
information from the study will be analysed to assess the results in an anonymous
fashion.
Please note that all your doctors and nurses are specialised in this form of
treatment, and all of us are here to help. If you do have any questions or queries
then please do not hesitate to contact us.
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Womens'H althIniti tive study37
1993
Randomised, controlled,primary preventiontrial
16,608 healthy post¬ menopausal women
5.2years (planned duration8 years)
Todeterminetherisksand benefitsofestrogenplu progestinonverallhealth
(i)oestrogenplus medroxyprogesterone (ii)placebo




1,08410 women between50- 64years
4.1years
Toinvestigatetheeffec sf specificty esoHRTn incidentandfatalbreas cancer
Studyquestionnaire senttowomen attendingforroutine mammography. Informationabout useofHRTcollected




23,178 female nursesaged 45yearsand above
6years
Todeterminetherisksand benefitsassociatedwith differenttyp sofHRTvia questionnaires
(i)oestrogenalon (ii)combinedHRT (iii)tibolone
Currentus rsofHRTat increasediskofbre tc . Oestrogenal neRR1.96[95% CI1.16-3.35],ombinedHRT RR2.70[1.96-3.73.Tibolone RR4.27[1.74-10.51]compared withneverusedHRT





Todeterminetheff ctf differenttyp sofHRT theriskofbreastcancerin postmenopausalwomen
6,347incidentcases ofbreastcancerwer matchedwith31,516 controls
Opposedoestrogensassociated withincreasedi kofbr st cancerRR1.38[95%CI0.8 - 1.43].Unopposedoestrog nsRR 0.97[ .8601.09],TiboloneRR 0.86[CI.65-1.13]
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4538 post¬ menopausal women
34months
Totestifibolonereduc s riskofvertebralfractures+/- modifiesriskbreast cancer,DVTC D
(i)tibolone1.25mg (ii)placebo




3148 post¬ menopausal womenith BMDT- score<2.5
3.1years
Toestablishbr stcancer recurrence/vasomotor symptomsaftertiboloneus versusplaceboinwomen withvasomotorsympt ms
(i)tibolone2.5mg (ii)placebo






Toassessthvaluefu ing tamoxifenforbreastcancer preventioninwomea increasedri k
(i)tamoxifen20mg (ii)placebo






Toexaminetheffectsf zoledronicacidt combinationfeither goserelin+tamoxifer goserelin+anastrozolei womenithearlyhormone responsivebr a tcancer
(i)goserelin3.6mg+ tamoxifen20mg (ii)goserelin3.6mg+ anastrozoleImg+/- zoledronicacid4mg intravenously
94%DFSingroupthatreceived endocrinetherapy+zoledro ic acidversus90.8%DFSing oup thatreceivedendocrinet rapy alone.Zoledronicciddit on resultedinar latived c ionof 36%intheriskofdisease progression.Hazardrati0.64% [95%CI0.46-0.91].No significantdifferentet cted betweentamoxifenand anastrozole
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therolefexem staneplus GnRHanaloguesadjuvant therapyforpr menopausal womenithendocri e responsivebr a tcancer




Randomised, double-blind, multicenters udy
337post¬ menopausal women
4months
Tocomparetheanti-tumour activityofletr zole vs.tamoxifenin postmenopausalwomenith ERand/orPgR+veprimary untreatedbreastcanc r
(i)letrozole2.5mg (si)tamoxifen20mg
Overallobjectiveresponsate (clinicalpalp tion)was statisticallyignificant superiorinthletrozolegr up, 55%comparedtamoxif n, 36%(p<001)Secondary endpointsofultras und response,35%vs2(= 0.042).Mammographic response,34%vs16(P< 0.001),andBCS. 45%vs.3(p=0.022) betweenthletrozoleand tamoxifengroups,respectively, showedletrozolebe significantlyuperior






Toinvestigateeffec sn surgicalo tcomesf neoadjuvantletrozolei postmenopausalwomenith earlyhormonereceptor positivebreastcancer
letrozole2.5mg
Neoadjuvantletrozoleimproved operabilityandfacilitatedbre st conservingsurgery.Clinical responseate64%
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PhaseIII randomised, double-blind, multicentertrial
330post¬ menopausal women
13weeks
Totesthehyp th sisa theclinicaland/orbiologic effectsofneoadjuvant tamoxifencomparedwith anastrozolendwiththe combinationftamoxifen andnastrozolebefore surgeryinpostmenopausal womenithER+ve, invasive,nonmetastatic breastcancermighpredict foroutcomeintheATAC trial
(i)tamoxifen20mg (ii)anastrozolelmg (iii)tamoxifen+ anastrozole
Therewernosignificant differencesinORthent nt- to-treatpopulationbetween patientsrec ivingtamox fe , anastrozole,othecombinati n. Inpatientswhoereass ss d requiringmastectomyt baseline,44%ofpatients receivedBCSafternas rozole comparedwith31%fpat ents aftertamoxifen(p=0.23). Neoadjuvantanastrozolewass effectiveandw lltol rateds tamoxifen,buthehypoth sis thatclinicaloutcomemight predictforlong-te mou comei adjuvantther pywasnot fulfilled
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2000
Randomised, double-blind, multicenters udy
451post¬ menopausal women
5years
Tocompareanastrozolewith tamoxifenaspreoperative treatmentofpostmenopausal womenithlarg ,operable, orpotentiallyperablebreast cancer.
(i)anastrozolelmg+ tamoxifenplacebo +/-chemotherapy (ii)tamoxifen20mg +anastrozolepl cebo +/-chemotherapy
ORforanastrozolend tamoxifenoccurredin39.5% and35.4%respectivelyoUSS, and50.0%46 2 respectivelyu ingcali rs. Feasiblesurg rytba el n improvedaft r3m nthsn 43.0%ofanastrozolepatients and30.8%receivingtamoxifen (p=0.04).
269
































Nodifferencesinsurgical outcomeincludingpreoperat ve endocrineprognosticindex (PEPI)scoreoKi67 suppressionweredetected betweenthdrugs.TBCSrate formastectomy-onlyp tients presentationwas51%. NeoadjuvantAIsmarkedly improvedsurgicalo tcomes. Ki67andPEPId ta demonstratedthatere agentstest drebiologically equivalentandth reforelik lyo havesimilaradjuv ntctiv ties.
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Appendix G CONSORT diagram - disposition of patients
throughout the ALIQUOT study
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